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Abstract 
Phosphodiesterases (PDEs) play a key role in the control of cardiac contraction. PDE 
inhibitors are associated with cardiotoxicity, and increased knowledge of 
cardiomyocyte PDEs is required for improved pharmaceutical development. PDE 
activity and function were compared in animal and human cardiomyocytes in order to 
determine a suitable model for the human response, and to generate new insights into 
the role of cardiomyocyte PDEs. Ventricular myocytes were isolated from rat, guinea 
pig and diseased human heart. PDE gene expression was measured using RTPCR; 
PDE activity was measured using a scintillation proximity assay and isoform-specific 
PDE inhibitors. Effects of PDE inhibition on cardiomyocyte contractility were 
measured using electrically paced isolated cells. The human cardiomyocyte PDE 
expression and activity profile was closer to the guinea pig than the rat. High levels of 
PDE1 activity against cAMP and lower levels of possible PDE5 activity were found 
in guinea pig and human cardiomyocytes, but not rat. Non-specific PDE inhibition 
increased basal cardiomyocyte percentage shortening in cells from all three species; 
PDE3 inhibition only increased percentage shortening in guinea pig and human 
cardiomyocytes; PDE4 inhibition did not affect basal percentage shortening in 
cardiomyocytes from any of the three species. Further studies using rat 
cardiomyocytes found that PDE3 and PDE4 inhibition both significantly increased 
percentage shortening when cAMP levels were raised; rat β1- and β2- adrenergic 
receptors were also differentially regulated by PDE3 and PDE4. The functional 
effects of PDE1 inhibition were investigated in guinea pig cardiomyocytes but no 
significant effects were measured. Dual PDE1/PDE5 inhibition was shown to have a 
small negative effect on isoprenaline-stimulated contractility in rat, guinea pig and 
human cardiomyocytes. This study has revealed new insights into cardiomyocyte 
PDEs and demonstrated that the guinea pig may be a more suitable model for diseased 
human cardiomyocytes than the rat. 
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CHAPTER 1 INTRODUCTION 
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Phosphodiesterases are the only enzymes capable of degrading the second messenger 
cyclic nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP). The original “second messenger”, cAMP was first 
discovered and characterised by Earl Sutherland some five decades ago in 1958 (Rall 
& Sutherland 1958; Sutherland & Rall 1958). The structurally similar cGMP was 
identified five years later in 1963 (Ashman et al. 1963). Sutherland’s work on 
hormones would eventually lead to him being awarded the Nobel Prize for Physiology 
and Medicine in 1971. 
 
Although cAMP was first identified in the liver, it was almost immediately recognised 
that the heart, amongst other organs, was another important source of this substance 
(Rall & Sutherland 1958). Rall and Sutherland further showed that large amounts of 
cAMP were formed by heart tissue in the presence of adrenaline. The existence of a 
phosphodiesterase activity in the heart, capable of catalysing the breakdown of cAMP 
via its hydrolysis to the acyclic form, was later recognised and the enzyme responsible 
for this activity purified (Butcher & Sutherland 1962). 
 
It is now known that the actions of the sympathetic nervous system upon the heart are 
mediated at the subcellular level by cAMP, produced following the binding of 
adrenaline and noradrenaline to G-protein-coupled β-adrenergic receptors on the 
surface of cardiac muscle cells (see below). As the sole terminators of the cAMP 
signal, phosphodiesterases are poised to play a key role in regulating cardiomyocyte 
contraction, making them of interest to all cardiac researchers and in particular those 
wishing to understand and treat the contractile dysfunctions that occur in heart failure 
and other related cardiac disease. 
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Yet despite the fifty years that have elapsed since the seminal discoveries of 
Sutherland and his fellow researchers, the roles played in the heart by cAMP, cGMP 
and phosphodiesterases remain far from fully elucidated. Molecular biology has 
revealed the existence of potentially hundreds of different phosphodiesterase 
isoforms, and new techniques of microscopy and living-cell visualisation are 
demonstrating that complex gradients of second messengers exist within the cytosol 
of a single cell that can be shaped by the action of specific phosphodiesterases. 
 
Taken together, the above facts demonstrate that a comprehensive study of the 
phosphodiesterases in the heart is of great importance to basic research, pharmacology 
and medicine. This thesis presents the results of research aimed at providing such a 
study of the phosphodiesterases in cardiomyocytes from human, rat and guinea pig 
heart. 
 
1.1 The cardiomyocyte 
Cardiomyocytes give the heart its pumping abilities. They represent a third and unique 
type of muscle after skeletal and smooth muscle, namely cardiac muscle, and are 
found solely in this organ. Cardiac muscle is striated, but unlike skeletal muscle is not 
composed of large multi-nucleated fibres; rather each cardiac muscle cell retains its 
individuality but is electrically coupled to its neighbours via gap junctions. These 
associations of channels span the plasma membranes of adjacent cells and permit the 
transmittance of action potentials, thus allowing synchronised contraction of cardiac 
muscle. Ventricular cardiomyocytes have a rod-shaped structure and are 
approximately 100–150 µm in length by 20–35 µm in width (Severs 2000), with 
clearly visible striations [figure 1.1]. 
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Figure 1.1 Isolated rat cardiomyocytes 
 
Cardiac contraction is initiated by action potentials spontaneously generated in 
specialised pacemaker cells of the heart. The process by which electrical stimulation 
of the cardiomyocyte initiates a contraction is known as excitation-contraction (EC) 
coupling (Bers 2002). Key to this process is the movement of Ca2+ into and out of the 
cytosol, causing rapid changes in cytosolic Ca2+ concentrations during each 
contraction cycle. It is the binding of Ca2+ to troponin I which triggers the 
conformational changes in the myofibrils leading to muscle contraction. Electrical 
stimulation depolarises the cardiomyocyte sarcolemmal membrane, leading to the 
opening of voltage-gated L-type Ca2+ channels on the cell surface. The subsequent 
inward flow of Ca2+ down its concentration gradient into the cytosol leads to the 
further release of much greater amounts of Ca2+ from the sarcoplasmic reticulum 
(SR). This membrane-bound organelle, analogous to the endoplasmic reticulum in 
non-excitable cells, has on its surface many calcium release channels, otherwise 
known as ryanodine receptors (RyR) due to their propensity to bind the plant alkaloid 
ryanodine. The topology of the SR and sarcolemma places RyRs and L-type Ca2+ 
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channels in close proximity, such that the inward flow of Ca2+ following membrane 
depolarisation leads to a rapid increase in Ca2+ concentration in the vicinity of the 
RyRs. This in turn leads to the opening of the RyR calcium channels via the currently 
accepted mechanism of calcium-induced calcium release (CICR). These two 
processes lead to a large increase in the cytosolic concentration of free Ca2+, leading 
to Ca2+ binding to troponin and contraction of the myofilaments. 
 
Contraction is terminated by the removal of Ca2+ from the cytosol. The two primary 
mechanisms by which this occurs are through active transport into the sarcoplasmic 
reticulum via the Sarcoplasmic (-Endoplasmic) Reticulum Calcium ATPase 
(SERCA), and via a sarcolemmal antiporter protein which exchanges three Na+ for 
every two Ca2+ (the sodium-calcium exchanger, or NCX). Ca2+ uptake into the 
mitochondria and transport out of the cytosol via the sarcolemmal Ca2+ ATPase are 
secondary mechanisms which account for a smaller amount of Ca2+ handling (Bers 
2002). 
 
1.2 Modulation of cardiac contraction by the sympathetic 
nervous system - the role of cAMP and PKA 
Beating activity is an intrinsic property of the heart and can occur in isolated hearts 
completely detached from any central nervous system input. Countless students of 
physiology have witnessed this phenomenon occur in excised frog hearts, and the 
Langendorff technique for perfusing an ex vivo heart is common throughout 
pharmacological research. The heart is innervated by sympathetic nerves which 
release noradrenaline from their terminals. By binding to β-adrenergic receptors 
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(βARs) present on the surface of cardiomyocytes, noradrenaline (and adrenaline, 
which acts primarily in an endocrine fashion following its release from the adrenal 
medulla) is able to increase heart rate (chronotropy), force of contraction (inotropy), 
and rate of relaxation (lusitropy) (Brodde & Michel 1999; Xiao 2001). 
 
βARs belong to the larger class of G-protein coupled receptors (GPCRs) and exert 
their effects primarily through the stimulation of adenylate cyclase and the consequent 
production of cAMP. Stimulation of β-adrenergic receptors causes an associated 
trimeric stimulatory G-protein (Gs) to exchange a bound molecule of GDP for one of 
GTP, so becoming activated. Active Gs dissociates into Gαs and Gβγ, with Gαs in turn 
activating membrane-bound adenylate cyclase (AC) (Salazar et al. 2007), which 
catalyses the formation of cAMP. Nine isoforms of adenylate cyclase have been 
identified, with AC5 and AC6 predominant in the heart (Cooper 2003). 
 
Cyclic AMP is a small, easily diffusible molecule which exerts its effects primarily 
through the activation of cAMP-dependent protein kinase, more commonly known as 
protein kinase A (PKA). The binding of cAMP to the regulatory R subunits of PKA 
causes them to dissociate from the catalytic C units, allowing their activation. Active 
PKA catalytic units phosphorylate multiple target proteins involved in the control of 
calcium cycling in the cardiomyocyte, thus affecting contractility. Relevant PKA 
targets in the cardiomyocyte include phospholamban, the L-type Ca2+ channel, the 
cardiac ryanodine receptor, troponin I and myosin binding protein C (Zaccolo 2006; 
Lohse et al. 2003; Bers 2002). 
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PKA mediates both the inotropic and lusitropic effects of cardiac sympathetic 
stimulation on the cardiomyocyte (Bers 2002). Positive inotropic effects arising from 
PDE inhibition can be attributed to the increased and sustained PKA activity that will 
result from an increase in intracellular cAMP levels. During systole, increased 
amounts of Ca2+ are made available for contraction, resulting in the development of 
increased inotropy. A number of mechanisms are responsible for this. 
Phosphorylation of the L-type Ca2+ channel allows an increased flow of extracellular 
Ca2+ into the cell through these voltage-gated channels, and phosphorylation of RyR 
(the SR Ca2+ release channel) increases its open probability, again allowing more Ca2+ 
into the cytosol during systole. Interestingly, a “hyperphosphorylated” state of RyRs 
has been proposed to exist during heart failure, due to decreased local PDE4D 
activity; this in turn increases Ca2+ leakage through RyR, raising the probability of 
arrhythmias and worsening the disease state (Lehnart et al. 2005). 
 
The majority of the Ca2+ influx into the cytosol during contraction comes from the 
SR. Phosphorylation of phospholamban removes its inhibitory influence on SERCA. 
By increasing Ca2+ uptake into the SR during diastole, increased SERCA activity has 
a positive lusitropic effect (together with the phosphorylation of troponin I, which 
speeds up Ca2+ dissociation from the myofilaments), and by increasing the amount of 
Ca2+ in the SR available for release during systole, increased SERCA activity also has 
a significant positive inotropic effect (Bers 2002). 
 
The measurement of cardiomyocyte contractility provides an effective means of 
monitoring the functional changes associated with an increase in intracellular cAMP 
levels.  
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1.3 Epac, an alternative target for cAMP 
Exchange Protein Activated by Cyclic AMP (Epac) has emerged in recent years as 
another physiologically relevant mediator of the cAMP signal in cardiomyocytes. 
Epac is a guanine nucleotide exchange factor (GEF) able to activate Ras-like small 
GTPases; it is directly activated by cAMP (independently of any PKA activity), 
binding the cyclic nucleotide with a similar affinity to the R-subunit of PKA (Morel et 
al. 2005). 
 
Increasing Epac activity via pharmacological means, overexpression of wildtype Epac 
or expression of constitutively active Epac has been demonstrated to increase 
cardiomyocyte size and to activate the hypertrophic calcineurin/NFAT signalling 
pathways in isolated rat cardiomyocytes (Morel et al. 2005). Further evidence of a 
role for Epac in cardiac hypertrophy comes from observations that cardiac Epac1 
expression increases in cardiomyocytes from aortic-banded rats. The same study also 
showed that Epac1 activated the small G-protein Ras in response to β-adrenergic 
stimulation, independent of PKA activity (Metrich et al. 2008). 
 
Epac has also been suggested to have a role in the control of Ca2+ handling, following 
research showing that pharmacological Epac activation increased the frequency of 
Ca2+ sparks in quiescent rat cardiomyocytes (Pereira et al. 2007). However, the same 
pharmacological activation of Epac did not affect cardiomyocyte contractility. 
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1.4 β-adrenergic signalling in the cardiomyocyte 
Cardiomyocyte βARs are divided into three subtypes (Brodde & Michel 1999). Those 
of key relevance to the cardiomyocyte are the β1 and β2 subtypes, with the β1 being 
predominant at 70–80 %, depending on species (Lohse et al. 2003). There is also 
evidence of β3AR activity in the cardiomyocyte (see below).  
 
Stimulation of both β1- and β2ARs in principle activates the Gs–AC–cAMP–PKA 
pathway, and it is in this fashion that non-specific stimulation of cardiac βARs by the 
sympathetic nervous system and sympathomimetic agents is able to have positive 
inotropic, lusitropic and chronotropic effects on the heart (Xiao 2001). It has been 
accepted for some time that while stimulation of β1ARs produces the same effect as 
non-selective βAR stimulation, stimulation of β2ARs does not always have an effect 
on cell relaxation, depending on the species studied (Xiao 2001). In rat ventricular 
myocytes, both β1AR and β2AR stimulation acts to increase cell percentage 
shortening, L-type Ca2+ current and the intracellular Ca2+ transient, yet only β1AR 
stimulation increases the speed at which the cells relax following contraction, and the 
rate at which the Ca2+ transient decays (Xiao & Lakatta 1993). However, more recent 
research has challenged this notion, showing that β2AR stimulation can shorten 
relaxation time in adult rat hearts (Bartel et al. 2003). 
 
The role of the β2AR is further complicated by observations revealing that this 
receptor can also couple to the inhibitory G-protein Gi as well as Gs. Following its 
stimulation, PKA phosphorylation of the β2AR switches the receptor into a 
confirmation that couples with Gi. This has been demonstrated in cultured HEK293 
cells (Daaka et al. 1997), but more importantly in primary cardiomyocytes, including 
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rat and mouse (Baillie et al. 2003; Xiao et al. 1999). Coupling of the β2AR to Gi 
initiates protective effects by activating cell survival and anti-apoptotic pathways, and 
potentially gives the β2AR an importance that belies its relatively low numbers 
compared to the β1AR; by contrast, excessive β1AR stimulation is linked to increased 
cardiomyocyte death (Zhu et al. 2001). Signalling through Gi, the β2AR is able to 
increase the activity of the survival kinase Akt, as well as activating the kinases ERK 
and PI3K (Chesley et al. 2000). 
 
βAR signalling is profoundly altered as part of the pathology of heart failure, with 
β1AR expression being reduced by up to 50 %, depending on the severity of the 
disease, while β2AR expression stays constant (Lohse et al. 2003). Recent research 
measuring membrane cAMP levels in rat cardiomyocytes has demonstrated that 
β1AR- and β2AR-derived cAMP may be differentially controlled by PDE3 and PDE4 
(Rochais et al. 2006). The relevance of these findings to cardiomyocyte contractility is 
explored in depth in chapter seven. 
 
Unlike the positive inotropic effects of β1AR and β2AR stimulation, stimulation of  
β3ARs can have negative inotropic effects. This has been shown in human ventricle 
using isoprenaline in combination with nadolol, a β1/β2 antagonist (Gauthier et al. 
2000). Use of the β3AR agonist BRL 37344 in isolated guinea pig hearts showed that 
β3AR stimulation again had a negative inotropic effect, as well as causing a minor 
decrease in the Ca2+ transient (Kitamura et al. 2000). The effect of BRL 37344 was 
reduced using the nitric oxide synthase (NOS) inhibitor L-NAME, and the β3AR has 
been proposed to exert its negative inotropic effects through coupling to a Gi–NO 
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pathway (Gauthier et al. 2000). The effects of NO are mediated through cGMP, 
discussed in the next section. 
 
1.5 Cyclic GMP and the cardiomyocyte 
Cardiomyocyte cGMP has not been subject to the same levels of research as cAMP, 
and cGMP has traditionally been thought of as mainly of relevance to smooth muscle 
(where an increase in intracellular levels of cGMP mediates smooth muscle 
relaxation). However, cGMP is in fact directly relevant to the cardiomyocyte as well 
as the cardiac vasculature.  
 
Cyclic GMP is produced in an analagous fashion to cAMP by guanylate cyclase (GC) 
enzymes. While there are multiple adenylate cyclase isoforms, guanylate cyclase 
exists as a membrane-bound particulate form (pGC) and a soluble cytosolic form 
(sGC). The activity of pGC is stimulated by the natriuretic peptides, such as ANP and 
BNP (atrial and brain, respectively), whereas the activity of sGC is stimulated by NO 
donors (Fischmeister et al. 2006). Direct effects of cGMP are mediated via the 
activation of protein kinase G (PKG), while indirect effects of cGMP arise from its 
effects on the activity of certain PDE isoforms, such as PDE2 and PDE3. 
 
High concentrations of NO have a negative effect on cardiac contractility, signalling 
through the sGC–cGMP–PKG pathway. PKG decreases the sensitivity of troponin I to 
Ca2+ and can also decrease the open probability of L-type Ca2+ channels; these two 
effects combined act to decrease contractility (Rastaldo et al. 2007; Takimoto et al. 
2007). Pharmacological inhibition of “neuronal” NOS (nNOS) or the use of cells from 
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nNOS–/– mice enhances contractility and Ca2+ transients in mouse left ventricular 
myocytes (Sears et al. 2003). 
 
As discussed below and addressed in chapter six, cGMP has direct and opposite 
effects on the activity of PDE2 and PDE3. The phosphodiesterase activity of PDE2 is 
stimulated by cGMP binding, whereas the breakdown of cAMP by PDE3 is 
competitively inhibited by cGMP. These mechanisms introduce the potential for 
cAMP/cGMP crosstalk, whereby a change in the intracellular levels of cGMP could 
indirectly affect levels of cAMP (Zaccolo & Movsesian 2007). The authors of a study 
carried out in neonatal rat ventricular myocytes using cAMP-sensing FRET probes 
have proposed an important role for both PDE2 and the β3AR in the negative 
regulation of cardiomyocyte contractility (Mongillo et al. 2006). In this scheme, the 
β3AR stimulates the production of cGMP via “endothelial” NOS (eNOS)-produced 
NO and the activation of sGC. The cGMP so produced stimulates the activity of 
PDE2, leading to a decrease in cAMP levels and a negative inotropic effect. In this 
way, it is proposed that activation of this β3AR signalling pathway may serve as a way 
of limiting potentially damaging effects of excessive β1- and β2AR stimulation. 
 
Further cardiomyocyte effects of cGMP have been uncovered through the use of 
inhibitors of the cGMP-specific PDE5. PDE5 inhibition using sildenafil has been 
shown to have a negative effect on isoprenaline-stimulated contractility in isolated 
mouse cardiomyocytes (Takimoto et al. 2007). This effect was dependent on NOS3, 
and again attributed to cGMP-mediated PKG activation. Studies in mice have also 
revealed PDE5 inhibition as playing a role in cardioprotection (Das et al. 2005; Fisher 
et al. 2005). 
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1.6 PDE molecular biology 
The cyclic nucleotide phosphodiesterases comprise a large group of enzymes 
subdivided into a number of families based on genetic sequence. There are currently 
eleven known families of PDE (Soderling & Beavo 2000); each family may contain 
multiple genes, and the products of each gene can be subdivided into further isoforms. 
These are formed in turn from the use of alternative start codons within a given gene 
or from differential splicing of RNA transcripts (Beavo 1995). Current PDE 
nomenclature follows the pattern HSPDE8A2, where HS is the species (homo 
sapiens), PDE8 is the gene family, A is the gene within that family, and 2 is the splice 
variant or alternative transcript (Beavo 1995). 
 
Amino acid sequence homology within a PDE family is 65 % or greater, but 
homology between families is less than 40 %; what similarity there is between PDE 
families exists primarily at the level of the catalytic domain (Beavo 1995). All PDEs 
have a catalytic domain approximately 270 amino acids in size, sited in the C-terminal 
half of the molecule. The catalytic domain has 20–45 % homology between PDE 
families. Between the N-terminus and the catalytic domain lie regulatory regions 
which define the properties of each PDE family member. PDEs from families 2, 5, 6, 
10 and 11 feature GAF domains, which are able to bind cGMP as an allosteric 
regulator. Further sites including the calmodulin binding site of PDE1 and 
phosphorylation sites are also located within these regulatory regions (Lugnier 2006; 
Omori & Kotera 2007). The acronym “GAF” is derived from the names of the first 
three classes of proteins identified as containing such domains: cGMP-
specific/regulated PDEs, adenylate cyclase, and the E. coli transcription factor FhlA 
(Martinez et al. 2002). 
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Figure 1.2 PDE regulatory and catalytic domains (Lugnier 2006) 
 
For the purposes of this thesis, only PDE families 1–5 and 7 are further detailed. 
Compared to these families, much less is known about PDEs 8–11 (PDE6 is found 
only in the eye), and isoform-specific inhibitors for these families are not yet 
available. It was therefore decided to restrict investigation to PDEs 1–5 and 7. 
 
1.6.1 PDE1 
PDE1 is a dual substrate PDE (a property also pertaining to PDE2 and PDE3), capable 
of hydrolysing both cAMP and cGMP. PDE1 is unique amongst PDEs in possessing a 
binding domain for Ca2+/calmodulin (CaM). The binding of CaM causes a 
conformational change in the PDE1 molecule that removes enzyme auto-inhibition, 
leading to an increase in cyclic nucleotide hydrolytic activity (Goraya & Cooper 
2005). 
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Three PDE1 genes A–C give rise to a total of nine PDE1 isoforms: A1, A2, B1, B2 
and C1–5. Sensitivity to CaM is decreased by PKA-mediated phosphorylation in the 
case of PDE1A1 and A2, and by CaMKII-mediated phosphorylation in the case of 
PDE1B1 (Lugnier 2006). The different PDE1 gene products have differing affinities 
for the two cyclic nucleotides: PDE1A and 1B both have a high affinity for cGMP and 
lower affinities for cAMP (with that of 1B higher than that of 1A). PDE1C has an 
equal affinity for cGMP and cAMP (Rybalkin et al. 2003). 
 
1.6.2 PDE2 
PDE2 hydrolyses both cAMP and cGMP with equal affinity and similar Vmax. 
A single gene has been identified for PDE2, from which three different gene products 
can be derived, A1–3. The binding of cGMP to regulatory GAF domains stimulates 
the activity of PDE2, and this enzyme has in the past been referred to as cGMP-
stimulated PDE. PDE2 activity is also stimulated by PKC-mediated phosphorylation 
(Maurice et al. 2003; Lugnier 2006; Omori & Kotera 2007). 
 
1.6.3 PDE3 
The final dual substrate PDE, PDE3 has a high affinity for both cAMP and cGMP. 
PDE3 has a lower Vmax for cGMP than cAMP, effectively making cGMP a 
competitive inhibitor of cAMP hydrolysis. In this way, PDE3 has been referred to as 
the cGMP-inhibited PDE (Omori & Kotera 2007; Maurice et al. 2003). 
 
Two PDE3 genes, A and B, give rise to four gene products in total – three from 
PDE3A and one from PDE3B; the three PDE3A cDNAs are generated from 
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alternative transcription start sites (Movsesian 2002). At the N-terminal end of PDE3 
are found two hydrophobic regions named NHR1 and NHR2. These domains are 
approximately 200 and 50 amino acids in length, respectively, and are postulated to be 
membrane association domains involved in intracellular targeting of PDE3 activity. 
PDE3 activity is regulated by both PKA- and PKB-mediated phosphorylation at sites 
located between NHR1 and NHR2. A second PKA phosphorylation site exists 
downstream of NHR2 (Movsesian 2002; Omori & Kotera 2007). PDE3B isoforms 
have also been reported to interact with PI3Kγ (Patrucco et al. 2004). 
 
1.6.4 PDE4 
PDE4 family members are cAMP specific. This large family contains four genes  
A–D, which give rise to over 20 possible PDE4 isoforms via the usage of alternative 
promoters and differential mRNA splicing (Houslay et al. 2007). PDE4 amino acid 
sequences can be classified according to their possession of “upstream conserved 
regions” (UCRs). According to this classification, “long” PDE4 isoforms possess 
UCR1 and UCR2, “short” isoforms possess UCR2, “super short” isoforms possess a 
truncated UCR2 only, and “dead short” isoforms have no UCR. UCR1 features a PKA 
phosphorylation site, allowing PKA to increase the activity of “long” PDE4 isoforms. 
Interestingly, ERK-mediated phosphorylation of PDE4 long forms has the opposite 
effect to PKA-mediated phosphorylation, decreasing PDE4 activity (Houslay et al. 
2007). 
 
PDE4 isoforms have been shown to interact via direct protein-protein interactions 
with a number of different proteins involved in intracellular scaffolding and 
anchoring. These include A-kinase anchoring proteins (AKAPs), receptor for 
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activated C-kinase (RACKs), and β-arrestins 1 and 2 (Houslay et al. 2007). These 
interactions provide a means by which PDE4 activity could be localised to discreet 
subcellular locations (see below). 
 
1.6.5 PDE5 
PDE5 is cGMP specific. One gene, PDE5A, gives rise to three different proteins. Like 
PDE2, PDE5 possess GAF domains in the N-terminal half of the molecule which bind 
cGMP. Both PKA and PKG phosphorylation sites are found within the PDE5 
molecule, with phosphorylation leading to enhanced enzymatic activity (Maurice et 
al. 2003; Omori & Kotera 2007). 
 
1.6.6 PDE7 
Two genes are known for this cAMP specific PDE, A and B (Lugnier 2006). 
 
1.7 PDEs in the heart 
Historically, the majority of studies looking at cardiac PDE expression and activity 
have used whole heart, as have many functional studies. PDE3 and PDE4 have been 
the focus of much of this research due to their perceived importance, which in part 
stems from the fact that these two PDEs have been found to make up the vast majority 
of PDE activity in certain systems, such as 90 % of total PDE activity in neonatal rat 
cardiomyocytes (Mongillo et al. 2004). 
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Until recent years, consensus held that PDEs 1–4 were found in whole heart, with 
only PDEs 2–4 being present in the myocyte fraction. A 1991 study using high-
performance liquid chromatography (HPLC) found activity from PDEs 1–4 in rat 
ventricular tissue, but activity only from PDEs 2–4 in the ventricular myocytes 
themselves (Bode et al. 1991). Other studies also supported this picture of PDE 1–4 
activity in rat heart (Shahid & Nicholson 1990; Dubois et al. 1993). PDEs 1–4 have 
also been found to be active in guinea pig heart (Muller et al. 1992). 
 
Cardiac PDE function has been investigated using both broad-spectrum and isoform-
specific PDE inhibitors, as well as specific gene knockouts. Non-specific PDE 
inhibition has positive inotropic effects on both isolated whole hearts and cardiac 
muscle strips, in both rat and guinea pig (Osadchii et al. 2005; Rapundalo et al. 1989; 
Shahid & Nicholson 1990). PDE3 inhibition increases contractility in isolated guinea 
pig hearts (Zausig et al. 2006; Rapundalo et al. 1989), but does not affect contractility 
in rat papillary muscle (Shahid & Nicholson 1990). PDE4 inhibition using rolipram 
does not produce any positive inotropic effect on guinea pig left atria under basal 
conditions (Muller et al. 1990), and PDE4 inhibition using Ro 20-1724 has only a 
small (<10 %) effect on heart rate in rats (Herzer et al. 1998). 
 
Studies using human atrial myocytes have demonstrated that PDE2 inhibition and 
PDE3 inhibition can both increase the L-type Ca2+ current under basal conditions 
(Kirstein et al. 1995), yet PDE4 inhibition has no effect (Kajimoto et al. 1997). 
Inhibition of individual PDE isoforms in rat cardiomyocytes has no effect on basal 
L-type Ca2+ current, but can significantly potentiate the effect of isoprenaline, with an 
order of effectiveness of PDE 4>3>2>1 (Verde et al. 1999) (this study did, however, 
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rely on the PDE1 inhibitor MIMX, which has questionable selectivity over PDE5 
(Lugnier 2006)).  
 
Cardiac PDEs and their involvement in cardiac disease have been recently reviewed 
by Osadchii (Osadchii 2007). 
 
1.8 Current concepts of cyclic nucleotide signalling 
Research into cyclic nucleotide signalling over the last thirty years has led to the 
current concept of signal localisation or compartmentation (also referred to as 
compartmentalisation). Simply stated, this idea holds that the effect of cAMP or 
cGMP depends on its subcellular location, and that cyclic nucleotide diffusion can be 
restricted such that cAMP or cGMP produced in a given location may not necessarily 
have access to the entire cytosol. This concept goes against the traditional idea that the 
small cyclic nucleotide second messengers can freely diffuse throughout the cell. 
Currently, it is believed that cAMP or cGMP can be produced in, and confined to, 
specific subcellular locations depending on the nature of the surface receptors 
stimulated, allowing two different receptors which both signal via cAMP to produce 
functionally different effects within the cardiomyocyte (Fischmeister et al. 2006). 
 
The idea of cyclic nucleotide compartmentation grew out of observations regarding 
the differential effects on the heart of isoprenaline and prostaglandin E1 (PGE1). The 
application of both of these compounds to isolated, perfused rat hearts caused an 
increase in intracellular cAMP accumulation and PKA activity, but only isoprenaline 
increased cardiac contractility and the activity of phosphorylase kinase and glycogen 
phosphorylase (Hayes et al. 1979). Similar observations were made regarding isolated 
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cardiomyocytes, where again only isoprenaline was shown to activate glycogen 
metabolism enzymes, while both isoprenaline and PGE1 increased intracellular levels 
of cAMP and PKA activity (Buxton & Brunton 1983). This latter paper served to 
demonstrate that the differential effects of isoprenaline and PGE1 could not be 
attributed to their acting on different populations of cells within the heart. 
 
Applying the current knowledge of cAMP signalling allows the observations of Hayes 
and Buxton, above, to be explained broadly as follows. Stimulation of β-adrenergic 
receptors by isoprenaline and of PGE1 receptors by PGE1 leads to the activation of 
adenylate cyclase and consequent production of cAMP. However, the signalling 
components from receptor to adenylate cyclase are not randomly arranged within the 
cell, allowing specific receptors to activate cyclases in defined locations. The cAMP 
produced following isoprenaline stimulation activates PKA that can then interact with 
the cellular machinery controlling contractility. By contrast, the cAMP produced 
following PGE1 stimulation is prevented from diffusing to where it could affect the 
same machinery, and can only activate a subset of PKA molecules unconnected with 
contractility. The activity of PGE1-derived cAMP is confined to a limited locality, or 
compartment, and the cAMP signal is localised. 
 
Much of contemporary cyclic nucleotide research focuses on understanding the 
cellular mechanisms that allow signal compartmentation, and the cardiomyocyte has 
become the model of choice due to its well-studied internal signalling pathways, 
coupled with its complex cellular architecture. A number of non-exclusive 
mechanisms have been proposed by which the cyclic nucleotide signal can be 
compartmented (Fischmeister et al. 2006). Some components of certain signalling 
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pathways may be collectively localised to defined areas of the plasma membrane, 
such as caveolae and t-tubules, allowing particular receptors to activate defined 
adenylate cyclases in a non-random manner. Furthermore, the effector of cAMP, PKA 
can itself be localised to particular subcellular locations through the use of A-kinase 
anchoring proteins (AKAPs). This would allow PKA-mediated phosphorylation to be 
confined to specific locations. 
 
Of greatest relevance to this thesis, however, is the notion that it is PDEs which play a 
key role in localising cyclic nucleotide signalling within the cardiomyocyte. This 
would help explain why evolution has provided so many different enzymes in order to 
fulfil what is, at first sight, an apparently simple task. As described above, the varied 
molecular biology of the different PDEs allows for the many different isoforms to be 
controlled by a number of different signalling pathways and, in the case of families 
such as PDE4, provides a means by which PDE isoforms could be localised to defined 
subcellular locations in a manner similar to the interaction of PKA with AKAPs. 
 
A number of different technological approaches have been used to enable researchers 
to directly measure, and in some cases visualise, cAMP production in intact, living 
cardiomyocytes, and to study the effects of PDE inhibition. One approach has been to 
use fluorescence resonance energy transfer (FRET)-based probes. These protein-based 
probes each contain two different fluorescent proteins; fluorescence energy is 
transferred from one to the other by the FRET process, allowing the stimulation of 
one protein to lead to a signal being emitted from the second. The strength of the 
FRET is dependent on the distance between the two proteins, and the probes are 
constructed such that the binding of cAMP alters the distance between the two 
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fluorescent proteins and changes the signal. The change in signal is proportional to the 
local cAMP concentration in the vicinity of the probe, allowing local fluctuations in 
cAMP levels to be monitored throughout the cell. Studies using PKA-based FRET 
probes in neonatal rat cardiomyocytes have provided further evidence regarding the 
functional role of PDEs within the cardiomyocyte, by showing that both PDE3 
inhibition with cilostamide and PDE4 inhibition with rolipram significantly increases 
the positive effect of noradrenaline on intracellular cAMP levels, with PDE4 
inhibition having a greater and more sustained effect (Mongillo et al. 2004). 
 
A separate study using adult mouse cardiomyocytes engineered to constitutively 
express an alternative FRET probe (one based on the cAMP-binding domain of a 
cyclic nucleotide-activated channel) also demonstrated the potentiating effect of PDE 
inhibition on isoprenaline-stimulated cAMP production. PDE4 inhibition was again 
shown to have a greater effect than PDE3 inhibition, and both had a greater effect 
than PDE2 inhibition (Nikolaev et al. 2006). 
 
An alternative approach to the above FRET-based studies has been to use a 
membrane-bound cyclic nucleotide gated channel (non-native to cardiomyocytes) 
which is activated by the binding of cAMP or cGMP and creates a current 
proportional to sarcolemmal cyclic nucleotide levels, measurable using 
electrophysiological techniques. Using this technique, PDE3 and PDE4 inhibitors 
(applied individually) were shown to have no effect on basal levels of sarcolemmal 
cAMP, but significantly potentiated the effect of isoprenaline (with the effect of PDE4 
inhibition being greater than that of PDE3 inhibition). 
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1.9 PDE inhibitors 
PDE inhibitors such as milrinone were originally developed as drugs to treat heart 
failure. The positive inotropic effects of PDE3 inhibition were to be used as a way to 
restore some of the contractile function lost in the failing heart. However, subsequent 
meta-analyses of a number of different clinical trials have revealed that despite the 
initial positive benefits of PDE inhibitors, the chronic use of these drugs is associated 
with a significant long-term increased mortality risk in heart failure patients 
(Amsallem et al. 2005; Nony et al. 1994). 
 
The most well-known PDE inhibitor is of course the PDE5 inhibitor sildenafil, which 
has achieved some considerable renown amongst the general public as an anti-
impotence treatment, but was in fact originally developed by Pfizer to treat angina. 
Considerable testing during the development of this drug led to the belief that PDE5 
was absent from cardiomyocytes (Wallis et al. 1999), but this concept has been 
challenged by studies in mice (referenced in section 1.5, above) demonstrating 
significant effects of PDE5 inhibition on both isoprenaline-stimulated contractility 
and cardioprotection in isolated cardiomyocytes. Work presented in chapter three 
further addresses this question. 
 
Multiple PDE inhibitors were used in the experiments presented in this thesis, and the 
use of each is discussed in depth in the relevant chapters. As with many other 
compounds used as pharmacological agents, the specificity of a given PDE inhibitor is 
not absolute, and is dependent on its concentration; excessively high concentrations 
may lead to PDEs other than the intended target isoform being inhibited, and there 
may also be non-PDE effects. The PDE inhibitors IBMX (non-specific), milrinone 
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(PDE3), cilostamide (PDE3), rolipram (PDE4) and BRL 50481 (PDE7) were chosen 
as they are commercially-available compounds whose effects have been investigated 
in much previously published research. The PDE1 inhibitor UK 90234 and the PDE5 
inhibitor UK 114542 are both Pfizer compounds provided by our collaborators at 
Pfizer Global Research and Development. UK 90234 is more potent than the 
commercially-available PDE1 inhibitor 8-methoxymethyl-3-isobutyl-1-methyl-
xanthine (MIMX), as MIMX also equally inhibits PDE5 (Lugnier 2006). UK 114542 
is of similar effectiveness to Pfizer’s commercially successful PDE5 inhibitor 
sildenafil and is closely related structurally. 
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Table 1.1 Details of PDE inhibitors 
A variety of potencies and selectivities have been reported for PDE inhibitors. 
Inhibitor (target PDE) IC50 (target) IC50 (non-target) 
UK 90234 (PDE1) 20 / 250 / 4 nM (PDE1A/B/C)1 PDE5: 2 µM2 
EHNA (PDE2) 4 µM (mouse)1  
Cilostamide (PDE3) 27 / 50 nM (PDE3A / B) 
(human recombinant)1 
PDE4: 89 µM1 
Milrinone (PDE3) 56 nM (human platelet)1 
150 nM (Ki, bovine 
myocardium)2 
300 nM (bovine myocardium)3 
0.45 / 1 µM (PDE3A / B) 
(human recombinant)4 
PDE4: 17.5 µM (rat 
recombinant)4 
Rolipram (PDE4) 1 µM1 
0.45 (rat)2 
 
UK 114542 (PDE5) IC50 (nM): 1.71 IC50 (nM) PDE1: 931 
BRL 50481 (PDE7) 0.26 / 2.4 µM1 
(at 50 nM / 1 µM substrate 
conc., human recombinant 
PDE7) 
PDE1, 2, 5: >100 µM1 
PDE3: 490 µM 
PDE4: 62 µM 
(purified canine enzymes) 
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References in table 1.1: 
UK 90234 – 1: Reported by Kruuse (Kruuse et al. 2005), 2: Pfizer data (and see 
discussion in relevant chapters) 
EHNA – 1: (Michie et al. 1996) 
Milrinone – 1: (Tang et al. 1994), 2: (Ito et al. 1988), 3: (Harrison et al. 1986), 
4: (Sudo et al. 2000) 
Cilostamide – 1: (Sudo et al. 2000) 
Rolipram – 1: (Beavo & Reifsnyder 1990), 2: (Sudo et al. 2000) 
UK 114542 – 1: (Timmons & MacInnes 2002) (and see discussion in relevant 
chapters) 
BRL 50481 – 1: (Smith et al. 2004) 
 
1.10 Project aims 
There remains much to be discovered about PDEs and cyclic nucleotide signalling 
within the heart. By studying PDEs at the level of the isolated cardiomyocyte, a true 
picture of the role played by these enzymes in the control of cardiac contractility can 
emerge. At present, perhaps not enough attention is given to the choice of animal to 
use as experimental subject, and results can be inappropriately extrapolated from 
animal to human. Translational research emphasises the importance of using the 
appropriate animal model that will allow increased confidence in later human results. 
A deeper understanding of PDE activity and function within both animal and human 
cardiomyocytes is required to enable both the development of improved cardiac drugs 
and to avoid any unnecessary problems of cardiotoxicity in drugs destined for non-
cardiac use. 
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The aims of the work presented in this are as follows: 
 
1. To study animal and human cardiomyocytes and determine a suitable model 
for the patterns of PDE expression, activity and function found in the human. 
The development of safe and effective new pharmaceuticals requires 
knowledge of the human cells that will ultimately be targeted. It is also crucial 
to determine which animal cells respond to PDE inhibition in a manner closest 
to the human response. In this way the drug discovery process can be rendered 
more efficient, leading to a decrease in the number of animals used and a 
decrease in the number of candidate drugs discarded due to unwanted side-
effects that appear during human testing.  
 
2. To carry out an in-depth study of PDE expression and activity in isolated 
cardiomyocytes. The issue of which PDEs are expressed and functional in 
actual cardiomyocytes, as opposed to whole heart, is unclear. Resolving this 
uncertainty, especially as it relates to lesser-studied PDEs such as PDE1 and 
PDE5 will be of great benefit. 
 
3. To use isoform-specific PDE inhibitors to study the functional effects of PDE 
inhibition on cardiomyocyte contractility, and to attempt to determine the roles 
played in contraction by each PDE. 
 
4. To generate new insights into the role of PDEs in controlling cardiomyocyte 
contractility. 
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This work is aimed at studying PDEs in isolated cardiomyocytes and generating new 
data relating to PDE activity and function within the cardiomyocyte. It is not the 
intention to compare animal models of heart failure with human failing heart; such a 
study would be complex and should not be carried out before more initial data on 
cardiomyocyte PDEs have been obtained. A key facet of this work is that it is carried 
out using isolated cardiomyocytes and not cardiac tissue. This removes all potential 
confounding influences of other cardiac cell types and increases the utility of the data 
gained. 
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CHAPTER 2 METHODS 
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2.1 Cell isolation 
Ventricular myocytes were isolated from rat (Harding et al. 1988), guinea pig (Brown 
et al. 1990) and human (Brown et al. 1990) heart using enzymatic digestion methods 
to separate the cardiomyocytes from the surrounding extracellular matrix. All three 
methods have been used successfully at the National Heart and Lung Institute for 
many years. 
 
2.1.1 Rat 
Rat ventricular myocytes were isolated primarily by Peter O’Gara. A number of 
isolations were carried out by myself. 
 
Ventricular myocytes were obtained from adult male Sprague-Dawley rats weighing 
250-350 g. The animal was sacrificed via cervical dislocation and the heart rapidly 
excised and placed in ice-cold Krebs-Henseleit buffer (concentrations in mM: NaCl 
119.10, KCl 4.70, MgSO4 0.94, KH2PO4 1.20, NaHCO3 25.00, glucose 11.50; 
subsequently referred to as “Krebs”) containing heparin (1000 IU in 50 ml) and 1 mM 
Ca2+, and equilibrated with 95 % O2 / 5 % CO2 gas. The aorta was cannulated and the 
heart mounted on a Langendorff apparatus. Retrograde perfusion of the coronary 
arteries was carried out at a constant flow rate of 6–8 ml per minute per gram of heart 
weight.  
 
The heart was initially perfused with Krebs containing 1 mM Ca2+ for 5 min at 37°C. 
A “low calcium” buffer (concentrations in mM: NaCl 120.0, KCl 5.4, MgSO4 5.0, 
pyruvate 5.0, glucose 20.0, taurine 20.0, HEPES 10.0, nitrilotriacetic acid 5.0) 
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containing calcium at 12–15 µM and oxygenated with 100 % O2 gas was then used 
for a further 5 min at 37°C. The heart was then perfused with an “enzyme solution” 
(concentrations in mM: NaCl 120.0, KCl 5.4, MgSO4 5.0, CaCl2 0.05, pyruvate 5.0, 
glucose 20.0, taurine 20.0, HEPES 10.0, nitrilotriacetic acid 5.0) containing 1 mg/ml 
collagenase (Sigma) and 0.6 mg/ml hyaluronidase (Sigma) for a further 10 min at 
37°C. 
 
The heart was removed from the Langendorff and the atria and right ventricle were 
cut off with scissors. The left ventricle was chopped into chunks of approximately 
1mm3 using a razor blade. The tissue was added to 10ml of the collagenase / 
hyaluronidase solution that had been re-circulated through the heart during the 
perfusion step. The tissue was incubated at 37°C for 5 min under a 100 % O2 
atmosphere; during this incubation the tissue was gently shaken to ensure that all 
pieces remained free and in contact with the oxygenated solution to avoid hypoxia. 
Following this first tissue digestion the remaining tissue was collected by filtration 
through 300 µm gauze. The filtrate was centrifuged at approximately 13 × g for 1 min 
to collect the relatively heavy cardiomyocytes (compared to other cells and debris), 
the supernatant removed and discarded, and the myocyte-containing pellet 
resuspended in “enzyme solution” (see above for composition) containing 200 µM 
Ca2+. This re-suspension was termed “digest 1”. The tissue was meanwhile incubated 
for a second digestion with fresh collagenase/hyaluronidase for 30 min, under the 
same conditions as previously. Following this second incubation, the filtrate was 
centrifuged as before and the pellet again resuspended in “enzyme solution” 
containing 200 µM Ca2+. This yielded “digest 2”. Both digest 1 and digest 2 contained 
cells suitable for experimentation. 
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2.1.2 Guinea pig 
Guinea pig ventricular myocytes were isolated by Matthew Edenbrow, Sammy Mason 
and Peter O’Gara. 
 
Ventricular myocytes were isolated from adult Dunkin-Hartley guinea pigs weighing 
550–750 g. The isolation method was identical to that used for isolating rat myocytes, 
with the exception that an additional perfusion step using 0.145 mg/ml protease 
(Sigma) for one minute followed the low-calcium perfusion. 
 
2.1.3 Human 
Human ventricular myocytes were isolated by myself, Allan Zheng, Motoki Sato and 
Edwin Garcia. 
 
Human ventricular myocytes were isolated from explanted failing heart tissue or 
biopsies obtained from patients undergoing corrective surgery for hypertrophic 
obstructive cardiomyopathy. The method used was the same in both instances. 
Langendorff perfusion methods are not possible with human tissue, as only small 
pieces, often lacking a viable artery, are available. The method used below is less 
efficient, but can still produce viable isolated cardiomyocytes suitable for 
experimentation. 
 
Upon removal from the patient, tissues samples were stored in ice-cold cardioplegia 
solution (“Plegivex”, St. Thomas No.1 formulation, composition in g/litre: NaCl 8.60, 
KCl 1.49, MgCl2 3.25, CaCl2 0.33, procaine HCl 0.27) until use. Maximum time from 
patient to laboratory was four hours. Upon receipt of the tissue, approximately 1 g 
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was removed for cardiomyocyte isolation and chopped into pieces approximately 1 
mm3 in size. Straight, vertical cuts with a razor blade were used, avoiding any 
shearing forces which are damaging to cardiomyocytes. The tissue pieces were 
washed for 4 × 3 min at 35°C in oxygenated “low calcium” solution (composition in 
mM: NaCl 120.0, KCl 5.4, MgSO4 5.0, pyruvate 5.0, glucose 20.0, taurine 20.0, 
HEPES 10.0, nitrilotriacetic acid 5.0); the nitrilotriacetic acid buffers Ca2+ from the 
tissue to an effective 1–2 µM. During each wash the tissue was gently circulated 
around the solution, which was kept oxygenated throughout. Between washes the 
tissue was collected by filtration and the old wash solution discarded. Following 
washing the tissue was subjected to enzymatic digestion. The first digestion consisted 
of a 45 min incubation at 35°C under a 100 % O2 atmosphere in “enzyme” solution 
(see above for composition) containing 4 U/ml protease (Sigma). Following the 
protease digestion, the remaining undigested tissue was collected by filtration through 
300 µm gauze and incubated for a further 45 min in “enzyme” solution containing 1 
mg/ml human collagenase (Sigma), again at 35°C under 100 % O2. After this time the 
solution was filtered as before. The filtrate was centrifuged at 13 × g for 1–2 min, and 
the myocyte-containing pellet resuspended in “enzyme” solution. The re-suspension 
was then centrifuged and washed a second time. The remaining tissue was incubated 
with fresh collagenase solution for a further 45 min under the same conditions. 
Following this period the filtrate was again centrifuged and washed twice, yielding a 
second myocyte suspension in “enzyme” solution. Cells from either collagenase 
digest were used for experimentation. 
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Table 2.1 Human sample details 
Experiments conducted 
Sample 
number 
Area Disease Sex Age 
PCR SPA 
Myocyte 
contraction 
Other 
1 IVS HOCM F 63   IBMX  
2 LV IHD M 41 Y Y IBMX, MIL LVAD 
3 IVS HOCM M 48   IBMX, ROL  
4 RV Congenital HD F 38   ROL  
5 RV Congenital HD M 22   IBMX, MIL, ROL  
6 IVS HOCM M 42   IBMX  
7 IVS HOCM M 58  Y ROL  
8a RV DCM M 57 Y Y MIL ICD 
8b LV DCM M 57  Y   
9 RV IHD M 51   MIL, ROL LVAD 
10 LV IHD M 52   ROL  
11 RV DCM M 20   ROL  
12 IVS HOCM M 58   ROL  
13 LV IHD M 57   UK90234 Pacemaker 
14 RV Myocarditis F 27  Y   
15 RV DCM M 53 Y    
16 RV CF F 26 Y    
17 LV DCM M 34   UK90234  
18 RV IHD M 49   UK90234  
 
LV: left ventricle; RV, right ventricle; IVS, interventricular septum; HOCM, 
hypertrophic obstructive cardiomyopathy; IHD, ischaemic heart disease; HD, heart 
disease; DCM, idiopathic dilated cardiomyopathy; CF, cystic fibrosis; SPA, 
scintillation proximity assay; IBMX, 3-isobutyl-1-methylxanthine; MIL, milrinone; 
ROL, rolipram; LVAD, left ventricular assist device; ICD, implantable 
cardiodefibrillator. 
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2.1.4 Purity of isolated cardiomyocytes 
With each isolation method, the low speed centrifugation following each wash 
ensured that only the relatively heavy cardiomyocytes were pelleted, excluding any 
smaller cells that might have survived the digestion process. Cell digests were also 
visually checked to ensure that only cardiomyocytes were present. 
 
2.1.5 Cardiomyocyte preparation for RTPCR and PDE activity analysis 
Cardiomyocytes for RTCPR and PDE activity analysis were frozen shortly after 
isolation in order that further study could be undertaken at a later date, and to 
facilitate transport between laboratories. The procedure was the same for each species. 
 
Isolated cardiomyocytes in suspension following the standard digestion processes 
were centrifuged at 12,000 × g in a bench top micro centrifuge for 2 min to form a 
compact cell pellet. The supernatant was discarded and the cells were snap-frozen in 
liquid nitrogen before being stored at –80°C until use. 
 
2.2 Reverse Transcriptase PCR (RTPCR) 
RTPCR allows the level of transcription of any sequenced gene to be determined, by 
measuring the amount of transcribed mRNA of that gene present in the cell at any one 
time. The technique uses the viral reverse transcriptase enzyme (RT) to copy all 
mRNA sequences present in the cell to their complementary DNA (cDNA) sequence. 
The greater the number of mRNA transcripts for a given gene, then the greater the 
number of cDNA sequences for that gene produced by the RT. The Polymerase Chain 
Reaction (PCR) is used to amplify these sequences for the genes of interest, using 
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specific custom-designed primers. Each gene is probed for in a separate reaction tube, 
and the amount of genetic material produced is proportional to the original number of 
mRNA transcripts of that gene. By running the products of each PCR reaction on a 
gel, the presence or absence of mRNA transcripts for each gene is shown, and the 
intensity of each band reflects the original level of transcription. 
 
Cardiomyocytes used for RTPCR analysis were isolated, centrifuged and frozen for 
storage as in an identical fashion to those used for SPA (scintillation proximity assay) 
analysis. All plasticware was autoclaved to remove nuclease contamination. 
Glassware was treated with 0.1 % DEPC (diethylpyrocarbonate) before autoclaving to 
remove nuclease contamination. Gloves were worn at all times while handling 
samples, and work areas chemically treated to remove nucleic acid and nuclease 
contamination. Nuclease-free water was used throughout. Ethanol was of molecular 
biology grade. 
 
2.2.1 RNA isolation 
RNA was isolated from cardiomyocytes (previously frozen – see section 2.1.5) with 
the “Promega RNAgents Total RNA Isolation System” as follows: 
 Cells were first resuspended in 120 µl ice-cold denaturing solution and lysed 
on ice using a Dounce glass homogeniser for 30–60 s.  
 12 µl 2 M sodium acetate (pH 4) was added to the reaction tube and mixed by 
inverting the tube 4–5 times.  
 120 µl of the lower organic phase of a 125:24:1 mixture of 
phenol:chloroform:isoamyl alcohol was added to the reaction tube.  
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 The tube contents were mixed by inversion 3–5 times and the tube was then 
shaken vigorously for 10 s before being chilled on ice for 15 min.  
 The tube was centrifuged at 10,000 × g for 20 min at 4°C.  
 The top aqueous phase (containing RNA) was removed, taking care not to 
disturb the interface, and transferred to a new tube. The organic phase was 
discarded.  
 An equal volume of isopropanol was added to the aqueous phase. The tube 
contents were mixed and incubated at –20°C for 60 min to precipitate the 
RNA.  
 The RNA was pelleted by centrifugation at 10,000 × g for 10 min at 4°C. The 
supernatant was removed and the pellet resuspended in 1 ml of 75 % ethanol.  
 RNA was again pelleted by centrifugation at 10,000 × g for 10 min at 4°C. 
 The supernatant was removed and the RNA pellet air-dried for 10–20 min, 
depending on size. 
 Finally the pellet was re-dissolved in 20–25 µl nuclease-free water to give 
“RNA (total)” samples. 
 
2.2.2 RNA purity and concentration 
2 µl of RNA (total) was diluted 300-fold in nuclease-free water. The absorbance at 
260 and 280 nM was measured in a spectrophotometer, and the Abs 260 / Abs 280 
ratio used to gauge the purity of the recovered sample. RNA concentration was 
determined from the Abs 260 value, where 1 Abs (A260) equals 40 µg/ml RNA. 
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2.2.3 DNase treatment of total RNA samples 
Where indicated, total RNA samples were treated with “Promega RQ1 RNase-free 
DNase”, as per manufacturer’s instructions, in order to control for any contamination 
of RNA with genomic DNA. A second RNA extraction was carried out on the treated 
sample, and the RNA purity and concentration determined as before. 
 
The RNA sample was digested with RNase-free DNase at 37°C for 15 min. The RNA 
was then extracted from the sample with an equal volume of 99:24:1 
phenol:chloroform:isoamyl alcohol (pH 4.7). After vortexing for 1 min to ensure 
mixing, the sample was centrifuged at 12,000 × g for 2 min at 4°C. The upper 
aqueous phase was transferred to a new tube, and a second extraction performed using 
24:1 chloroform:isoamyl alcohol; this was carried out in the same manner as the 
previous extraction. The upper aqueous phase was again transferred to a new tube and 
the RNA precipitated by the addition of sodium acetate to 0.3 M and 2.5 volumes of 
100 % ethanol. Following mixing, the tube was incubated at –20°C for 30 min, before 
being centrifuged at 12,000 × g for 5 min at 4°C. The RNA pellet was washed with 
500 µl of 70 % ethanol, centrifuged again, and air-dried for 10–20 min before being 
resuspended in 25 µl nuclease-free water. 
 
2.2.4 Reverse Transcriptase reaction 
The “Platinum Taq” kit from Applied Biosystems was used.  
The following were mixed in 0.5 ml microcentrifuge tubes: 
10 µl buffer, 22 µl MgCl2, 20 µl dNTP, 2.5 µl oligo-dT, 2.5 µl random hexamers,  
2 µl RNase inhibitor, 2.5 µl Reverse Transcriptase, 2 µg RNA sample (volume 
dependent on sample concentration), nuclease-free water to 100 µl. 
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The tubes were incubated in a thermal cycler as follows: 
25°C for 10 min 
48°C for 30 min 
95°C for 5 min 
4°C until tubes removed 
If not used immediately cDNA was stored at –80°C. 
 
2.2.5 Polymerase Chain Reaction (PCR) 
PCR was carried out on the cDNA samples using “Platinum Taq” DNA polymerase 
from Invitrogen, according to the manufacturer’s instructions. The same primers were 
used for all three species, with the exception of PDE4C, where different primers for 
human and rodent were used. Primers were supplied by Sigma-Genosys. Primers were 
designed by Sarah Able of Pfizer using areas of low homology between receptor 
subtypes; primer sequences were then checked for specificity against known 
sequences to exclude matches against non-target genes. Primer sequences were as 
follows (all 5′–3′, F=forward primer, R=reverse primer):  
 
PDE1A (F) CCACTTTGTGATCGGAAGTC 
PDE1A (R) TTCTGCTGAATGATGTCCACC 
PDE1B (F) CAGGGTGACAAGGAGGCAGAG 
PDE1B (R) GACATCTGGTTGGTGATGCC 
PDE1C (F) TCTCAAAGGATGACTGGAGG 
PDE1C (R) GCTTCTCTGTCACCCTGTC 
PDE2A (F) CCTCCTGTGACCTCTCTGACC 
PDE2A (R) TGAACTTGTGGGACACCTTGG 
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PDE3A (F) TCACAGGGCCTTAACTTACAC 
PDE3A (R) GGAGCAAGAATTGGTTTGTCC 
PDE3B (F) CCTCAGGCAGTTTTATACAATG 
PDE3B (R) TGCTTCTTCATCTCCCTGCTC 
PDE4A (F) GTGGAGAAGTCTCAGGTGGG 
PDE4A (R) TGGAACTTGTCAGGCAGGG 
PDE4B (F) TAGAAGATAACAGGAACTGG 
PDE4B (R) GCAATGTCTATGTCAGTCTC 
PDE4C (rodent) (F) ACGTGGCGTACCACAACAGC 
PDE4C (rodent) (R) TACCGCGAGGTGATGGTTCTC 
PDE4C (human) (F) TGATCTGAGCAACCCCACCAAG 
PDE4C (human) (R) GGTGAGGTCTGAGGGACTTCG 
PDE4D (F) GGATAATGGAGGAGTTCTTCC 
PDE4D (R) CGATTGTCCTCCAAAGTGTCC 
PDE5A (F) CCCTGGCCTATTCAACAACGG 
PDE5A (R) GTGGGTCAGGGCCTCATACAG 
PDE7A (F) TGGACAAGCCAAGTGTATGCTG 
PDE7A (R) TTTAAGTAACAGTGCATGGCC 
 
Expected sizes of PCR products were as follows: 
PDE1A: ~300 base pairs 
PDE1B: 300-350 bp 
PDE1C: 200-250 bp 
PDE2A: 250-300 bp 
PDE3A: ~350 bp 
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PDE3B: 350-400 bp 
PDE4A: ~200 bp 
PDE4B: ~200 bp 
Rodent PDE4C: ~250 bp 
Human PDE4C: ~300 bp 
PDE4D: ~200 bp 
PDE5A: ~170 bp 
PDE7A: ~250 bp 
 
The reaction was carried out in a thermal cycler as follows:  
94°C for 2 min 
Then the following steps for 34 cycles: 
94°C for 30 s 
55°C for 30 s 
72°C for 1 min 
PCR products were used immediately or stored overnight at 4°C before use. 
 
PCR products were run on a 1.2 % agarose gel at 120 mA for approximately 60 min, 
and visualised under ultraviolet light using ethidium bromide staining. 
 
2.2.6 PCR controls 
β-actin primers were used as a standard positive control, due to the ubiquitous nature 
of β-actin expression. A negative control was included that used water in place of 
cDNA, with β-actin primers; this controlled for the possibility that the PCR reaction 
components might themselves generate positive results in the absence of cDNA. A 
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further control used some of the total RNA sample (where still available) in place of 
cDNA. This was to check that the RNA had not been contaminated with genomic 
DNA that could then contaminate the cDNA, giving rise to false positives. RNA 
controls were run after the first main PCR runs, and used PDE4D primers following 
the discovery that PDE4D was clearly expressed in all species. It was felt that it was 
not practical (or possible in the case of the RNA control), to run controls against all 12 
PDE isoforms, and that this would complicate procedures unnecessarily. 
 
2.3 PDE activity using a scintillation proximity assay (SPA) 
All procedures involving protein solutions were carried out on ice unless otherwise 
indicated. 
 
2.3.1 Cell lysis 
Frozen cardiomyocyte pellets (see section 2.1.5) were resuspended in 500 µl ice-cold 
lysis buffer (120 mM Hepes, 1 mM EDTA, 250 mM sucrose, 0.1 % v/v Triton-X-100, 
“Roche Complete Protease Inhibitor cocktail”, pH 7.4) and subjected to 
homogenisation with a Dounce glass homogeniser, followed by sonication for 5 s. 
These two procedures ensured that the cardiomyocytes (possessing greater mechanical 
strength than many other cell types) would be sufficiently lysed; the inclusion of 
Triton-X-100 detergent solubilised membrane proteins. The lysate was centrifuged at 
10,000 × g and 4°C for 10 min to remove insoluble cellular debris, and the 
supernatant retained. The supernatant formed the cardiomyocyte lysate that was the 
subject of experimentation subsequently. 
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2.3.2 Protein determination 
Protein concentration in the cardiomyocyte lysate was determined using the Biorad 
DC protein assay kit as per manufacturer’s instructions. The method used is similar to 
the Lowry method, and uses the reaction of the protein with Folin reagent and an 
alkaline copper tartrate solution to produce a colour whose absorbance is read at  
750 nm (http://www.bio-rad.com/LifeScience/pdf/Bulletin_9005.pdf). 
 
2.3.3 FPLC 
Fast Protein Liquid Chromatography (FPLC) is a powerful technique used for a 
separating and purifying mixtures of proteins for further analysis. We used an anion-
exchange column (Amersham Hi-Trap Q HP) to separate proteins on the basis of their 
charge. The column contains a large number of positive charges which bind all the 
proteins in the sample. The column is then washed through with a steadily increasing 
salt concentration. The negative charges in the salt out-compete those on the proteins 
for affinity with the column, causing the proteins to become unbound and to elute 
from the column. Those proteins most weakly bound elute first. 
 
2.3.3.1 FPLC procedure 
Two buffers, A and B, were used.  
Buffer A: 20 mM Hepes, 1 mM EDTA, pH 7.4.  
Buffer B: as A, with the addition of 1 M NaCl. 
Both buffers were filtered through a 0.22 µm filter before use. 
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The FPLC system was housed and run in a cold-room at 4°C. Samples of 
cardiomyocyte lysate were diluted in buffer A to approximately 2 ml in order to 
provide adequate volume for loading onto the FPLC column (approximately 0.25–1 
mg protein were loaded). The FPLC system was primed with buffers A and B, and the 
column washed through with several volumes of buffer A before starting. The sample 
was loaded onto the sample loop via a syringe, taking care not to introduce any air 
into the system. 
 
The FPLC system was computer-controlled and programmed to elute 95 × 1ml 
fractions over a continuous gradient from 0-100 % salt (produced by steadily 
increasing the ratio of buffer B to buffer A, until 100 % buffer B is flowing through 
the column). Two runs were also made using a two-step gradient over 130 × 1 ml 
fractions, whereby 0–50 % buffer B was used over fractions 1–100 before the gradient 
changed to 50–100 % buffer B over fractions 100–130. The two-step gradient uses a 
shallower salt gradient over the first 100 fractions (where the majority of PDE activity 
lies) in order to increase the separation and thus resolution of the PDE activity peaks 
in these fractions. Eluted fractions were collected automatically in a carousel-style 
fraction collector, and transferred to 96-well blocks at the end of the run. The sample 
blocks were stored at –80°C until use. 
 
2.3.3.2 Preparation of dog ventricle homogenate 
Dog ventricular tissue was placed in ice-cold homogenisation buffer (20 mM Hepes, 1 
mM EDTA, 250 mM sucrose, “Roche Complete Protease Inhibitor Cocktail”, pH 7.4) 
and homogenised on ice using a Polytron tissue homogeniser. The homogenate was 
sonicated and poured through gauze before being centrifuged at 100,000 × g for  
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60 min at 4°C in a Sorvall Ultracentrifuge. The pellet was discarded and the 
supernatant filtered through a 0.22 µM filter before use. 
 
2.3.4 SPA protocol 
A scintillation proximity assay was used to measure the amount of PDE activity in 
both eluted FPLC fractions and unfractionated whole-cell cardiomyocyte lysates. The 
SPA measures the conversion of 3H-radiolabelled cyclic-AMP or cyclic-GMP to the 
corresponding linear 5′-mononucleotides by any PDE activity present in the sample. 
SPA beads specific to the PDE assay are used (Amersham). The beads bind 
3H-5′AMP or -5′GMP produced by PDE activity; when this occurs, the radiolabel is 
brought into close proximity with a scintillant in the bead, transferring energy via 
radioactive decay which excites the scintillant, causing it to emit light which is 
detected by a standard scintillation counter. Unbound radiolabel remains too far from 
the bead to excite the scintillant. The amount of light emitted is thus proportional to 
the amount of labelled 5′-AMP or 5′-GMP products in the sample. The beads are 
composed of yttrium silicate, which in the presence of zinc sulphate (added by the 
manufacturer) preferentially binds linear nucleotides compared to cyclic nucleotides. 
The assay cannot distinguish between cAMP and cGMP breakdown, and so cAMP-
PDE and cGMP-PDE activity must be measured separately. The presence and activity 
of specific PDE isoforms can be inferred by the use of isoform-specific PDE 
inhibitors – the sample or fraction is assayed multiple times simultaneously with 
vehicle and PDE inhibitors, comparisons are then made between the total PDE 
activity shown with vehicle only, and the reduced activity in the presence of a PDE 
inhibitor. 
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The SPA was carried out in white 96-well plates. In the case of the eluted FPLC 
fractions, this allowed all 95 to be assayed simultaneously. Where cell lysate was 
used, each measurement was carried out in duplicate and the mean of the results used 
in analysis. Each well contained the following: 20 µl assay buffer (20 mM 
Tris[hydroxymethyl]methylamine, 5 mM MgCl2, pH 7.4), 0.01 % w/v BSA, 5 µl 
DMSO/PDE inhibitor, 25 µl sample (eluted fraction or cell lysate), 50 µl cAMP or 
cGMP substrate (a mixture of 3H-labelled and unlabelled cAMP or cGMP (all from 
Sigma) to give 0.5 µM cAMP or cGMP, with 0.1 µCi radioactivity).  
 
Stock 3H-cAMP had a specific activity of 20.0 Ci/mmol. Stock 3H-cGMP had a 
specific activity of 15.1 Ci/mmol. Blank (control) values for each assay were obtained 
by omitting any sample from two wells; this gave a measurement of the non-specific 
radioactivity not due to any PDE activity. 
 
Cell lysate fractions were diluted using assay buffer. A number of experiments were 
carried out to optimise dilutions (detailed in the results chapter). 
 
PDE inhibitors were prepared in DMSO and diluted to the following final (in-well) 
concentrations: UK90234 (PDE1i) 1 µM, EHNA (PDE2i) 10 µM, cilostamide 
(PDE3i) 1 µM, rolipram (PDE4i) 10 µM, UK114542 (PDE5i) 0.1 µM, BRL50481 
(PDE7i) 10 µM, IBMX (non-specific PDEi) 100 µM. 
 
Plates were shaken at 30°C for 30 min, before the addition of 50 µl/well PDE-SPA 
beads. Plates were shaken for a further 20 min at 30°C. Shaking was stopped and the 
plates allowed to rest for 30 min (to enable settling of well contents) at 30°C; plates 
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were then read on a TopCount scintillation counter. Initial data readout from the 
scintillation counter was in counts per minute (CPM). 
 
This protocol had been used successfully at Pfizer on a number of occasions, with 
results known to be obtained using the PDE1, PDE3 and PDE4 inhibitors listed 
above. As this work had not to our knowledge been carried out on isolated 
cardiomyocytes previously, we wanted to keep to a minimum the number of changes 
made. 
 
2.3.5 Analysis of SPA data from FPLC 
Graphs derived from FPLC data showed CPM measurements to provide a direct 
visual comparison of the activity levels in each fraction.  
 
2.3.6 Analysis of SPA data from whole-cell lysate assays 
We measured both the total cAMP-PDE or cGMP-PDE activity, and the activity in 
the presence of specific PDE inhibitors. The value for non-specific radioactivity was 
subtracted from each result (this value was obtained by averaging the CPM from two 
blank wells in each SPA from which the cardiomyocyte sample itself was omitted; 
this gave a value for how much radioactivity was due to non-specific linear nucleotide 
binding to the SPA beads). PDE activity in the presence of a PDE inhibitor was 
normalised to percentage of the total activity; this allowed PDE activity to be 
compared between species. 
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PDE activity could also be expressed in absolute terms as pmol cyclic nucleotide 
converted per minute per mg protein (pmol/min/mg). This required conversion of the 
measured CPM values to the actual disintegrations per minute (DPM) values. The 
difference between CPM and DPM is due to the inability of any scintillation counter 
to detect every single radioactive disintegration. Conversion from CPM to DPM was 
done using the formula CPM / efficiency = DPM. The efficiency of the TopCount for 
measuring tritium had been determined to be 30 % by measuring known standards. 
 
Further details are given in chapter three. 
 
2.4 Cell contraction 
Cell contraction experiments were carried out using custom myocyte baths which 
allowed cells to be kept at a constant temperature and continuously superfused with 
oxygenated buffer. Myocytes were stimulated electrically to contract, and a computer-
linked digital camera allowed the length of contracting individual myocytes to be 
measured and recorded. 
 
2.4.1 Apparatus setup 
2.4.1.1 Cell bath 
A drop of isolated myocyte suspension was placed into a central well in a specially-
constructed myocyte bath on the stage of an inverted Nikon microscope. The well was 
approximately 10.0 × 2.5 × 6.5 mm in dimension, the bottom formed by a glass 
coverslip. The coverslip overlapped the edges of the well, allowing it to be fixed to 
the bath using silicone grease. The coverslip was untreated, and the myocytes adhered 
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solely through simple electrostatic interactions, allowing them to freely contract. The 
coverslip was removed and discarded following each experiment in order that new 
cells could be used each time. The myocytes were allowed to settle and adhere to the 
coverslip for a maximum of 10 min before buffer flow was re-established. Settling 
times were a compromise between the need to have cells firmly attached to the 
coverslip and the fact that the pH in the bath will drop when the Krebs is no longer 
being circulated (constant gassing of Krebs with 95 % O2 / 5 % CO2 is required to 
maintain pH). Platinum electrodes inside the bath provided pacing. 
 
2.4.1.2 Superfusion and temperature 
Cardiomyocytes were superfused with Krebs, gassed with 95 % O2 / 5 % CO2 in order 
to ensure an oxygenated solution at physiological pH, 7.4. The flow rate was  
1.5–2 ml/min, verified before each experiment, generated by a peristaltic pump. 
Superfusate entered the bath via an orifice at one end of the central well; after flowing 
through the well, superfusate was removed via a vacuum pump and directed into a 
waste bottle for later disposal. The superfusate was not re-circulated at any time. The 
superfusate was heated to the desired temperature via an electric heater through which 
the superfusate passed before entering the bath. A thermocouple connected to the 
heater provided feedback control to keep the temperature constant. The temperature 
inside the bath was measured before each experiment using a second thermocouple 
(an automatic feedback system that constantly measured the temperature within the 
bath was not possible, as the electrical pulses used to pace the cells would interfere 
with the thermocouple signal). 
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Rat and guinea pig cardiomyocytes were superfused at 36.5 ± 0.5°C, human 
cardiomyocytes at 32.0 ± 0.5°C. Previous experiments in this laboratory have shown 
that isolated human cardiomyocytes develop greater amplitude at 32°C than 37°C, so 
using this lower temperature greatly increases the proportion of cells available for 
contraction experiments. 
 
2.4.1.3 Pacing 
Cardiomyocytes were paced using a biphasic electric pulse at 50 V, the biphasic 
nature shown to reduce the accumulation of detrimental electrolytic products. Rat 
cells were paced with a pulse width of 0.5 ms at a frequency of 0.5 Hz, guinea pig 
cells with 1 ms at 0.5 Hz, and human cells with 2 ms at 0.2 Hz. Pulse width was kept 
as low as possible to reduce the production of electrolytic products. Human 
cardiomyocytes used historically in this laboratory have mostly been from failing 
heart, but some have also come from non-failing donor heart. Non-failing 
cardiomyocytes show an increase in contraction amplitude in response to an increase 
in pacing frequency. This “force-frequency” relationship is not seen in failing 
cardiomyocytes, but it has been found that at 0.2 Hz there is no significant difference 
in contraction amplitude between failing and non-failing cardiomyocytes (Davies et 
al. 1995). 
 
2.4.2 Criteria for cardiomyocyte selection 
It was important to select cells for experimentation that had survived the isolation 
process and did not appear damaged. Cardiomyocytes had to be rod-shaped and 
lacking any signs of hypercontracture – hypercontracted cells have contracted 
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excessively such that they have suffered mechanical damage to the myofilaments and 
are no longer representative of normal cardiomyocytes. Damage to the sarcolemma 
may disrupt the ionic gradients across the membrane, leading to excess calcium 
accumulation within the cell, triggering the excessive contraction of the calcium-
sensitive myofilaments. Fully hypercontracted cells have a rounded appearance quite 
unlike healthy cardiomyocytes, but cells may also show lesser degrees of 
hypercontracture, manifested by distinct rounded or curled ends. Clearly defined 
edges were required for cell tracking (see below), and cells had to be contracting 
along their long axis in order for accurate length measurements to be taken. 
 
Once a cardiomyocyte had been chosen according to the criteria above, tracking was 
established and a minimum of 10 min allowed to elapse before beginning an 
experiment. This ensured that the contraction amplitude was stable, and that the 
relaxed length of the cell was not altering over time. 
 
No other selection criteria were applied to the cardiomyocytes, those that were being 
only to avoid hypercontracted (damaged) cells and ensure that adequate tracking was 
possible. This minimised the potential for selection bias, although it cannot be 
discounted that the isolation process itself may induce some unintended bias whereby 
certain cells survive isolation more readily than others. 
 
2.4.3 Measurement of cell contraction 
The contraction amplitude (percentage shortening) of individual contracting 
cardiomyocytes was measured using a computerised system from IonOptix 
Corporation (Milton, MA, USA). 
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The image of a single contracting cardiomyocyte was captured in real-time by a 
digital camera and sent to the IonOptix software programme. Focusing and light 
levels were adjusted to maximise the contrast between the cardiomyocyte edges and 
the surrounding image. The software was then able to track the moving edges of the 
cardiomyocyte as the cell contracted and relaxed. This gave a continuous trace of cell 
length, with downward peaks corresponding to each contraction. Cardiomyocyte 
contractility under a given set of experimental conditions was determined by 10–15 
contractions from a steady-state period. Subsequent analysis using IonOptix software 
calculated baseline cell length, percentage shortening (the reduction in cell length at 
maximum contraction amplitude, expressed as a percentage of total cell length), time 
to peak of contraction (TTP), time to 50 % relaxation (R50) and time to 90 % 
relaxation (R90). 
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Figure 2.1 Example Ionoptix trace showing stable rat cardiomyocyte 
contractions 
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Figure 2.2 Example single-contraction traces, inverted to show the increase in 
percentage shortening seen with IBMX 
 
[Base Traces] Edge-Length : Length
Le
ng
th
s
320
340
360
380
400
100 200 300 400 500  
Figure 2.3 Example contraction trace, showing how an increase in cardiomyocyte 
percentage shortening appears during an experiment 
Trace shows an increase in rat cardiomyocyte percentage shortening following 
stimulation with isoprenaline and PDE inhibitors. Absolute cell length is measured. 
The top of the trace represents the relaxed cell length; each contraction produces a 
decrease in length and a corresponding downward peak. With an increase in 
percentage-shortening, the downward peaks for each contraction grow larger, while 
the relaxed length remains nearly unchanged. 
basal
max IBMX
0.5s 
5% Rat 
Guinea pig
0.5s 
5% 
Human
0.5s 
5% 
 73
2.4.4 General experimental protocol 
Experimental drugs were diluted in the superfusate as required to achieve the desired 
concentration. Cardiomyocyte percentage shortening was monitored for a minimum 
period of 5 min in the case of isoprenaline, and 10 min in the case of PDE inhibitors, 
or until stable following any changes. If percentage shortening remained unchanged 
after the minimum period, it was assumed that there was no effect at that 
concentration, and the drug concentration was increased or the experiment terminated. 
 
Experiments were terminated by washing with Krebs. This removed the drug(s) from 
the bath, allowing percentage shortening to return to basal levels. Failure to return to 
basal could indicate that a change in percentage shortening had been spontaneous, and 
so results were discarded if this occurred. Experiments were also terminated if a cell 
became irreversibly arrhythmic, contracting at a high frequency in the absence of 
stimulation. In the case of positive inotropic effects, such as with isoprenaline, the 
point at which a cell became arrhythmic was deemed to be the point at which it had 
reached its maximum percentage shortening, indicating that the drug concentration 
should not be increased further, and that the experiment should be terminated by 
washout. 
 
2.4.5 PDE inhibitors 
The following PDE inhibitors were used in contractility experiments: IBMX (non-
specific PDEi, Sigma), UK90234 (PDE1i, Pfizer), milrinone (PDE3i, Tocris), 
cilostamide (PDE3i, Tocris), rolipram (PDE4i, Tocris), UK114542 (PDE5i, Pfizer). 
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PDE inhibitors were initially dissolved in DMSO before further dilution in Krebs 
buffer. Maximum final DMSO concentration was 0.1 % unless otherwise indicated. 
 
Early experiments used concentration-response curves in the approximate range  
10-9 M to 10-4 M to determine the inhibitor concentrations needed to affect 
cardiomyocyte percentage shortening (if possible). Any subsequent experiments in 
which single concentrations of PDE inhibitor(s) were applied used concentrations 
where PDE specificity was maintained. In the case of UK 90234 and especially UK 
114542, information on specificity gained in chapter three determined the 
concentrations used in later functional studies. 
 
The concentrations of PDE inhibitors used in this thesis are in line with those used by 
other investigators in previously published work (see relevant chapters). 
 
2.5 Human Embryonic Stem Cell-derived Myocytes (hESCMs) 
2.5.1 Human Embryonic Stem Cell culture and differentiation 
All culture work on embryonic stem cells (ESC) was carried out by Nadire Ali and 
Jamie Wright at the National Heart and Lung Institute. 
 
Human ESC (H7 line), supplied by Geron Corporation (Menlo Park, CA), were 
maintained under feeder cell–free conditions on Matrigel-coated 6-well plates in 
mouse embryonic fibroblast-conditioned medium (MEF-CM), supplemented with  
8 ng/ml recombinant basic human fibroblast growth factor (bFGF). Cells were fed 
daily by complete media change. The procedures for preparation of the MEFs, 
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MEF-CM, subculturing and differentiation of H7 cells were as described by Geron 
(http://www.geron.com/PDF/scprotocols.pdf), with the exception of mouse strain used 
(MF-1 mouse, instead of CF-1), and the method of mitotic inactivation of MEFs 
(treatment with 0.01 mg/ml mitomycin C instead of irradiation). Briefly, following 
isolation and expansion in culture, MEFs were mitotically inactived at passage 3. 
After overnight attachment of 12 million inactive MEFs onto pre-gelatinised T225 
flasks in 10 % FCS, medium was replaced by “human ES medium” containing 20 % 
knockout serum replacement (KOSR), 1mM L-glutamine, 10mM non-essential amino 
acids (1 % of stock), 0.1 mM β-mercaptoethanol, antibiotics (50 U/ml penicillin, 50 
µg/ml streptomycin) and 4 ng/ml bFGF. Collections of 150 ml of MEF-CM were 
made daily for a week. Undifferentiated H7 cells were fed each day with filtered 
MEF-CM which was further supplemented with 8 ng/ml human bFGF. Prior to 
subculturing or induction of differentiation, the latter usually one week following 
subculturing, spontaneously differentiated fibroblast-like cells amongst the ESC 
colonies were removed by 10 min collagenase treatment at 37°C. H7 embryoid bodies 
(EBs) were made by mechanically breaking the hESC colonies (scraping with the tip 
of a 5-ml pipette), followed by culturing for 4 days in suspension (in low-adherence 
6-well plates) in hESC differentiation medium (20 % FCS; without bFGF). The 
differentiation medium contained 80 % KO-DMEM, 1 mM L-glutamine, 0.1 mM  
ß-mercaptoethanol,  10 mM non-essential amino acids, and 20 % non-heat-inactivated 
FCS. Spontaneous cardiac differentiation was initiated by inducing EB (embryoid 
body) formation from undifferentiated hESC. After four days of culturing in 
suspension, EBs were plated out onto 0.5 % gelatin-coated glass coverslips. From day 
9–12 following induction of differentiation, spontaneously beating cardiomyocytes 
emerged as rhythmically contracting clusters in the outgrowths of differentiating EBs. 
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Although only a very few (approximately 1–2 %) EBs with beating areas were seen at 
d9, this increased dramatically (70–80 %) by d15-d16. Contracting cells are present in 
long-term cultures up to 6 months following differentiation (the longest time cultured 
so far by this laboratory). The cardiac cell nature of the beating areas has been 
confirmed by immunostaining with an antibody that recognizes both α- and β-cardiac-
specific myosin heavy chains (MHC).  
 
2.5.2 Contractility experiments on hESCMs 
Contractility experiments using hESCMs measured the spontaneous beating rate of a 
given beating cardiac cell cluster; for this reason, no electrical stimulation was 
required. The apparatus, methodology and experimental conditions were near 
identical to those used with adult ventricular myocytes. A glass coverslip onto which 
was adhered a beating cluster of hESCMs was placed in a cell bath and superfused 
with Krebs buffer exactly as described above. The superfusate was heated to 32°C to 
match the conditions used with adult human ventricular myocytes. Coverslips were 
left to equilibrate with the circulating superfusate for a minimum of 30 min before any 
experiments were carried out. Cover slips could be removed from the cell bath 
following an experiment and replaced in culture, allowing multiple experiments to be 
performed on the same cardiac cell cluster. Upon removal from the cell bath, cover 
slips were washed twice in PBS at room temperature, and replaced into a culture well 
containing freshly prepared culture medium. 
 
Beating rate was measured by tracking the cluster in the same manner as for adult 
ventricular myocytes. In the case of hESCMs, individual cells are not tracked; rather 
the entire synchronised beating cluster is tracked. The clusters have an amorphous 
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shape, and tracking required that a high-contrast part of the cluster could be identified 
that was moving with each beat. To aid in this process, the clusters were seeded with 
5–30 µm particles of inactivated charcoal to provide high contrast points for tracking. 
Due to the spontaneous beating of the clusters, electrical pacing was not required. The 
experimental protocol was as described above. 
 
2.6 Statistical analysis 
All data values are quoted as mean ± S.E.M. (standard error of the mean). GraphPad 
Prism software was used for statistical analysis of results, including calculation of 
means and standard errors.  
 
GraphPad Prism was used to fit sigmoidal dose-response curves with a variable slope 
to appropriate data sets using non-linear regression. Parameter values for the top and 
bottom of the curve were not fixed unless stated otherwise. EC50 values (the 
concentration of drug or inhibitor producing 50 % of the maximal effect) were 
calculated by the curve-fitting program, as were 95 % confidence intervals and other 
statistical data. 
 
The F-test was used where appropriate to compare concentration-response data and 
determine if two data sets were significantly different. When discussing 
concentration-response curves, maximum percentage shortening is given as the actual 
mean ± S.E.M. of the individual maximum responses measured in each repetition of 
the experiment, rather than the value calculated by non-linear regression as the 
theoretical maximum of the concentration-response curve.  
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Student’s t-test was used to compare data in the form of two columns only (for 
example the effect on cardiomyocyte contractility of the addition of a single 
compound). Data in the form of multiple columns (such as contractility experiments 
involving the sequential addition of multiple compounds) were analysed using one-
way ANOVA; matched data used one-way ANOVA repeated measures, unmatched 
data did not have the repeated measures test applied. Bonferroni’s post test was used 
with both types of one-way ANOVA to determine if there were statistically 
significant differences between tested columns. Paired tests were used wherever 
appropriate. In all tests, P-values less than 0.05 were taken to be statistically 
significant. 
 
2.7 Materials 
2.7.1 Digestion enzymes 
 Protease: Type XXIV bacterial proteinase, Sigma, P8038-1G. 
 Collagenase (rat / guinea pig digestion): CLS2, Lorne disagnostic, LS04176. 
 Collagenase (human digestion): Collagenase Type V, Sigma, C9263. 
 Hyaluronidase: Sigma, H3506. 
 
2.7.2 PDE inhibitors: IUPAC names and suppliers 
 IBMX (3-isobutyl-1-methylxanthine), non-specific PDEi, Sigma.  
 UK90234 (5-[[4-(diethylamino)phenyl]methyl]-1,4-dihydro-1-methyl-3-
propyl-7H-Pyrazolo[4,3-d]pyrimidin-7-one), PDE1i, Pfizer.  
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 EHNA (erythro-9-[2-Hydroxy-3-nonyl]adenine hydrochloride), PDE2i, 
Tocris.  
 Cilostamide (N-Cyclohexyl-N-methyl-4-[1,2-dihydro-2-oxo-6-
quinolyloxy]butyramide), PDE3i, Tocris.  
 Milrinone (1,6-dihydro-2-methyl-6-oxo-(3,4’-bipyridine)-5-carbonitrile), 
PDE3i, Tocris.  
 Rolipram (4-[3-[Cyclopentyloxy]-4-methoxyphenyl]pyrrolidin-2-one), PDE4i, 
Tocris.  
 UK114542 (5-[2-ethoxy-5(morpholinylacetyl)phenyl]-1,6-dihydro-1-methyl-
3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one methanesulphanate 
monohydrate), PDE5i, Pfizer.  
 BRL50481 (N,N,2-Trimethyl-5-nitro-benzenesulfonamide), PDE7i, Tocris. 
 
2.7.3 β-adrenergic receptor antagonists 
CGP 20712A, β1AR antagonist, Sigma-Aldrich. 
ICI 118551, β2AR antagonist, Sigma-Aldrich. 
 
2.7.4 Protease Inhibitor Cocktail 
Roche, Cat. No. 04 693 124 001. Inhibits a broad spectrum of serine, cysteine and 
metalloproteases as well as calpains. 
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2.7.5 Suppliers 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
 
Tocris Bioscience 
Tocris House 
IO Centre 
Moorend Farm Avenue 
Avonmouth 
Bristol 
BS11 0QL 
 
Roche Diagnostics Ltd 
Charles Avenue 
Burgess Hill 
West Sussex 
RH15 9RY 
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CHAPTER 3 PDE EXPRESSION AND ACTIVITY IN 
ISOLATED CARDIOMYOCYTES 
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3.1 Introduction 
The aim of the work detailed in this chapter was to obtain a definitive picture of the 
PDEs both expressed and active in cardiomyocytes and eliminate the uncertainty that 
has long surrounded this issue, in particular the presence or absence of PDEs other 
than PDE3 and PDE4. Multiple approaches are required to achieve this aim and 
provide the most complete picture. We used Reverse Polymerase Chain Reaction 
(RTPCR) to look at PDE gene expression (section 3.2) and a Scintillation Proximity 
Assay (SPA) to examine PDE protein activity. We initially investigated the use of 
Fast Protein Liquid Chromatography (FPLC) to fractionate the PDE activity in 
cardiomyocyte lysates, followed by SPA to measure PDE activity (section 3.3). 
Following difficulties with the FPLC procedure, we used the SPA directly on 
unfractionated cell lysates (section 3.4). 
 
By examining levels of mRNA transcripts, RTPCR reveals which genes are actively 
being transcribed in the cell, and allows for a basic comparison of the relative levels 
of transcription. This highly sensitive technology enables the useful analysis of the 
small amount of mRNA that can be recovered from isolated cardiomyocytes, and was 
used to provide a comparison to the data gained from the SPA work. The ability to 
design primers for specific genetic sequences means that it is possible to study PDE 
expression on the level of different isoforms of the same PDE family (for example, 
PDE1A, 1B etc). 
 
The SPA by contrast relies on the use of pharmacological inhibitors to identify PDE 
activity. This can only discriminate between members of different PDE families, as at 
present no inhibitors exist with specificity sufficient to differentially target members 
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of the same PDE family. However, the information on enzyme activity is of great 
importance, as it is actual PDE activity that determines the effect on cardiomyocyte 
function. Together, information on PDE expression and activity proves highly 
complementary. 
 
The work presented in this chapter was carried out by myself at the laboratories of 
Pfizer Global Research and Development in Sandwich, Kent. 
 
3.2 RTPCR 
RTPCR was carried out as described in chapter two. Analysis was carried out on n=5 
samples of rat cardiomyocytes, and n=4 samples of guinea pig and human 
cardiomyocytes. All human samples used cardiomyocytes isolated from explanted 
failing heart, three from right ventricle and one from left ventricle. This was dictated 
by sample availability and by the need to have as large a number of cells as possible, 
due to the minimal amounts of total RNA that could be recovered; myectomy samples 
proved too small to yield practical amounts of RNA. 
 
DNase treatment of total RNA was carried out on one sample from each species. 
Previous experience in the Pfizer laboratory had shown that DNase treatment can lead 
to significant loss of RNA (approaching 50 % of the sample) and as such it was not 
felt that it was appropriate to use this procedure on all samples due to the minimal 
amounts of RNA recovered in each case. Controls for genomic contamination of total 
RNA were also carried out where sufficient RNA remained once it had been used for 
the cDNA reaction. 
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PCR primers were designed by Sarah Able of Pfizer, using published PDE sequence 
data. The same primers were used for all three species, with the exception of PDE4C 
which used separate human and rodent primers. A lack of available data on guinea pig 
PDE sequences meant that a generic rodent sequence was used. PDE7A primers were 
purchased after some initial RTPCR runs had already been made. The cDNA reaction 
produces enough cDNA for multiple PCR runs, and so it was possible to carry out 
PCR for PDE7A on cDNA samples that had already been used for the initial runs. In 
these cases it can be seen that the PDE7A band comes from a separate gel; PDE4D 
was run at the same time as a positive control on these gels [figures 3.1–3.3]. All 
bands identified were of the expected size. 
 
3.2.1 RTPCR results 
3.2.1.1 Rat 
All five rat samples showed a highly similar pattern of PDE expression [figure 3.1]. 
Expression of all PDE1 isoforms was extremely low, with very little discernable 
signal. PDEs 2A, 4A, 4B and 4D showed the strongest signals, and were clearly 
expressed in each sample. PDEs 3A and 4C were also expressed, although not clearly 
present in each sample. In common with PDE1, PDEs 3B, 5A and 7A showed very 
weak signals with little expression. PDE expression in the sample treated with DNase 
(Rat 4) was unchanged from the untreated samples. 
 
3.2.1.2 Guinea pig 
All four guinea pig samples showed strong signals for PDEs 1C, 2A, 4D, 5A and 7A 
[figure 3.2]. A very weak PDE1B signal could be seen in three of the samples. PDEs  
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Figure 3.1 Rat RTPCR 
RTPCR for PDE expression in five samples of isolated rat ventricular myocytes, all 
from different hearts. 
 
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
300bp
200bp
400bp
 
Rat sample 1. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
 
300bp
200bp
400bp
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
 
Rat sample 2. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
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300bp
200bp
400bp
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
 
Rat sample 3. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
 
 
7A5A4D4C4B4A3B3A2A1C1B1A
300bp
200bp
400bp
 
Rat sample 4. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
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300bp
200bp
400bp
7A5A4D4C4B4A3B3A2A1C1B1A
 
Rat sample 5. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
 
7A4D7A4D7A4D
300bp
200bp
400bp
 
Additional rat PDE7A data. Columns (L-R): 
DNA ladder; rat sample 1 PDE4D (as control), rat 1 PDE7A; rat 2 PDE4D, rat 2 
PDE7A; rat 3 PDE4D, rat 3 PDE7A. 
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Figure 3.2 Guinea pig RTPCR 
RTPCR for PDE expression in four samples of isolated guinea pig ventricular 
myocytes, all from different hearts. 
 
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
300bp
200bp
400bp
 
Guinea pig sample 1. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
 
300bp
200bp
400bp
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
 
Guinea pig sample 2. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
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7A5A4D4C4B4A3B3A2A1C1B1A
300bp
200bp
400bp
 
Guinea pig sample 3. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
 
200bp
400bp
7A5A4D4C4B4A3B3A2A1C1B1A
 
Guinea pig sample 4. Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
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300bp
200bp
400bp
7A4D7A4D
 
Additional guinea pig PDE7A data. Columns (L-R): 
DNA ladder; guinea pig sample 1 PDE4D (control), guinea pig 1 PDE7A; guinea 
pig 2 PDE4D (control), guinea pig 2 PDE7A [other bands from human samples, see 
below]. 
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Figure 3.3 Human RTPCR 
RTPCR for PDE expression in four samples of isolated human ventricular myocytes, 
all from different hearts. 
 
300bp
200bp
400bp
(con-
trol)
5A4D4C4B4A3B3A2A1C1B1A
 
Human sample 1 (right ventricle). Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, β-actin. 
 
300bp
200bp
400bp
7A5A4D4C4B4A3B3A2A1C1B1A
 
Human sample 2 (left ventricle). Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
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300bp
200bp
400bp
7A5A4D4C4B4A3B3A2A1C1B1A
 
Human sample 3 (right ventricle). Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
 
300bp
200bp
400bp
7A5A4D4C4B4A3B3A2A1C1B1A
 
Human sample 4 (right ventricle). Columns (L-R):  
DNA ladder, PDE1A, 1B, 1C, 2A, 3A, 3B, 4A, 4B, 4C, 4D, 5A, 7A. 
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200bp
400bp
7A7A4D7A4D7A4D7A4D
 
Additional human PDE7A data. Columns (L-R): 
DNA ladder; [columns 1-4 – guinea pig]; human sample 1 PDE4D (control), human 1 
PDE7A; human 2 PDE4D, human 2 PDE7A; human 3 PDE4D, human 3 PDE7A; 
human 4 PDE4D, human 4 PDE7A; human 1 PDE7A (repeat). 
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3A–4C showed a complete absence of signal; the lack of even very faint bands 
strongly suggests that the primers did not match the guinea pig PDE sequences. The 
DNase-treated sample (G-pig 4) did not show a different expression pattern for the 
untreated samples. 
 
3.2.1.3 Human 
When compared to the rat and guinea pig samples, increased variation in PDE 
expression was seen between the human samples [figure 3.3]. Furthermore a greater 
range of PDEs was expressed in the human samples, compared to the rat. All samples 
showed expression of PDEs 1C, 3A, 3B, 4B (albeit at a low level in human sample 3, 
from RV), 4D, 5A and 7A (at a low level in human sample 2, from LV). Additionally, 
PDE1A expression was clearly seen in the three RV samples, but not the LV sample. 
PDE1B expression was seen in two samples, both from RV; these same samples also 
showed PDE4C expression. 
 
3.3 Use of FPLC to identify PDE isoforms in isolated 
cardiomyocytes 
FPLC separates the proteins in isolated cardiomyocyte lysates, including all PDEs, on 
the basis of charge, producing multiple fractions. The fractions are assayed for PDE 
activity using an SPA, allowing a graph of activity versus fraction number to be 
plotted. Separation of PDEs should lead to distinct peaks of PDE activity on the 
graph, such that the number of isoforms present can be readily determined. PDE 
isoforms can be identified by assaying the fractions for differential sensitivity to 
isoform-selective PDE inhibitors. Combined with the sensitivity of the radioactivity-
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based SPA, this is a powerful method that shows which PDEs are present in the 
sample as active proteins; RTPCR techniques by comparison can only show which 
PDE mRNAs are present. 
 
An initial pilot FPLC run using isolated human cardiomyocytes had been carried out 
on behalf of our laboratory at Pfizer by Sarah Able. This first attempt had proven 
successful, and so the method was repeated using the same protocol (described in 
chapter two). 
 
Each sample used contained cardiomyocyte protein from one individual heart only 
(cardiomyocytes from different hearts were not combined). 
 
3.3.1 FPLC results 
The soluble fraction of one sample of isolated rat cardiomyocytes was run on an 
FPLC system using the single-step salt gradient (0–100 % salt over 95 fractions). The 
95 eluted fractions were assayed separately for cAMP-PDE and cGMP-PDE activity 
using the SPA [figures 3.4 and 3.5]. 
 
cAMP-PDE activity was confined to one broad peak that was spread from 
approximately fractions 35 to 60, with very little activity measured outside of this 
peak. Maximum activity was approximately 1200 CPM. cGMP-PDE activity showed 
little discernible pattern, with a number of apparent spikes in activity, and no smooth 
transitions between peaks. Maximum activity was higher at approximately 3000 
CPM. 
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Figure 3.4 Total cAMP-PDE activity in rat cardiomyocyte fractions from single-
step gradient FPLC 
Approximately 1 mg of rat cardiomyocyte protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 105600 = total pmols substrate turned over 
per assay well. 
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Figure 3.5 Total cGMP-PDE activity in rat cardiomyocyte fractions from single-
step gradient FPLC 
Approximately 1 mg of rat cardiomyocyte protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 79728 = total pmols substrate turned over 
per assay well. 
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As this first run using rat cardiomyocytes did not yield multiple peaks of PDE 
activity, a sample of dog left ventricle soluble fraction, known to yield PDE1 and 
PDE3 activity, was used as a positive control to determine if the FPLC protocol was 
functioning correctly (dog tissue was used in this context solely as a diagnostic tool). 
Dog left ventricle soluble fraction was run using the single-step gradient [figure 3.6]. 
This run resolved a large peak of PDE activity between fractions 40 and 70, with two 
smaller peaks between fractions 1 and 30. Maximum activity was far higher than with 
the rat, at approximately 30,000 CPM, reflecting the greater amount of protein 
isolated and loaded from the whole dog ventricular tissue. In order to increase the 
resolution of the two lesser peaks, a second sample of dog left ventricle was run using 
the two-step gradient (0–50 % salt over fractions 1–100, 50–100 % salt over fractions 
100–130) [figure 3.7]. This broadened the two early peaks, and in this second run 
their activity was also higher than previously. 
 
Having confirmed with the dog ventricle homogenate that the FPLC protocol was 
indeed capable of resolving separate peaks of PDE activity, a second rat sample was 
run using the two-step gradient to see if this change in protocol could resolve the one 
broad peak of PDE activity seen with the single-step gradient into multiple peaks 
[figure 3.8]. The two-step gradient produced a peak positioned between fractions 65 
and 80 (approximately), with two further spikes between fractions 95 and 105 
(approximately). There was, however, a lack of a smooth gradient between the data 
points. Fractions 37–121 from this run (where PDE activity was located) were then re-
assayed using the following PDE inhibitors: 10 µM UK 90234 (PDE1i), 10 µM 
cilostamide (PDE3i), and 10 µM rolipram (PDE4i). As this was the first such attempt 
using PDE inhibitors, relatively high concentrations of inhibitors were chosen to try  
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Figure 3.6 Total cAMP-PDE activity in dog left ventricle fractions from single-
step gradient FPLC 
Approximately 70 mg of dog ventricular protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 105600 = total pmols substrate turned over 
per assay well. 
 100
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
1 11 21 31 41 51 61 71 81 91 101 111 121
fraction
C
PM
 
Figure 3.7 Total cAMP-PDE activity in dog left ventricle fractions from two-step 
gradient FPLC 
Approximately 70 mg of dog ventricular protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 105600 = total pmols substrate turned over 
per assay well. 
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Figure 3.8 Total cAMP-PDE activity in rat cardiomyocyte fractions from two-
step gradient FPLC 
Approximately 5 mg of rat cardiomyocyte protein was loaded onto an anion-exchange 
column and separated using 0–50 % salt over fractions 1–100, and 50–100 % salt over 
fractions 100–130. Fractions are numbered in order of elution from the column. CPM 
/ 105600 = total pmols substrate turned over per assay well. 
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and guarantee a response, which could be refined using lower inhibitor concentrations 
in subsequent assays if necessary. All inhibitors used had an effect on cAMP-PDE 
activity in the fractions, but there was little specificity, and it was difficult to discern a 
pattern [figure 3.9]. 
 
Having shown that it was in principle possible to lower cAMP-PDE activity in the 
cardiomyocyte fractions, the dog left ventricle fractions were re-assayed to see it was 
possible to use PDE inhibitors to inhibit the specific PDE activity peaks in the eluted 
fractions. Use of the inhibitors at 10 µM having shown possible problems of non-
specificity, 1 µM of both UK 90234 (PDEi) and cilostamide (PDE3i) was used, 
chosen as both PDEs were known to exist in dog left ventricle. There was clear 
inhibition by UK 90234 of two peaks of PDE activity in the first 15 fractions, but 
little effect of cilostamide on the two larger peaks in later fractions [figure 3.10]. 
 
Previous experience in the Pfizer laboratory had shown that in instances where PDE 
inhibitors seemed to have little effect, diluting the fractions 10-fold in assay buffer 
before carrying out the SPA may resolve the problem. This was carried out on the dog 
left ventricle fractions from the single-step gradient FPLC, again using 1 µM UK 
90234 (PDE1i) and 1 µM cilostamide [figure 3.11]. While a greater effect of 
cilostamide was seen, the overall cAMP-PDE activity profile was also altered 
compared with figure 3.7. 
 
A sample of guinea pig cardiomyocyte soluble fraction was separated on a single-step 
gradient. The guinea pig had not been tried before, and so the simplest FPLC protocol 
was used. However, as with the rat there was poor separation, with cAMP-PDE  
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Figure 3.9 cAMP-PDE activity in rat cardiomyocyte fractions from two-step 
gradient FPLC, assayed with PDE inhibitors 
Approximately 5 mg of rat cardiomyocyte protein was loaded onto an anion-exchange 
column and separated using 0–50 % salt over fractions 1–100, and 50–100 % salt over 
fractions 100–130. Fractions are numbered in order of elution from the column. CPM 
/ 105600 = total pmols substrate turned over per assay well. Total cAMP-PDE activity 
achieved in the absence of any PDE inhibitors is marked by the blue diamonds; 
cAMP-PDE activity in the presence of 10 µM of the PDE1 inhibitor UK 90234 is 
marked by the purple squares; cAMP-PDE activity in the presence of 10 µM of the 
PDE3 inhibitor cilostamide is marked by the black triangles; cAMP-PDE activity in 
the presence of 10 µM of the PDE4 inhibitor rolipram is marked by the red crosses. 
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Figure 3.10 cAMP-PDE activity in dog left ventricle fractions from single-step 
gradient FPLC, assayed with specific PDE inhibitors 
Approximately 70 mg of dog ventricular protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 105600 = total pmols substrate turned over 
per assay well. Total cAMP-PDE activity achieved in the absence of any PDE 
inhibitors is marked by the blue diamonds; cAMP-PDE activity in the presence of 
1 µM of the PDE1 inhibitor UK 90234 is marked by the purple squares; cAMP-PDE 
activity in the presence of 1 µM of the PDE3 inhibitor cilostamide is marked by the 
black triangles. 
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Figure 3.11 cAMP-PDE activity in dog left ventricle fractions from single-step 
gradient FPLC, diluted 10-fold, assayed with specific PDE inhibitors 
Approximately 70 mg of dog ventricular protein was loaded onto an anion-exchange 
column and separated using 0–100 % salt over 95 fractions. Fractions are numbered in 
order of elution from the column. CPM / 105600 = total pmols substrate turned over 
per assay well. Total cAMP-PDE activity achieved in the absence of any PDE 
inhibitors is marked by the blue diamonds; cAMP-PDE activity in the presence of 
1 µM of the PDE1 inhibitor UK 90234 is marked by the purple squares; cAMP-PDE 
activity in the presence of 1 µM of the PDE3 inhibitor cilostamide is marked by the 
black triangles. 
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activity spread across one broad peak [figure 3.12]. Those guinea pig fractions which 
had shown cAMP-PDE activity were re-assayed with the specific PDE inhibitors  
1 µM UK 90234 (PDE1i), 10 µM EHNA (PDE2i), 1 µM cilostamide (PDE3i) and  
10 µM rolipram (PDE4i) [figure 3.13]. PDE1 inhibition abolished activity in fractions 
23–37, but also diminished activity in the main peak centred on fraction 43. PDE3 
inhibition had no effect on fractions 23–37, but reduced activity in the main peak 
surrounding fraction 43. PDE4 inhibition had no effect on PDE activity in any 
fraction, whilst PDE2 inhibition with EHNA actually increased PDE activity in 
fractions 23–37.  
 
The guinea pig fractions were also assayed for cGMP-PDE activity, with and without 
1 µM UK 114542 (PDE5i) [figure 3.14]. cGMP-PDE activity was again poorly 
resolved into multiple peaks. Overall activity was much higher compared to cAMP-
PDE activity, with a peak at approximately 40,000 CPM. 1 µM UK 114542 greatly 
reduced cGMP-PDE activity in all fractions where it was present. 
 
3.3.2 Analysis of FPLC results and subsequent switch to whole-cell 
lysate SPA 
It had been hoped that FPLC would unambiguously demonstrate which PDEs were 
present in isolated cardiomyocytes, but this was not the case. It was shown that it was 
possible to retrieve PDE activity from the cardiomyocyte soluble fraction, but passage 
through the FPLC column was not able to clearly resolve this activity into multiple 
separate peaks corresponding to different PDE isoforms. Altering the conditions of 
the FPLC process by using a different salt gradient or diluting the sample had only a 
limited effect. PDE activity was differentially affected across the fractions by specific  
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Figure 3.12 Total cAMP-PDE activity in guinea pig cardiomyocyte fraction from 
single-step gradient FPLC 
Approximately 2 mg of guinea pig cardiomyocyte protein was loaded onto an anion-
exchange column and separated using 0–100 % salt over 95 fractions. Fractions are 
numbered in order of elution from the column. CPM / 105600 = total pmols substrate 
turned over per assay well. 
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Figure 3.13 cAMP-PDE activity in guinea pig cardiomyocyte fractions from 
single-step gradient FPLC, diluted 10-fold, assayed with specific PDE inhibitors 
Approximately 2 mg of guinea pig cardiomyocyte protein was loaded onto an anion-
exchange column and separated using 0–100 % salt over 95 fractions. Fractions are 
numbered in order of elution from the column. CPM / 105600 = total pmols substrate 
turned over per assay well. Total cAMP-PDE activity achieved in the absence of any 
PDE inhibitors is marked by the blue diamonds; cAMP-PDE activity in the presence 
of 1 µM of the PDE1 inhibitor UK 90234 is marked by the purple squares; cAMP-
PDE activity in the presence of 10 µM of the PDE2 inhibitor EHNA is marked by the 
black triangles; cAMP-PDE activity in the presence of 1 µM of the PDE3 inhibitor 
cilostamide is marked by the red crosses; cAMP-PDE activity in the presence of 10 
µM of the PDE4 inhibitor rolipram is marked by the dark purple stars. 
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Figure 3.14 cGMP-PDE activity in guinea pig cardiomyocyte fractions from 
single-step gradient FPLC, assayed with the PDE5 inhibitor UK114542 
Approximately 2 mg of guinea pig cardiomyocyte protein was loaded onto an anion-
exchange column and separated using 0–100 % salt over 95 fractions. Fractions are 
numbered in order of elution from the column. CPM / 79728 = total pmols substrate 
turned over per assay well. Total cGMP-PDE activity achieved in the absence of any 
PDE inhibitors is marked by the blue diamonds; cGMP-PDE activity in the presence 
of 1 µM of the PDE5 inhibitor UK 114542 is marked by the purple squares. 
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PDE inhibitors, demonstrating that some separation of isoforms had occurred, but the 
results were unclear. All PDE inhibitors tested decreased rat cAMP-PDE activity, but 
over a broad spectrum of fractions, rather than concentrated in specific areas or peaks, 
suggesting both a possible lack of specificity at the concentrations used and a lack of 
separation of PDE isoforms. 
 
Guinea pig cAMP-PDE activity was resolved moderately better, and use of PDE 
inhibitors strongly suggested the presence of PDE1 in the lower-numbered fractions 
(corresponding with the results obtained using dog ventricular tissue), and PDE3 in 
the higher-numbered fractions. However, there was no effect of the PDE4 inhibitor 
rolipram, and the PDE2 inhibitor EHNA confounded the results by increasing the 
cAMP-PDE activity in some of the fractions. Guinea pig cGMP-PDE activity was 
also only resolved as one broad peak, all of which was sensitive to inhibition by the 
PDE5 inhibitor UK 114542. This may partly be explained by concurrent PDE1 
inhibition; however, full resolution of the cGMP-PDE activity into separate peaks 
would negate this problem as the different isoforms would be clearly seen. 
 
Having concluded that the FPLC procedure was not producing edifying results, it was 
decided to adopt a more simplified method for assessing the PDE activity in isolated 
cardiomyocytes. The cardiomyocyte soluble fraction was used in the SPA directly, 
bypassing the FPLC fractionation step. The original primary aim of using FPLC had 
been to determine which PDE isoforms were present in isolated cardiomyocytes; 
obtaining quantitative data on PDE activity levels would have been a secondary 
objective. Using the SPA directly (in combination with the use of selective PDE 
inhibitors) would still enable the accomplishment of these objectives. 
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3.4 PDE activity in cardiomyocyte whole-cell lysates 
3.4.1 Method 
Isolated cardiomyocytes were lysed as described in chapter two. Cardiomyocyte 
lysate was first assayed for cAMP-PDE activity over a range of dilutions in assay 
buffer: undiluted, 5×, 10×, 20×, 50×, 100×, and 500×. As noted above, previous 
experience had shown that highly concentrated samples could show lower PDE 
activity than diluted samples, although an explanation for this phenomenon was not 
known. Measuring the PDE activity over a wide range of dilutions allowed any such 
dilution effects to be detected. Where total cAMP-PDE activity was high (over 10,000 
CPM) in the undiluted sample, dilution increased measurable cAMP-PDE activity 
until a point was reached at which further dilution served to decrease cAMP-PDE 
activity again. Further experiments used a dilution that gave cAMP-PDE activities of 
approximately 1500–3000 CPM for each species; this was always on the part of the 
dilution curve where dilution served to decrease PDE activity. This normalised 
samples from different species such that the overall amount of PDE activity present in 
the assay was approximately equal, and matched activity in the guinea pig and human 
samples to the lower activity levels seen in the rat samples. Each measurement in the 
SPA was carried out in duplicate, and the results averaged. 
 
Where the combined effect of all specific PDE inhibitors used was tested, a master 
mix of all the inhibitors together was prepared; concentrations of inhibitors were 
20-fold the final desired concentration, to allow for the dilution in the assay wells. 
This master mix was then added to the assay as required, avoiding the need to add 
each inhibitor individually. 
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Control experiments were carried out in which inhibitors specific for cAMP-PDEs 
only (rolipram, PDE4, and BRL 50481, PDE7) were tested solely against cGMP-PDE 
activity, and inhibitors specific for cGMP-PDEs only (UK 114542, PDE5) tested 
solely against cAMP-PDE activity. This confirmed the specificity of these inhibitors; 
however, this method could not be used with inhibitors that targeted dual specificity 
cAMP/cGMP-PDEs. 
 
Further control experiments were carried out to determine the ideal concentration of 
the PDE5 inhibitor UK 114542 to use. 
 
3.4.2 Whole-cell lysate SPA results 
Table 3.1 SPA for cAMP-PDE activity 
 cAMP-PDE activity remaining,  % of total 
Inhibitor Rat n=5 Guinea pig n=4 Human n=5 
UK 90234 1 µM (PDE1i) 101.9 ± 2.7 32.6 ± 5.7*** 43.5 ± 4.1*** 
EHNA 10 µM (PDE2i) 112.0 ± 3.2 102.3 ± 1.1 109.2 ± 1.4 
Cilostamide 1 µM (PDE3i) 63.8 ± 6.2*** 72.7 ± 3.9** 74.0 ± 3.1*** 
Rolipram 10 µM (PDE4i) 74.5 ± 4.9** 92.8 ± 3.3 88.6 ± 3.9 
BRL 50481 10 µM (PDE7i) 115.1 ± 4.0 103.7 ± 5.4 103.6 ± 3.5 
 
The effect of PDE inhibition on cAMP-PDE activity in cardiomyocyte lysates, displayed as the 
activity remaining following PDEi treatment when compared to the total activity. Results are 
mean ± SEM. Results were analysed for each species using one-way ANOVA (repeated 
measures) with Bonferroni post test comparing all columns. *P<0.05, **P<0.01, ***P<0.001. 
(Comparisons between species are made in figure 3.15) 
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Figure 3.15 SPA for cAMP-PDE activity  
(Note: the negative results for EHNA and BRL50481 are excluded for clarity). Stars 
show statistical significance between species. To determine if any of the differences in 
PDE activity between species were statistically significant, data were analysed with 
one-way ANOVA using Bonferroni’s multiple comparison test for selected columns 
(statistical significance of differences in PDE activity within each species is given in 
the text). *P<0.05 vs. rat, ***P<0.001 vs. rat. 
 
Figures 3.15–3.20: 
Columns show cAMP-PDE / cGMP-PDE  activity in the presence of a given isoform-
specific PDE inhibitor. Activity is expressed as a percentage of the total activity 
measured in the absence of any inhibitors. Data are mean ± S.E.M. 
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Table 3.2 SPA for cGMP-PDE activity 
 cGMP-PDE activity remaining,  % of total 
Inhibitor Rat n=5 Guinea pig n=4 Human n=5 
UK 90234 1 µM (PDE1i) 60.6 ± 2.6** 20.0 ± 4.6*** 15.1 ± 4.4*** 
EHNA 10 µM (PDE2i) 56.1 ± 2.6*** 77.6 ± 3.4** 90.4 ± 2.4 
Cilostamide 1 µM (PDE3i) 60.7 ± 10.4** 89.4 ± 3.6 89.5 ± 2.9 
UK 114542 0.1 µM (PDE5i) 106.4 ± 1.5 81.2 ± 4.9* 80.7 ± 2.7** 
 
The effect of PDE inhibition on cGMP-PDE activity in cardiomyocyte lysates, displayed as the 
activity remaining following PDEi treatment when compared to the total activity. Results are 
mean ± SEM. Results were analysed for each species using one-way ANOVA (repeated 
measures) with Bonferroni post test comparing all columns. *P<0.05, **P<0.01, ***P<0.001. 
(Comparisons between species are made in figure 3.16) 
 
When comparing between species, there were no statistically significant differences 
between guinea pig and human. The PDE activity profile in the rat however, was 
noticeably different from guinea pig and human [figures 3.15 and 3.16]. 
 
In guinea pig and human, PDE1 was the major PDE activity for both cAMP and 
cGMP breakdown. By contrast, in the rat PDE1 inhibition using UK 90234 had no 
effect on cAMP-PDE activity, but did decrease cGMP-PDE activity. No effect of 
PDE2 inhibition using EHNA was seen on cAMP-PDE activity in any of the three 
species, but EHNA did decrease cGMP-PDE activity in rat and to a lesser extent in  
 115
0
25
50
75
100
125
PDE1i, UK90234 1 µM
PDE2i, EHNA 10 µM
PDE3i, cilostamide 1 µM
PDE5i, UK114542 0.1 µM
Rat Guinea pig Human
n=5 n=4 n=5
***
*
**
**
***
***
*** **
%
 o
f t
ot
al
 c
G
M
P-
PD
E
ac
tiv
ity
 r
em
ai
ni
ng
 
Figure 3.16 SPA for cGMP-PDE activity 
To determine if any of the differences in PDE activity between species were 
statistically significant, data were analysed with one-way ANOVA using Bonferroni’s 
multiple comparison test for selected columns (statistical significance of differences 
in PDE activity within each species is again given in the text). *P<0.05 vs. rat, 
**P<0.01 vs. rat, ***P<0.001 vs. rat. 
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guinea pig, but not human. PDE3 inhibition using cilostamide had a similar effect on 
cAMP-PDE activity in all three species, but a greater effect on cGMP-PDE activity in 
the rat. The effects of PDE4 inhibition using rolipram were only significant in rat. 
PDE5 inhibition using UK 114542 had a significant effect on cGMP-PDE activity in 
both guinea pig and human cardiomyocytes, but not on rat. PDE7 inhibition using 
BRL 50481 had no effect on cAMP-PDE activity in any of the three species. 
 
Expressing the results for total PDE activity shown in tables one and two in absolute 
terms, as pmol cyclic nucleotide catabolised per min per mg protein (pmol/min/mg), 
shows very large differences between the three species in the overall PDE activity 
recovered from the isolated cardiomyocytes [table 3.3]. 
 
Table 3.3 Absolute PDE activity 
PDE activity, pmol / min / mg protein  
Rat n=5 Guinea pig n=4 Human n=5 
Total cAMP-PDE 4.55 ± 0.50 136.20 ± 7.53 91.38 ± 26.26 
Total cGMP-PDE 2.49 ± 0.64 157.60 ± 9.12 83.55 ± 24.86 
 
PDE activity measured as pmol cyclic nucleotide broken down per minute per milligram of 
protein. Results were analysed using one-way ANOVA with Bonferroni post test, comparing 
between species. 
cAMP-PDE: rat vs. guinea pig P<0.001, rat vs. Human P<0.01, guinea pig vs. human P>0.05. 
cGMP-PDE: rat vs. guinea pig P<0.001, rat vs. Human P<0.05, guinea pig vs. human P<0.05. 
 
The SPA for both cAMP- and cGMP-PDE activity was repeated using all inhibitors 
combined together, and the result compared with the effect of 100 µM IBMX. IBMX 
 117
at 10-4 M will inhibit the activity of PDEs 1, 2, 3 and 4 by approximately 98 %, 93 %, 
97 % and 87 %, respectively (Rochais et al. 2006). If the effect of our combined 
inhibitors had been much less than that of IBMX, this might have suggested that there 
were PDE isoforms present in our sample that were not affected by any of the specific 
inhibitors being used. In fact our combined inhibitors were, in the case of rat and 
human cAMP-PDE activity, slightly more effective than IBMX; any other PDE 
isoforms that might be present would have to be present in very small quantities or 
have very low activity levels. 
 
Table 3.4 Effect of total PDE inhibition on cAMP-PDE activity 
 cAMP-PDE activity remaining,  % of total 
Inhibitor Rat n=4 Guinea pig n=4 Human n=5 
IBMX 100 µM 10.2 ± 0.5 9.9 ± 1.2 11.8 ± 0.5 
Combined 7.0 ± 0.2*** 7.7 ± 1. 7.3 ± 1.0** 
 
The effect of total PDE inhibition on cAMP-PDE activity in cardiomyocyte lysates, displayed 
as the activity remaining following PDEi treatment when compared to the total activity. Results 
are mean ± SEM. Results were analysed using one-way ANOVA (repeated measures) with 
Bonferroni post test, comparing IBMX vs. combined for each species. **P<0.01, ***P<0.001. 
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Table 3.5 Effect of total PDE inhibition on cGMP-PDE activity 
 cGMP-PDE activity remaining,  % of total 
Inhibitor Rat n=4 Guinea pig n=4 Human n=5 
IBMX 100 µM -6.3 ± 4.7 2.8 ± 2.5 11.3 ± 9.9 
Combined -5.1 ± 4.9 -0.3 ± 4.3 -12.9 ± 8.9 
The effect of total PDE inhibition on cGMP-PDE activity in cardiomyocyte lysates, displayed 
as the activity remaining following PDEi treatment when compared to the total activity. Results 
are mean ± SEM. Results were analysed using one-way ANOVA (repeated measures) with 
Bonferroni post test, comparing IBMX vs. combined for each species. **P<0.01, ***P<0.001. 
 
3.4.2.1 Human SPA results from individual samples 
Human samples used for SPA came from five different patients, and comprised two 
failing left ventricle, two failing right ventricle, and one HOCM. Tables six and seven 
present the results for individual samples.  
 
Table 3.6 cAMP-PDE activity in individual human samples 
 cAMP-PDE activity remaining, % of total 
Sample (see table 
2.1) 
2 
LV (LVAD) 
8b 
LV 
8a  
RV 
14  
RV 
7 
HOCM 
UK 90234 1 µM 29.3 50.5 40.4 52.2 45.2 
EHNA 10 µM 112.1 109.7 110.1 103.7 110.4 
Cilostamide 1 µM 82.6 74.9 77.7 64.8 70.2 
Rolipram 10 µM 87.0 78.2 100.1 94.2 83.4 
BRL 50481 10 µM 100.3 100.0 107.7 114.9 95.0 
 
 119
Table 3.7 cGMP-PDE activity in individual human samples 
 cGMP-PDE activity remaining, % of total 
 
2 
LV (LVAD) 
8b 
LV 
8a  
RV 
14  
RV 
7 
HOCM 
UK 90234 1 µM 8.9 24.5 3.7 26.4 12.0 
EHNA 10 µM 96.8 82.6 90.4 88.6 93.7 
Cilostamide 1 µM 85.5 92.8 89.2 98.4 81.5 
UK 114542 0.1 µM 73.2 78.8 86.8 77.4 87.1 
Sample dates refer to when cardiomyocytes were isolated. LV left ventricle, RV right ventricle, 
LVAD indicates tissue came from patient who had had a left ventricular support device, 
HOCM hypertrophic obstructive cardiomyopathy (the HOCM biopsy removes tissue from the 
left ventricular septum). 
 
With only two samples each of left and right ventricle it is difficult to discern any 
patterns that might indicate significant differences in PDE activity between the two 
sides. PDE1 activity was greatest in the left ventricular sample taken from an LVAD 
patient, but the remaining LV sample did not show greater PDE1 activity than the two 
RV samples. PDE4 activity was greater in LV than in RV, with 10 µM rolipram 
having little effect on PDE activity in right ventricle. PDE3 activity against cAMP 
was slightly greater in RV than LV, but this was not matched by activity against 
cGMP. 
 
3.4.3 Control experiments 
Control experiments confirmed that 10 µM rolipram and 10 µM BRL 50481 inhibited 
cAMP-PDE activity only (as would be expected from their target PDEs) and did not 
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reduce cGMP-PDE activity. cGMP-PDE activity was unchanged by 10 µM rolipram 
(rat 112.1 ± 4.7 % of total activity, guinea pig 101.3 ± 3.0 %, human 110.4 ± 2.2 %; 
no significant differences compared to total activity by one-way ANOVA (repeated 
measures) with Bonferroni’s multiple comparison test), and by 10 µM  BRL 50481 
(rat 111.4 ± 5.0 % of total activity, guinea pig 98.5 ± 3.6 %, human 113.2 ± 2.3 %; rat 
and guinea pig no significant differences compared to total activity, human P<0.05, 
by one-way ANOVA (repeated measures) with Bonferroni’s multiple comparison 
test). The same samples were used as in earlier SPAs, with the exception that only 
n=4 rat samples were used due to availability [figure 3.17]. 
 
Control experiments were also used to determine the optimum concentration of the 
PDE5 inhibitor UK 114542. These indicated that 1 µM UK 114542 was able to inhibit 
cAMP-PDE activity as well as cGMP-PDE activity in both guinea pig (cAMP-PDE 
activity with UK 114542 42.0 ± 5.5 % of total, P<0.001, n=4) and human 
cardiomyocyte lysates (cAMP-PDE activity with UK 114542 54.2 ± 3.6 % of total, 
P<0.001, n=5). As PDE5 is specific for cGMP, this suggested that 1 µM UK 114542 
was exhibiting non-specific activity [figure 3.18]. Available data from Pfizer and 
information in the literature indicated that the decrease in cAMP-PDE activity with  
1 µM UK 114542 was likely attributable to PDE1 inhibition (see discussion). 
(Interestingly, 1 µM UK 114542 actually increased cAMP-PDE activity in rat 
cardiomyocyte lysates, rather than having any inhibitory effect (cAMP-PDE activity 
120.6 ± 3.1 % of total, P<0.01, n=4)). Further experiments demonstrated that 0.1 µM  
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Figure 3.17 Control SPA for cGMP-PDE activity 
Control experiment testing the specificity of the cAMP-PDE-only inhibitors rolipram 
(PDE4) and BRL 50481 (PDE7) against cGMP-PDE activity. The PDE1 inhibitor 
UK 90234 was run simultaneously as a postive control for cGMP-PDE inhibition. 
Neither rolipram nor BRL 50481 significantly affected cGMP-PDE activity in rat, 
guinea pig and human cardiomyocyte lysates. ***P<0.05 vs. total. 
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Figure 3.18 Control SPA for cAMP-PDE activity 
Control experiment investigating whether the PDE5 inhibitor UK 114542 also 
decreased cAMP-PDE activity when used at 1 µM. The PDE1 inhibitor UK 90234 
and the PDE3 inhibitor cilostamide were run simultaneously as postive controls for 
cAMP-PDE inhibition. *P<0.05 vs. total, **P<0.01 vs. total, ***P<0.001 vs. total.
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UK 114542 was active against cGMP-PDE activity only, suggesting specificity for 
PDE5 at this concentration (rat cAMP-PDE activity 133.9 ± 7.5 % of total, P<0.01, 
n=4; guinea pig cAMP-PDE activity 99.9 ± 6.7 %, P>0.05, n=4; human cAMP-PDE 
activity 94.9 ± 2.4 %, P>0.05, n=5) [figure 3.19]. 
 
PDE1 inhibitor UK 90234 was also tested at the lower concentration of 0.1 µM. At 
this concentration, UK 90234 still significantly decreased cAMP-PDE and cGMP-
PDE activity in guinea pig and human cardiomyocyte lysates, but did not decrease 
either activity in rat cardiomyocyte lysates [figures 3.19 and 3.20]. cAMP-PDE 
activity with 0.1 µM UK 90234 was 128.6 ± 10.2 % of total in rat (P<0.05, n=4),  
70.4 ± 9.0 % of total in guinea pig (P<0.01, n=4), and 69.7 ± 4.7 % of total in human 
(P<0.001, n=5). cGMP-PDE activity with 0.1 µM UK 90234 was 107.1 ± 3.9 % of 
total in rat (P>0.05, n=4), 42.7 ± 4.6 % of total in guinea pig (P<0.001, n=4), and 50.3 
± 5.3 % in human (P<0.001, n=5). 
 
3.5 Discussion 
The data presented in this chapter from RTPCR and SPA experiments demonstrate 
that there are clear differences in both PDE expression and activity between rat, 
guinea pig and human cardiomyocytes, with guinea pig more closely resembling 
human than does rat. Of considerable interest is the fact that PDE1 and PDE5 show 
significant levels of activity in guinea pig and diseased human cardiomyocytes, 
despite until relatively recently being believed absent from cardiomyocytes (Maurice 
et al. 2003) – something these results argue against. 
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Figure 3.19 SPA for cAMP-PDE activity; low concentrations of UK 90234 and 
UK 114542 
Assay testing the efficacy of low concentrations of UK 90234 and UK 114542 against 
cAMP-PDE activity. *P<0.05 vs. total, **P<0.01 vs. total, ***P<0.001 vs. total.
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Figure 3.20 SPA for cGMP-PDE activity; low concentrations of UK 90234 and 
UK 114542 
Assay testing the efficacy of low concentrations of UK 90234 and UK 114542 against 
cGMP-PDE activity. *P<0.05 vs. total, **P<0.01 vs. total, ***P<0.001 vs. total. 
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When considering the role of cyclic nucleotide phosphodiesterases in the heart, it is 
PDE3 and PDE4 which have attracted the most attention over past decades (Maurice 
et al. 2003). Both enzymes are believed to play an important functional role in the 
myocardium, with studies documenting the positive effects of PDE3 and PDE4 
inhibition on several contractile parameters including force and rate of contraction 
(see chapter one). It is therefore of interest that the data presented here do not show 
PDE3 and PDE4 to be expressed or active at significantly greater levels than other 
PDE isoforms, and indeed PDE3 and PDE4 activity was markedly lower than that of 
PDE1 in guinea pig and human cardiomyocytes.  
 
3.5.1 PDE3 
PDE3A transcripts were more abundant than PDE3B transcripts in rat and human. 
The is in agreement with previous work that found PDE3A expression associated with 
cardiomyocytes, with PDE3B expression primarily in other cell types, including 
adipocytes and hepatocytes (Movsesian 2002). PDE3A knockout mice have increased 
heart rate compared to controls, whereas PDE3B knockouts do not (Sun et al. 2007). 
However, work by Patrucco et al. has shown that PDE3B is also present in the mouse 
heart with a functional role, and that its kinase-independent regulation by PI3Kγ can 
modulate cardiac contractility (Patrucco et al. 2004). 
 
Inhibition with 1 µM cilostamide had a similar effect on PDE3 activity against cAMP 
in all three species. Yet against cGMP-PDE activity, PDE3 inhibition had a 
pronounced effect only on rat cardiomyocyte lysate, with no significant effect on 
guinea pig or human. This may suggest that the cAMP-PDE function of PDE3 is 
active at the same level in all three species, while the cGMP-PDE function is 
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relatively more active in the rat than in guinea pig or human. Alternatively, a simpler 
explanation could be proposed, whereby the relative levels of PDE3 activity against 
both cAMP and cGMP are the same in all three species, but PDE3 cGMP-PDE 
activity constitutes a larger proportion of the total cGMP-PDE activity in the rat due 
to the lower levels of PDE1 and PDE5 cGMP-PDE activity. More detailed 
comparisons of enzyme activities between species using absolute PDE activity values 
(pmol cyclic nucleotide converted per minute per milligram of protein) are not 
feasible, as overall levels of PDE activity recovered from isolated rat cardiomyocytes 
were an order of magnitude lower than the levels recovered from guinea pig and 
human cardiomyocytes. These differences are likely to be genuine, rather than 
artifacts produced due to experimental procedure, as all the cells were isolated and 
frozen in fundamentally the same way on the same timescale. Due to the fact that 
human cardiomyocytes were isolated from non-healthy myocardial tissue without a 
Langendorff perfusion step, and that several hours often elapsed while the tissue was 
transported from hospital to laboratory, it is these cells which might be expected to 
have suffered the most degradation to protein function, rather than the relatively hardy 
rat cardiomyocytes. 
 
3.5.2 PDE4 
Species differences were also seen in the pattern of PDE4 expression; PDE4D was 
clearly present in all three species, but the other PDE4 isoforms were not consistently 
detected. Measurable PDE4 activity was low in all three species, with 10 µM rolipram 
only having a significant effect on rat cAMP-PDE activity and not on guinea pig or 
human. PDE4 is cAMP-specific, and control experiments showed that rolipram had 
no effect on cGMP-PDE activity. Of interest is the fact that PDE4 activity was greater 
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in human left ventricle than in right. Considering their perceived importance in the 
cardiomyocyte (Maurice et al. 2003), it is noticeable that expression levels of PDE3 
and PDE4 were not higher than that of other PDEs. This suggests that it is not the 
overall level of PDE expression which is the crucial factor in determining functional 
importance. 
 
3.5.3 PDE1 
Unlike PDEs 3 and 4, PDE1 has been the focus of little cardiac research. A 1991 
study using high-performance liquid chromatography (HPLC) reported that PDE1 was 
found only in the non-myocyte fraction of rat ventricle (Bode et al. 1991), and this 
position seems to have remained unchallenged for some time (Maurice et al. 2003). 
Yet the fact that PDE1 is regulated by Ca2+ should make it of immediate interest to 
any study of the heart, as it provides a mechanism by which cAMP levels could be 
linked to the cycling of Ca2+ in the cardiomyocyte. A relationship between cAMP and 
Ca2+ oscillations, mediated by Ca2+ activation of PDE1, has been demonstrated in 
human embryonic kidney cells (Willoughby & Cooper 2006), a model system whose 
results have often led to further significant experiments in cardiomyocytes. 
 
High levels of PDE1 activity were detected in both guinea pig and human 
cardiomyocyte lysates, where PDE1 inhibition reduced cAMP-PDE activity by 
greater than 55 %, compared to less than 25 % reduction by PDE3 inhibition. While 
no effect of PDE1 inhibition was seen on rat cAMP-PDE levels, a significant decrease 
of cGMP-PDE activity was observed. PDE1 expression in the rat (at the mRNA level) 
was extremely low compared to guinea pig and human, both of which showed 
relatively high levels of PDE1C expression, with human also showing notable levels 
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of PDE1A and 1B expression in some samples. While 1 µM UK 90234 was able to 
inhibit cGMP-PDE activity in all three species, a 10-fold lower concentration of 0.1 
µM failed to affect PDE activity in rat cardiomyocytes, while still having a significant 
effect on guinea pig and human cAMP-PDE and cGMP-PDE activity. These 
differences may be due to the presence of PDE1 isoforms in guinea pig and human 
cardiomyocytes that are not present in rat cardiomyocytes; those isoforms absent from 
the rat may be responsible for the cAMP-PDE activity of PDE1 shown in guinea pig 
and human, and may be more sensitive to inhibition by UK 90234. The products of 
the three different PDE1 genes differ in their affinities for cAMP and cGMP, with 
PDE1A and PDE1B having greater affinity for cGMP over cAMP, and PDE1C 
having equal affinity for the two cyclic nucleotides (Rybalkin et al. 2003); PDE1C 
isoforms also have the lowest Km values for cAMP and cGMP. PDE1C is highly 
expressed in guinea pig and human cardiomyocytes, and so may be the isoform 
responsible for the SPA results discussed above. 
 
However, some caution should be exercised when interpreting results obtained using 
UK 90234 as a PDE1 inhibitor. Kruuse et al. describe experiments on guinea pig and 
human cerebral arteries using UK 90234 and the PDE5 inhibitor UK 114542, and 
report a lack of PDE1 specificity for UK 90234 (Kruuse et al. 2005). While data from 
Pfizer is reported as giving UK 90234 an IC50 for PDE5 of 2 µM, Kruuse et al. report 
a personal communication from Rybalkin and Beavo which suggests an IC50 some 
10-fold lower for PDE5. These data would suggest that results obtained using UK 
90234 might in some circumstances be due to inhibition of both PDE1 and PDE5. 
This does, however, only apply to measurements of cGMP-PDE activity and not 
cAMP-PDE activity, due to the cGMP-specific nature of PDE5. 
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3.5.4 PDE2 
PDE2 was strongly expressed in all three species, yet no effect of 10 µM EHNA on 
cAMP-PDE was seen. PDE2 inhibition did however decrease cGMP-PDE activity, 
though to a greater extent in rat than guinea pig or human cardiomyocytes. The 
cAMP-PDE activity of PDE2 is known to be activated by cGMP (Michie et al. 1996), 
and in its absence cAMP-PDE activity may be too low to be measurably affected by 
inhibition with EHNA. 
 
3.5.5 PDE7 
The cAMP-specific PDE7 is currently of interest in the field of respiratory 
pharmacology, where it is hoped that PDE7 inhibitors may provide an alternative to 
nausea-inducing PDE4 inhibitors for the treatment of airway disease (Fan 2006). 
PDE7 expression has been observed by other research groups in immune and brain 
cells, and in human cardiomyocytes (Lugnier 2006; Smith et al. 2003). PDE7A 
expression was seen in guinea pig and human cardiomyocytes, but no effect of the 
PDE7 inhibitor BRL 50481 (10 µM) on cAMP-PDE activity was seen in any of the 
three species.  
 
3.5.6 PDE5 
The detection of PDE5A transcripts in guinea pig and human cardiomyocytes, and the 
ability of PDE5 inhibitor UK 114542 to decrease cGMP-PDE activity in guinea pig 
and human cardiomyocyte lysates, suggest the presence of functional PDE5 in these 
cardiomyocyte samples. This is an important finding, as it is only recently that 
evidence has begun to emerge supporting the notion that PDE5 is present and 
 131
functional in cardiomyocytes. The development of the PDE5 inhibitor sildenafil 
(Viagra, Pfizer) led to a large amount of research into possible cardiac effects of 
PDE5 inhibition. No PDE5 activity was found in human ventricle, and it was believed 
that any cardiac PDE5 was restricted to the vasculature, and not present in 
cardiomyocytes (Wallis et al. 1999). Sildenafil is regarded as having an excellent 
safety profile, with little significant effect on the heart (Jackson et al. 2006; Zusman et 
al. 1999), and this has been attributed to the supposed myocardial absence of PDE5. 
However, recent work has challenged the idea that PDE5 is functionally irrelevant in 
the heart, with a study demonstrating a blunting effect of sildenafil on dobutamine-
induced increases in human cardiac contractility in vivo (Borlaug et al. 2005). These 
effects might still be explained by vasodilatory effects of sildenafil acting on vascular 
smooth muscle, rather than a direct myocardial effect, thus leaving open the question 
of PDE5 in cardiomyocytes. Convincing evidence of a more molecular nature is 
provided by several studies which have identified PDE5 activity and expression in 
mouse myocardium and suggested a link between PDE5 and cardioprotection 
(Takimoto et al. 2005; Das et al. 2005; Fisher et al. 2005). PDE5 activity has since 
been identified in human right ventricular cardiomyocytes, using 
immunocytochemical techniques and quantitative RTPCR (Nagendran et al. 2007). 
Interestingly, only hypertrophied right ventricle from patients suffering from primary 
pulmonary hypertension was positive for cardiomyocyte PDE5, suggesting gene 
expression only in the diseased state. The results presented in this chapter demonstrate 
PDE5 activity in left ventricle as well as right; given that all the samples used came 
from failing or hypertrophied myocardium, this suggests that cardiomyocyte PDE5 
expression may be a hallmark of a variety of cardiac disease states. Myocardial 
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samples from healthy, non-failing, human heart are of course required to confirm this 
hypothesis, but for obvious reasons are in short supply. 
 
A study by Castro et al. has also shown a functional effect of sildenafil on rat 
cardiomyocytes (Castro et al. 2006). Using cyclic nucleotide gated channels to 
measure membrane cGMP levels it was found that 0.1 µM sildenafil was able to 
potentiate a NO-mediated increase in subsarcolemmal cGMP levels. This result stands 
in contrast to the absence of any PDE5 activity in rat cardiomyocytes as measured by 
SPA. It is possible that the resolution of the SPA is not sufficient to detect very low 
levels of PDE5 activity as might be present in rat cardiomyocytes. Alternatively, the 
result obtained by Castro et al. may be due to sildenafil acting on a target other than 
PDE5; the low concentration used and the absence of Ca2+ in the external solution 
makes it unlikely that any PDE1 inhibition occurred, but this does not exclude the 
possibility of other effects. 
 
Control experiments showed that the concentration of UK 114542 used, 0.1 µM, did 
not simultaneously inhibit PDE1 activity, allowing its effects to be ascribed solely to 
the presence of PDE5. The issue of PDE1 cross-reactivity is one which pertains to 
both UK 114542 and the related sildenafil, as at high concentrations both compounds 
inhibit PDE1 and PDE5 (UK114542 – PDE1 IC50 93 nM, PDE5 IC50 1.7 nM 
(Timmons & MacInnes 2002); sildenafil – PDE1 IC50 281 nM, PDE5 IC50 3.5 nM 
(Ballard et al. 1998)). 
 
As with the use of UK 90234 (see above), an element of caution must also be present 
when interpreting the results achieved with UK 114542 in the SPA and presented in 
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this thesis. Kruuse et al. report that the same concentration of UK 114542 used here in 
this thesis (0.1 µM) was able to inhibit approximately 50 % of Ca2+/CaM-stimulated 
cGMP hydrolysis in human and guinea pig cerebral arteries (Kruuse et al. 2005) This 
suggests that 0.1 µM UK 114542 is able to inhibit a significant amount of PDE1 
activity, as well as PDE5 activity. If the findings of Kruuse et al. are also applicable to 
the data presented in this thesis, then it is not possible to conclude with certainty that 
the decrease in cardiomyocyte cGMP-PDE activity seen with 0.1 µM UK 114542 is 
due solely to PDE5 inhibition; rather, it may be due to a combination of PDE1 and 
PDE5 inhibition. Lower concentrations of UK 114542 (0.01 µM) did not have an 
effect on cGMP-PDE activity (figure 3.20) 
 
The issue of PDE5 activity in isolated cardiomyocytes could be further explored using 
a different and more selective PDE5 inhibitor in the SPA. The PDE5 inhibitor 
tadalafil would be suitable in this regard, showing a selectivity ratio with respect to 
PDE1 of >1,000 – meaning that 1,000-fold higher concentrations of tadalafil are 
required to inhibit PDE1 in comparison to PDE5 (Bischoff 2004). 
 
The human samples analysed with RTPCR and SPA came from both left and right 
ventricle. End-stage heart failure requiring cardiac transplantation can arise from a 
number of different initial causes, and the severity of failure and pathology of the 
explanted hearts may not be identical. While differences in PDE activity between SPA 
left and right ventricle samples were slight, there was some variation in PDE 
expression between RTPCR samples. Studies have shown that changes in PDE 
expression may contribute to the altered cardiac phenotype seen in the failing heart. 
PDE3 expression has been found to be reduced in human failing hearts and mouse 
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hearts subjected to chronic pressure overload (Ding et al. 2005), while PDE4 
expression has also been shown to be altered in the failing heart (Lehnart et al. 2005). 
This may explain the variation in PDE expression shown in our human samples. 
 
3.5.7 Control experiments 
Certain anomalous results from rat cardiomyocytes were obtained in the control 
experiments, with low concentrations of PDE1 and PDE5 inhibitors appearing to 
actually stimulate, rather than inhibit, cAMP-PDE activity. These effects were not 
seen with guinea pig and human cardiomyocytes. While the use of either of these 
inhibitors could theoretically lead to an increase in cGMP levels and thus to an 
increase in PDE2 cAMP-PDE activity, the same effects were not seen with higher 
concentrations of the same inhibitors, and are thus difficult to explain. Furthermore, in 
contrast to guinea pig and human cardiomyocytes, no significant PDE5 activity could 
be detected in rat cardiomyocytes. A full discussion of the potential crosstalk between 
cAMP- and cGMP-metabolising PDEs is found in chapter six. 
 
3.5.8 Conclusion 
In conclusion, the data presented here show that there are clear differences in the 
PDEs expressed and active in rat, guinea pig and human cardiomyocytes, with the 
PDE activity profile of guinea pig cardiomyocytes closely matching that of the 
diseased human cardiomyocytes used. Cardiomyocytes from all three species contain 
PDEs 1, 2, 3 and 4; guinea pig and human cardiomyocytes also contain PDE5 
transcripts, with PDE7 expression but not activity noted. PDE5 activity in guinea pig 
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and human cardiomyoyctes is also suggested, but full confirmation may additionally 
require the use of more selective inhibitors. 
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CHAPTER 4 THE EFFECTS OF PDE INHIBITION ON 
ISOLATED CARDIOMYOCYTE CONTRACTILITY 
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4.1 Introduction 
The aim of this chapter was to establish if basal cardiomyocyte contractility could be 
affected by phosphodiesterase inhibition. In general terms, cardiomyocyte PDE 
inhibition would be expected to lead to a rise in intracellular cAMP, which would in 
turn increase the activity of PKA and effect an increase in cellular shortening during 
each contraction. The inhibitors IBMX, milrinone and rolipram were chosen for use in 
these experiments. IBMX is a non-specific PDE inhibitor and an obvious candidate to 
act as a departure point for further investigation of PDE function in cardiomyocytes, 
its use providing confirmation that PDE inhibition can in principle affect 
cardiomyocyte contraction. Milrinone and rolipram are specific inhibitors of PDE3 
and PDE4, respectively. PDE3 and PDE4 have been identified in cardiomyocytes 
from rat, guinea pig and human (chapter three), and have been the focus of the 
majority of research to date into cardiac PDEs (Maurice et al. 2003). Milrinone is a 
highly specific inhibitor of PDE3 with an IC50 of 56 nM (Tang et al. 1994), making it 
approximately equipotent with cilostamide (Tang et al. 1994). A low IC50 aids in the 
construction of concentration-response curves, as it avoids limitations imposed by 
vehicle concentration and non-specific effects of compounds at high concentrations. 
Both cilostamide and milrinone have identical solubility in DMSO (Tocris product 
information). Cilostamide was used in the SPA (chapter three) in keeping with the 
protocol established as effective at Pfizer. Milrinone is in current medical use for 
acute inotropic support of failing hearts, and this fact makes it more appropriate for 
testing in isolated cardiomyocytes. Rolipram is a specific PDE4 inhibitor with an IC50 
of 1 µM (Beavo & Reifsnyder 1990), originally developed as an anti-depressant. 
Although relatively less potent than milrinone, rolipram is widely used in 
pharmacological research as a PDE4 inhibitor. Another PDE4 inhibitor, Ro 20-1724, 
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has also been used in previously published research; its IC50 is 2 µM (Beavo & 
Reifsnyder 1990). 
 
4.2 Methods 
Functional experiments were carried out according to the general methodology 
described in chapter two. The availability and stability of isolated rat and guinea pig 
cardiomyocytes allowed the construction of cumulative concentration-response curves 
for IBMX, milrinone and rolipram. IBMX was used at concentrations of 10-8 M to 
10-4 M, milrinone and rolipram at 10-8 M to 10-4 M with rat cardiomyocytes and  
10-7 M to 10-4 M with guinea pig cardiomyocytes. Due to the unavoidable differences 
in the way human tissue is procured and isolation carried out, isolated human 
cardiomyocytes are not always as stable as those of other animals. Consequently, it 
was not always possible to maintain a cell in the cell bath for long enough to construct 
full concentration-response curves. Human cells were therefore also exposed to single 
high concentrations of PDE inhibitors to allow any possible effects to be measured. 
 
4.3 Results 
4.3.1 Effects of non-specific PDE inhibition with IBMX 
Inhibition of all cardiomyocyte PDEs with the inhibitor IBMX increased percentage 
shortening in cardiomyocytes from rat, guinea pig and human heart.  
 
IBMX was applied to rat and guinea pig cardiomyocytes in a cumulative fashion from 
10-8 M to 10-4 M, significantly increasing percentage shortening in a concentration-
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dependent manner in both cases. Rat cardiomyocyte percentage shortening was 
increased from a basal of 4.6 ± 0.8 % to a maximum of 10.7 ± 1.4 % (P<0.05 by t-test, 
n=6) [figure 4.1]. IBMX did not show itself to be a particularly potent inhibitor, with 
no effect on contractility being seen at concentrations less than 10-5 M, and an EC50 of 
3.94 × 10-5 M [figure 4.2]. Examination of the concentration-response curve suggests 
that a maximum was not reached, with the curve not having reached a plateau at  
10-4 M. The theoretical maximum of the IBMX concentration-response curve, as 
calculated by non-linear regression, was 12.27 % (95 % CI 3.51 to 21.02). For 
comparison, rat cardiomyocyte percentage shortening with maximal isoprenaline was 
15.81 ± 0.55 % (n=6, data from chapter five). 
 
Guinea pig cardiomyocyte percentage shortening was increased from a basal of 3.82 ± 
0.56 % to 7.97 ± 1.06 % (P<0.05 by t-test, n=6) [figure 4.3]. IBMX proved a slightly 
more potent compound in guinea pig cardiomyocytes compared to rat, with an EC50 of 
1.29 × 10-5 M [figure 4.4] (as compared to 3.94 × 10-5 M in the rat). Non-linear 
regression calculated the maximum of the curve as 9.23 % (95 % CI 6.87 to 11.58). 
 
Collected results from five separate experiments on human cardiomyocytes (one from 
failing left ventricle, one from failing right ventricle, and three from myectomy tissue) 
showed IBMX at concentrations of 3 × 10-5 M to 10-4 M increased percentage 
shortening from a basal of 3.22 ± 1.05 % to a maximum of 7.91 ± 2.50 % (P<0.05 by 
t-test, n=5) [figure 4.5]. Concentration-response curves from 10-7 M to 10-4 M IBMX 
were constructed in four of these experiments [figure 4.6]. The EC50 for IBMX was 
1.56 × 10-6 M, showing the compound to be of greater potency in human 
cardiomyocytes than either rat or guinea pig. One myectomy sample exhibited  
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Figure 4.1 Maximum IBMX response compared to basal in rat cardiomyocytes  
Isolated cardiomyocytes were superfused with increasing concentrations of the non-
specific PDE inhibitor IBMX as part of a concentration-response curve. 
Cardiomyocyte shortening is displayed as percentage shortening (defined in chapter 
two). The maximum response is displayed as mean ± S.E.M. From the same data as 
the concentration-response curve in figure 4.2. *P<0.05 using t-test, n=6. 
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Figure 4.2 IBMX concentration-response curve in rat cardiomyocytes 
Percentage shortening of rat cardiomyocytes when exposed to increasing 
concentrations of the non-specific PDE inhibitor IBMX. Data are mean ± S.E.M. 
EC50 3.94 × 10-5 M, 95 % CI 4.9 × 10-6 to 3.1 × 10-4 M, n=6. 
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Figure 4.3 Maximum IBMX response compared to basal in guinea pig 
cardiomyocytes  
From the same data as the concentration-response curve below. *P<0.05 using t-test, 
n=6. 
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Figure 4.4 IBMX concentration-response curve in guinea pig cardiomyocytes 
EC50 1.29 × 10-5 M, 95 % CI 5.04 × 10-6 to 3.28 × 10-5 M, n=6. 
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Figure 4.5 Maximum IBMX response compared to basal in human 
cardiomyocytes 
*P<0.05 by t-test, n=5. 
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Figure 4.6 IBMX concentration-response curve in human cardiomyocytes 
EC50 1.56 × 10-6 M, 95 % CI 1.64 × 10-8 to 1.48 × 10-4 M, n=4. 
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extremely low levels of basal percentage shortening at less than 0.5%; this contributed 
to the large error bars seen in figure 4.6. An alternative way of displaying the 
concentration-response results is to normalise the data to the percentage of the 
maximum increase reached [figure 4.7]. This gives a slight increase in the calculated 
EC50 to 4.92 × 10-6 M. 
 
4.3.2 Effects of PDE3 inhibition with milrinone 
Inhibition of PDE3 with milrinone had no effect on rat cardiomyocyte percentage 
shortening, but did significantly increase percentage shortening in cardiomyocytes 
from guinea pig and human heart. 
 
Milrinone was applied to rat cardiomyocytes in a cumulative fashion from 10-8 M to 
10-4 M; no effect on percentage shortening was seen. Basal percentage shortening was 
3.14 ± 0.89 % and was not significantly altered by the highest milrinone 
concentrations used (3 × 10-5 M and 10-4 M), remaining at 2.83 ± 0.71 % (no 
significant difference by t-test, n=5) [figure 4.8]. The PDE3 inhibitor cilostamide was 
also tested in a cumulative fashion from 10-9 M to 10-5 M; again, no effect on rat 
cardiomyocyte percentage shortening was seen (basal 6.10 ± 0.53, max cilostamide 
6.18 ± 0.83, no significant difference by t-test, n=8). 
 
In contrast to the results obtained with rat cardiomyocytes, milrinone caused a 
significant concentration-dependent increase in guinea pig cardiomyocyte percentage 
shortening. Milrinone was again applied in a cumulative fashion from 10-7 M to 10-4 
M, and increased cardiomyocyte percentage shortening from a basal of 4.11 ± 0.87 % 
to a maximum of 9.68 ± 0.77 % (P<0.001 by t-test, n=7) [figure 4.9]. Milrinone had a  
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Figure 4.7 IBMX concentration-response curve in human cardiomyocytes 
Data normalised to show percentage of maximal increase. 
EC50 4.92 × 10-6 M, 95 % CI 1.36 × 10-6 to 1.78 × 10-5 M, n=4 . 
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Figure 4.8 Maximum response to milrinone compared to basal in rat 
cardiomyocytes  
Isolated cardiomyocytes were superfused with increasing concentrations of the PDE3 
inhibitor milrinone. Cardiomyocyte shortening is displayed as percentage shortening 
(defined in chapter two). The maximum response is displayed as mean ± S.E.M. 
No significant difference by t-test, n=5. 
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Figure 4.9 Maximum response to milrinone compared to basal in guinea pig 
cardiomyocytes 
***P<0.001 by t-test, n=7. 
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much more potent effect on percentage shortening than IBMX, with an EC50 nearly 
100-fold lower at 4.73 × 10-7 M [figure 4.10]. 
 
Milrinone was applied to eight samples of human cardiomyocytes (one from failing 
left ventricle, seven from failing right ventricle) in the range 10-7 M to 10-4 M and, as 
with the guinea pig, PDE3 inhibition significantly increased percentage shortening. 
Maximum concentrations of milrinone used in n=8 experiments (10-5–10-4 M) 
increased percentage shortening from a basal of 2.75 ± 0.38 % to a maximum of 5.83 
± 0.87 % (P<0.01 by t-test, n=8) [figure 4.11]. Concentration-response curves from 
10-7 M to 10-4 M were constructed where possible, and are displayed in figure 4.12. 
From this limited data, it can be seen that milrinone exhibited a similar potency to 
IBMX in human cardiomyocytes, with an EC50 of 1.46 × 10-6 M. 
 
4.3.3 Effects of PDE4 inhibition with rolipram 
The PDE4 inhibitor rolipram was applied to rat, guinea pig and human 
cardiomyocytes at concentrations up to 10-4 M, but no effect on percentage shortening  
was seen despite the fact that this concentration was 50 times the IC50 value of  
2 µM. 
 
Rolipram was applied to rat cardiomyocytes in a cumulative fashion from 10-8 M to 
10-4 M. Percentage shortening did not change at even the highest rolipram 
concentrations (basal 7.37 ± 0.70 %, maximum rolipram 8.05 ± 1.11%, no significant 
difference by t-test, n=5) [figure 4.13]. Rolipram applied to guinea pig 
cardiomyocytes in the concentration range 10-7 M to 10-4 M also had no effect on 
percentage shortening (basal 4.29 ± 0.74 %, maximum rolipram 4.08 ± 0.72 %, no  
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Figure 4.10 Milrinone concentration-response curve in guinea pig 
cardiomyocytes 
Percentage shortening of guinea pig cardiomyocytes when exposed to increasing 
concentrations of the PDE3 inhibitor milrinone. 
EC50 4.73 × 10-7 M, 95 % CI 1.23 × 10-7 to 1.82 × 10-6 M, n=7. 
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Figure 4.11 Maximum response to milrinone compared to basal in human 
cardiomyocytes 
**P<0.01 by t-test, n=8. 
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Figure 4.12 Milrinone concentration-response curve in human cardiomyocytes 
EC50 of 1.46 × 10-6 M, 95 % CI 7.43 × 10-7 to 2.86 × 10-6 M, n=3. 
 
 
 152
basal max rolipram
0.0
2.5
5.0
7.5
10.0
12.5
%
 s
ho
rt
en
in
g
 
Figure 4.13 Percentage shortening at basal and at highest rolipram 
concentration reached in each experiment, rat cardiomyocytes 
No significant difference by t-test, n=5. 
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significant difference by t-test, n=5) [figure 4.14]. Rolipram was applied to nine 
samples of human cardiomyocytes (one from failing left ventricle, five from failing 
right ventricle, and three from myectomy tissue) in the concentration range 10-8 M to 
10-4 M. A slight decrease in percentage shortening was seen, which was statistically 
significant but of such small magnitude that it was unlikely to be of biological 
significance (basal 1.97 ± 0.43 %, maximum rolipram 1.46 ± 0.42 %, P<0.05 by t-test, 
n=8) [figure 4.15]. 
 
4.3.4 Combining milrinone and rolipram 
Having established that inhibition of PDE4 with rolipram did not affect 
cardiomyocyte percentage shortening by itself, rolipram was added to myocytes that 
were already pre-stimulated with milrinone to see if PDE4 inhibition could cause an 
increase in percentage shortening under conditions where PDE3 was also inhibited. At 
this stage a decision was taken to use R-rolipram in place of the standard racemic 
mixture of R and S rolipram. R-rolipram is the more potent enantiomer of the two and 
is reported to be approximately 2–10 fold more effective at inhibiting PDE4 than 
S-rolipram (Souness & Scott 1993). For this reason R-rolipram was used in all further 
functional experiments requiring PDE4 inhibition. 
 
Combining rolipram with milrinone did not cause any increases in percentage 
shortening over those seen with milrinone alone in cardiomyocytes from rat, guinea 
pig or human heart. 
 
In rat cardiomyocytes 10-5 M milrinone was combined with 10-5 M R-rolipram; no 
effect on percentage shortening was seen. Basal percentage shortening was 6.13 ±  
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Figure 4.14 Percentage shortening at basal and at highest rolipram 
concentration reached in each experiment, guinea pig cardiomyocytes 
No significant difference by t-test, n=5. 
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Figure 4.15 Percentage shortening at basal and at highest rolipram 
concentration reached in each experiment, human cardiomyocytes 
 *P<0.01 by t-test, n=9. 
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0.62 %; addition of 10-5 M milrinone did not significantly change this value (5.80 ± 
0.48 %), nor did further addition of 10-5 M rolipram (5.60 ± 0.46 %) (no significant 
difference in both cases by one-way ANOVA (repeated measures), n=5) [figure 4.16]. 
While the concentration of rolipram used was lower than in the following guinea pig 
and human experiments it was still enough to inhibit significant amounts of PDE4 
activity, and was chosen in order that this experiment could form part of a series 
conducted on rat cardiomyocytes using the same concentrations of milrinone and 
rolipram in combination with isoprenaline and forskolin (detailed in the next chapter). 
 
In guinea pig cardiomyocytes 10-4 M rolipram was added to cells already stimulated 
with 10-6 M milrinone; this concentration of the PDE3 inhibitor gave an increase in 
percentage shortening without causing a maximal response, allowing a potential 
further increase with rolipram. Milrinone increased percentage shortening from a 
basal of 4.83 ± 0.72 % to 7.79 ± 0.52 % (P<0.05 by one-way ANOVA (repeated 
measures), n=4); percentage shortening increased slightly on addition of 10-4 M 
rolipram to 8.11 ± 0.52 %, but this was not statistically significant (no significant 
difference between milrinone and rolipram by one-way ANOVA (repeated measures) 
or t-test, n=4) [figure 4.17]. 
 
Human cardiomyocytes were also pre-stimulated with 10-6 M milrinone before the 
addition of 10-4 M rolipram. As with the guinea pig, no further increase in percentage 
shortening was effected by rolipram (basal 3.45 ± 0.74 %, milrinone 5.78 ± 0.86 %, + 
rolipram 4.95 ± 0.71 %, no significant difference between milrinone and + rolipram 
by one-way ANOVA (repeated measures) or t-test, n=3) [figure 4.18]. 
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Figure 4.16 Combining milrinone and rolipram in rat cardiomyocytes 
Rat cardiomyocytes were exposed to a combination of the PDE3 inhibitor milrinone 
and the PDE4 inhibitor rolipram. Horizontal bars indicate the presence of the 
inhibitor, showing milrinone present alone initially, followed by milrinone present 
together with rolipram. 
No significant difference between columns by one-way ANOVA (repeated measures), 
n=5. 
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Figure 4.17 Combining milrinone and rolipram in guinea pig cardiomyocytes 
No significant difference between milrinone and rolipram by one-way ANOVA 
(repeated measures) or t-test, n=4. 
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Figure 4.18 Combining milrinone and rolipram in human cardiomyocytes 
No significant difference between milrinone and rolipram by one-way ANOVA 
(repeated measures) or t-test, n=3. 
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4.3.5 Alternative contractile parameters – TTP, R50 and R90 
Time to peak of contraction (TTP), time to 50 % relaxation (R50) and time to 90 % 
relaxation (R90) were also analysed in these early experiments. Few significant 
effects of PDE inhibition on these parameters could be detected for any of the three 
species 
 
For the non-specific PDE inhibitor IBMX, the only significant difference was a small 
increase in TTP for rat cardiomyocytes, from 0.053 ± 0.004 s to 0.065 ± 0.005 s 
(P<0.001, n=6). 
 
For the PDE3 inhibitor milrinone, guinea pig cardiomyocyte R90 significantly 
increased from 0.306 ± 0.049 s at basal to 0.615 ± 0.081 s at the highest milrinone 
concentration used (P<0.05, n=7). Human cardiomyocyte R50 significantly decreased 
from 0.173 ± 0.011 s at basal to 0.121 ± 0.19 s at maximum milrinone (P<0.05, n=8). 
 
When milrinone and rolipram were combined, rat cardiomyocyte R50 showed a 
significant but very minor decrease from 0.028 ± 0.003 s at basal to 0.026 ± 0.003 s 
when the two PDE inhibitors were combined (P<0.05, n=5). Guinea pig 
cardiomyocytes showed a significant increase in R90 from 0.385 ± 0.012 s at basal to 
0.574 ± 0.024 s for milrinone and rolipram combined (P<0.001, n=4). 
 
Although these results show that PDE inhibition does have some measurable effects 
on contractile parameters other than cardiomyocyte percentage shortening, they are 
still somewhat inconclusive. Analysis of TTP, R50 and R90 did not reveal any hidden 
effects of the PDE4 inhibitor rolipram, which had failed to have an effect on basal 
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cardiomyocyte percentage shortening. Neither were many effects on TTP, R50 and 
R90 seen in cases such as IBMX where significant effects on percentage shortening 
had been measured. 
 
It was therefore felt that cardiomyocyte percentage shortening remained the most 
suitable parameter by which to assess the effects of PDE inhibition, and it is 
percentage shortening results only which are reported in the remainder of this thesis. 
 
4.3.6 Vehicle controls 
The solvent used as the vehicle for all PDE inhibitors was dimethyl sulphoxide 
(DMSO, Sigma) which is widely used for this purpose in a great variety of cellular 
and pharmacological experiments. Exposure of cardiomyocytes to the maximum 0.1% 
DMSO concentration, using the same protocol as with other drugs, showed that 
DMSO did not affect percentage shortening, making it suitable for these and 
following experiments. 
 
Rat cardiomyocyte percentage shortening before and after DMSO exposure was 5.57 
± 0.89 % and 5.65 ± 0.92 %, respectively (no significant difference by t-test, n=5); 
guinea pig cardiomyocyte percentage shortening before and after DMSO exposure 
was 4.33 ± 0.75 % and 5.42 ± 1.12 %, respectively (no significant difference by t-test, 
n=5); human cardiomyocyte percentage shortening before and after DMSO exposure 
was 1.72 ± 0.33 % and 2.34 ± 0.53 % respectively (no significant difference by t-test, 
n=5). Preliminary experiments had also indicated that higher concentrations of DMSO 
had no effect on contractility, but is was decided to keep the vehicle concentration at 
or below a more conservative 0.1 % whenever possible. 
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4.4 Discussion 
The data presented in this chapter demonstrate that PDE inhibition is capable of 
having positive effects on basal cardiomyocyte contractility. Species differences in the 
response to PDE inhibition can also be clearly seen in these functional experiments. 
 
IBMX inhibits all PDEs with the exception of PDE8 and PDE9 (Fisher et al. 1998b; 
Hayashi et al. 1998; Fisher et al. 1998a) whose roles are as yet unknown. IBMX 
significantly increased percentage shortening in all three species tested, yet high 
concentrations of this compound were required to achieve this in rat and guinea pig 
cardiomyocytes. EC50 values for IBMX in rat and guinea pig cardiomyocytes were  
3.9 × 10-5 M and 1.29 × 10-5 M, respectively; human cardiomyocytes were more 
sensitive to IBMX, with an EC50 of between 1.56 × 10-6 M and 4.92 × 10-6 M 
(depending on the method of calculation), although this figure is derived from a 
smaller data set with larger error bars. The low IBMX-sensitivity in rat and guinea pig 
cardiomyocyte suggests that in the absence of any other inotropic stimulus, inhibition 
of PDEs needs to be near total before the rise in cAMP is sufficient to affect 
contractility (10-4 M IBMX will inhibit the activity of PDEs 1, 2, 3 and 4 by 
approximately 98 %, 93 %, 97 % and 87 %, respectively (Rochais et al. 2006)). The 
low IBMX-sensitivity of rat cardiomyocytes is also underlined by the fact that the 
concentration-response curve did not begin to plateau even at the high concentration 
of 10-4 M IBMX. 
 
The increase in cardiomyocyte percentage shortening caused by IBMX agrees with 
previously published data on both isolated cardiomyocytes and whole heart. IBMX at 
10-4 M has been shown to increase basal L-type Ca2+ current (ICa,L) by 120 % and 
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intracellular cAMP levels by 70 % in rat ventricular myocytes, making it as effective 
as a saturating concentration of isoprenaline (Verde et al. 1999); IBMX also induced a 
maximal response in a FRET probe for cAMP measurements in neonatal rat myocytes 
(Mongillo et al. 2004). In isolated guinea pig hearts, 10-4 M IBMX was shown to 
increase contractility (Rapundalo et al. 1989), and the non-specific PDE inhibitor 
pentoxifylline had a similar effect in rat hearts (Osadchii et al. 2005). 
 
In contrast to the results seen with IBMX, inhibition of individual PDE isoforms using 
PDE3 and PDE4 inhibition did not have a universal effect across the three species. 
While milrinone increased percentage shortening in guinea pig and human 
cardiomyocytes, no effect of PDE3 inhibition was seen in rat cardiomyocytes. In the 
guinea pig, milrinone showed itself to be a more potent compound than IBMX, with 
an EC50 nearly 100-fold lower than that of the non-specific inhibitor. While milrinone 
also raised guinea pig cardiomyocyte percentage shortening to a greater maximum 
than IBMX, the difference between the two maxima was not statistically significant. 
Milrinone was also effective in human cardiomyocytes, although to a lesser extent 
than in the guinea pig. Given the effectiveness of PDE3 inhibition in guinea pig and 
human cardiomyocytes, it is surprising that no effect at all could be seen in rat 
cardiomyocytes. PDE3 might simply play a less important role in rat cardiomyocytes, 
with the cAMP under its control being less closely linked to contractility than in 
guinea pig and human cardiomyocytes. Alternatively, basal cAMP levels in rat 
cardiomyocytes may be very low, meaning that while PDE inhibition will serve to 
increase those levels it will not raise cAMP above the threshold necessary for an 
increase in contractility to be observed; this second point is consistent with the low 
potency of IBMX in rat cardiomyocytes. Despite being the second messenger for 
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extracellular signals which increase cardiomyocyte percentage shortening, cAMP 
itself is not actually needed for cardiomyocytes to contract at a basal level, as has 
been shown in rat and human cardiomyocytes using the cAMP antagonist Rp-cAMPS 
(Bell & McDermott 1994; Gong et al. 2002). 
 
PDE4 inhibition with rolipram was unable to increase cardiomyocyte percentage 
shortening in cardiomyocytes from any of the three species, and even when rolipram 
was combined with milrinone no effect of PDE4 inhibition on contractility could be 
seen. If milrinone were also inhibiting PDE4 as well as PDE3, then addition of 
rolipram would not have an effect (PDE4 being inhibited already), and this might 
account for the negative results in the guinea pig and human experiments where the 
two PDE inhibitors were combined. However, while milrinone has been reported to 
inhibit PDE4 at high concentrations (Lugnier 2006), no PDE4 inhibition exists at the 
concentrations used here. Shakur et al., in experiments using isolated rabbit 
cardiomyocytes, showed that at milrinone concentrations of less than 15 µM a 
combination of milrinone and 5 µM rolipram had a greater inhibitory effect on 
cytosolic cAMP-PDE activity than milrinone alone (showing that milrinone was not 
inhibiting PDE4). These data demonstrate the PDE3 specificity of milrinone at 15 µM 
and lower concentrations (the data presented by Shakur et al. suggest that the PDE4 
inhibitory effect of milrinone does not become significant before concentrations of 30 
µM) (Shakur et al. 2002).  
 
The lack of a contractile response to rolipram may seem at odds with the professed 
importance of PDE4 in the heart and cardiomyocytes, but does not in fact run counter 
to much previously published work. PDE4 inhibition with rolipram and Ro 20-1724 
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has been shown to have no effect on guinea pig atria (Muller et al. 1990), and PDE4 
inhibition also with Ro 20-1724 has almost no effect on rat cardiac contractility in 
vivo, save for a minor increase in heart rate. (Herzer et al. 1998). Ro 20-1724 at  
0.1 µM had no effect on ICa,L in isolated rat ventricular myocytes, and effected only a 
small increase in intracellular cAMP levels (Verde et al. 1999). However, a 
combination of PDE3 and PDE4 inhibition using 0.1 µM cilostamide and 0.1 µM  
Ro 20-1724 was able to significantly increase ICa,L 50 % above baseline in the same 
study. Rolipram and cilostamide have also been shown to raise intracellular cAMP 
levels in neonatal rat ventricular myocytes, as measured by FRET (Mongillo et al. 
2004). 
 
The lack of an effect on percentage shortening does not mean that cAMP levels are 
not being raised in the cardiomyocyte. As discussed above, it may simply be the case 
that the rise is insufficient for an increase in contractility to occur. While cAMP levels 
are linked to contraction, they are not one and the same thing; multiple PKA 
phosphorylations of different target proteins are required to alter cardiomyocyte 
percentage shortening, and each step may be susceptible to interference. Therefore the 
effects of PDE3 and PDE4 inhibition in the published research discussed in the 
previous paragraph cannot be automatically assumed to lead to an increase in 
contractility. A further point is that the FRET experiments made use of neonatal rat 
myocytes, whose earlier stage of development compared to adult cells may mean an 
altered internal architecture and different cAMP compartmentation. 
 
PDE4 has been proposed to be closely linked to control of β-adrenergic signalling 
(Mongillo et al. 2004), and protein-protein molecular interactions can recruit PDE4D 
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isoforms to the β2 adrenergic receptor (Baillie et al. 2003). It may be that in the 
absence of β-adrenergic stimulation there might be little cAMP production in the 
vicinity of PDE4; inhibition of PDE4 would therefore have little effect on overall 
intracellular cAMP levels. These issues are further addressed in chapters five and 
seven. 
 
 166
CHAPTER 5 FURTHER INVESTIGATION OF THE 
EFFECTS OF PDE INHIBITION IN RAT 
CARDIOMYOCYTES 
 167
5.1 Introduction 
PDE3 and PDE4 expression and activity were confirmed in rat cardiomyocytes by the 
RTPCR and SPA work presented in chapter three. However, an initial investigation 
into the functional effects of PDE inhibition failed to find any effect of PDE3 and 
PDE4 inhibition on rat cardiomyocyte contractility (chapter four). The experiments 
presented in this chapter were designed to address this issue and find out if a 
functional effect of PDE3 and PDE4 inhibition on rat cardiomyocytes could be 
demonstrated under the right conditions. 
 
One possible explanation for the lack of effect of milrinone and rolipram in chapter 
four was that basal cAMP levels in the rat cardiomyocyte were extremely low, and 
PDE inhibition alone could not raise them sufficiently to influence contractility. The 
logical extension of this line of reasoning is to test PDE inhibitors on rat 
cardiomyocytes with raised levels of cAMP. This can be accomplished through 
β-adrenergic stimulation using the β-adrenergic receptor agonist isoprenaline, or the 
use of an adenylate cyclase stimulator such as forskolin. Several research groups have 
demonstrated that PDE inhibition can significantly potentiate the effects of 
β-adrenergic stimulation on isolated rat ventricular myocytes. Both PDE3 and PDE4 
inhibition, while having little effect alone, were shown to significantly increase 
isoprenaline-stimulated L-type Ca2+ current (ICa,L) (Verde et al. 1999), while in a 
similar experiment PDE3 and PDE4 inhibition also boosted the effect of isoprenaline 
on a cyclic nucleotide gated channel current (ICNG) (Rochais et al. 2004). In both of 
these electrophysiological experiments PDE4 inhibition had a greater potentiating 
effect on the β-adrenergic signal than did PDE3 inhibition. FRET technologies have 
also been used to measure intracellular cAMP levels, with similar effects of PDE3 and 
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PDE4 inhibition on β-adrenergic stimulation being demonstrated in neonatal rat 
cardiomyocytes and mouse cardiomyocytes (Mongillo et al. 2004; Nikolaev et al. 
2006). 
 
Research into the affects of PDE inhibition on stimulated cardiomyocytes is also of 
great interest when considering any possible pharmaceutical use of PDE inhibitors to 
treat cardiac conditions, as it is highly likely that PDE inhibitor treatment will 
coincide with sympathetic stimulation of the heart. In cases of heart failure a state of 
chronic sympathetic stimulation and raised plasma catecholamine levels can exist, 
making it vital that the interaction between PDE inhibition and β-adrenergic 
stimulation of the myocardium is understood (Lohse et al. 2003). 
 
5.2 Methods 
Two different experimental approaches were used to investigate the interaction 
between PDE inhibition and β-adrenergic stimulation. Both had the aim of 
establishing whether PDE inhibition could affect rat cardiomyocyte contractility in 
cells that were already stimulated by the β-adrenergic agonist isoprenaline. 
 
The first approach was to see if PDE inhibition (initially using IBMX and 
subsequently rolipram) could alter the isoprenaline concentration-response curve. This 
was achieved by carrying out two consecutive isoprenaline concentration-response 
curves on a single cardiomyocyte, with a period of washout in between. Following 
washout of the first isoprenaline response, IBMX was added to the superfusate at  
10-5 M and the concentration increased if necessary until an increase in percentage 
shortening was observed. This would confirm that IBMX was having an effect, and at 
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this point a second isoprenaline concentration-response curve was carried out while 
the concentration of IBMX remained steady. In this manner the first isoprenaline 
curve served as a direct control for the effect of IBMX on the second. Initial 
experiments with the two-isoprenaline curve method showed that percentage 
shortening following washout of the first isoprenaline curve was often substantially 
lower than the initial basal level, making comparison with a second curve difficult. In 
order to tackle this problem an initial 5 min exposure to 10-8 M isoprenaline followed 
by washout was carried out before the first concentration-response curve. This had the 
effect of lowering basal percentage shortening before the isoprenaline concentration-
response curves were commenced, so giving a more consistent baseline for both 
curves. 
 
The second method was used as an alternative to full isoprenaline concentration-
response curves. It was adopted as a way of investigating whether PDE inhibition 
could potentiate the isoprenaline signal even though milrinone and rolipram applied 
individually at concentrations up to 10-4 M had failed to have an effect on basal 
contractility, and rolipram had not altered the isoprenaline concentration-response 
curve. Therefore it was felt that a simpler approach might best establish if a functional 
response to PDE3 and PDE4 inhibition could be obtained in the rat. In this second 
method cardiomyocytes were exposed to a submaximal concentration of isoprenaline 
– established by adding isoprenaline at an initial concentration of 10-9 M and 
increasing the concentration until the first clear positive effect on percentage 
shortening was seen – which was kept constant while a single concentration of the 
relevant PDE inhibitor was added. Experiments were terminated by washing with 
Krebs as previously described. The aim of these experiments was to investigate the 
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effect of PDE inhibition on cardiomyocytes whose percentage shortening was raised 
above basal levels (indicating an increase in intracellular levels of cAMP); therefore 
the addition of PDE inhibitors in cases where isoprenaline had failed to increase 
percentage shortening (due to natural variation between cardiomyocytes) would not 
be of use, as it would not be possible to tell if intracellular levels of cAMP had 
actually been increased beforehand. It is for this reason that a variable concentration 
of isoprenaline was used; the aim being not to investigate isoprenaline per se, but 
rather to use the β-adrenergic agonist to effect a functional change in the 
cardiomyocyte that would be indicative of an increase in intracellular cAMP, and to 
then examine the effect of PDE inhibition on this changed functional state. In practice, 
isoprenaline was used at concentrations of 10-9–10-8 M. 
 
This second method as just described was repeated using the adenylate cyclase 
stimulator forskolin in place of isoprenaline. While isoprenaline will activate only the 
limited subset of adenylate cyclases coupled to β-adrenergic receptors, forskolin 
activates all adenylate cyclases throughout the cell. This enables comparisons to be 
drawn between the responses to PDE inhibition seen with β-adrenergic stimulation 
and with whole-cell adenylate cyclase stimulation, potentially revealing different 
patterns of activity. The concentration of forskolin was adjusted in the same fashion to 
effect an increase in cardiomyocyte percentage shortening before the addition of PDE 
inhibitors. Preliminary experiments, as well as data previously obtained in this 
laboratory, established the forskolin concentration-response curve. Following from 
this, forskolin was added to the cells starting at 3 × 10-7 M and the concentration 
increased until the first clear positive effect was observed at 1–3 × 10-6 M. 
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5.3 Results 
5.3.1 The effects of PDE inhibition on the isoprenaline concentration-
response curve in rat cardiomyocytes 
The presence of IBMX at a fixed concentration of 1–3 × 10-5 M produced a leftward 
shift to the isoprenaline curve of approximately half a log unit. The EC50 for 
isoprenaline in the absence of IBMX was 5.1 × 10-9 M; in the presence of IBMX it 
was 1.1 × 10-9 M (Two different curves by F-test, P<0.0001, n=6) [figure 5.1]. This 
leftward shift in the curve in the presence of IBMX indicates that PDE inhibition was 
able to sensitise the cardiomyocyte to β-adrenergic stimulation. With IBMX, 
maximum percentage shortening was reached at 10-8 M isoprenaline in all six cases; 
in the absence of IBMX, maximum percentage shortening was reached, in five out of 
six cases, at the ten-fold higher concentration of 10-7 M isoprenaline (the remaining 
case being at 3 × 10-8 M). Cardiomyocyte shortening is subject to physical and 
mechanical limits, and the maximal level of percentage shortening itself remained 
unchanged by IBMX (15.81 ± 0.55 % with isoprenaline alone vs. 15.63 ± 1.73 % in 
the presence of IBMX, no significant difference by t-test, n=6), confirming that 
β-adrenergic stimulation alone is sufficient to maximally increase cardiomyocyte 
contractility. 
 
Control experiments using matched concentrations of DMSO in place of IBMX  
(10-5 M IBMX being carried in a final concentration of 0.01% DMSO) showed that 
the DMSO vehicle alone had no effect on the isoprenaline concentration-response, 
with both data sets (without DMSO and with DMSO) fitting to the same curve as 
determined by non-linear regression and F-test [figure 5.2]. 
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Figure 5.1 The effect of IBMX on the isoprenaline concentration-response curve 
in rat cardiomyocytes 
Consecutive isoprenaline concentration-response curves, with washout between, were 
run on isolated rat cardiomyocytes; the second curve in the presence of a fixed 
concentration of the non-specific PDE inhibitor IBMX (1–3 × 10-5 M). Data are mean 
± S.E.M. 
Without IBMX: EC50 5.1 × 10-9 M, 95% CI 3.8 to 6.7 × 10-9 M.  
With IBMX: EC50 1.1 × 10-9 M, 95% CI 0.44 to 2.7 × 10-9 M. 
Different curve for each data set, P<0.0001 by f-test, n=6. 
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Figure 5.2 Vehicle control experiment demonstrating that DMSO (used as 
vehicle for IBMX) has no effect on the isoprenaline concentration-response curve 
in rat cardiomyocytes 
Identical experiment to that shown in figure 5.1, using DMSO vehicle only in place of 
IBMX. 
Without DMSO: EC50 6.8 × 10-9 M, 95% CI 2.77 × 10-9 M  to 1.67 × 10-8 M.  
With DMSO: EC50 9.7 × 10-9 M, 95% CI 2.94 × 10-9 M to 3.2 × 10-8 M. 
Same curve for each data set by f-test, n=6. 
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In contrast to the effect of IBMX, the isoprenaline concentration-response curve 
remained unchanged in the presence of 10-5 M rolipram [figure 5.3]. The EC50 values 
for the isoprenaline curve without and with rolipram were EC50 4.98 × 10-9 M and  
3.01 × 10-9 M, respectively. Statistical analysis using the F-test showed that both data 
sets could be fitted to one single curve, indicating that there was no statistically 
significant difference between the two isoprenaline concentration-response curves 
(n=5). 
 
5.3.2 The effects of adding milrinone and rolipram to cardiomyocytes 
pre-stimulated with the β-adrenergic agonist isoprenaline 
Both milrinone and rolipram, alone and combined, potentiated the effect of 
submaximal isoprenaline on rat cardiomyocyte percentage shortening. 
 
Basal cardiomyocyte percentage shortening of 5.91 ± 0.60 % was increased by the 
addition of submaximal isoprenaline (10-9 M to 10-8 M) to 7.87 ± 0.58 %. This 
moderate increase was statistically significant by t-test (P<0.05, n=9) but not by one-
way ANOVA (repeated measures). The subsequent addition of 10-5 M milrinone 
further increased percentage shortening to 9.92 ± 1.04 % (P<0.05 by t-test, n=9. 
P<0.05 by one-way ANOVA (repeated measures), n=9) [figure 5.4]. 
 
The same experiment was repeated using rolipram. Sub-maximal isoprenaline again 
increased percentage shortening from a basal of 5.83 ± 0.97 % to 7.82 ± 1.40 % 
(P<0.05 by one-way ANOVA (repeated measures), n=5); the further addition of  
10-5 M rolipram caused an additional rise in percentage shortening to 9.77 ± 1.71 %  
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Figure 5.3 Effect of 10-5 M R-rolipram on isoprenaline concentration-response in 
rat cardiomyocytes 
Consecutive isoprenaline concentration-response curves, with washout between, were 
run on isolated rat cardiomyocytes; the second curve in the presence of a fixed 
concentration of the PDE4 inhibitor rolipram (10-5 M). 
Without rolipram: EC50 4.98 × 10-9 M, 95% CI 2.11 × 10-9 M to 1.18 × 10-8 M. 
With rolipram 3.01 × 10-9 M, 95% CI 1.19 × 10-9 M to 7.64 × 10-9 M. 
Same curve for each data set by f-test, n=5. 
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Figure 5.4 Effects of the addition of either milrinone or rolipram to rat 
cardiomyocytes pre-stimulated with isoprenaline 
Rat cardiomyocytes were stimulated with a fixed sub-maximal concentration of 
isoprenaline (10-9–10-8 M) before the cumulative addition of either the PDE3 inhibitor 
milrinone or the PDE4 inhibitor rolipram. Horizontal bars indicate the presence of 
isoprenaline and milrinone or rolipram. Data are mean ± S.E.M. 
*P<0.05 by t-test and one-way ANOVA (repeated measures) comparing all columns 
and using Bonferroni’s multiple comparison test; n=9 (isoprenaline plus milrinone), 
n=5 (isoprenaline plus rolipram). Iso, isoprenaline; mil, milrinone; rol, rolipram. 
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(P<0.05 by one-way ANOVA (repeated measures), n=5), similar to the effect of  
10-5 M milrinone [figure 5.4]. 
 
Combining milrinone and rolipram in the presence of isoprenaline demonstrated that 
the two inhibitors together had an additive effect, increasing percentage shortening 
beyond the level seen with either one alone [figure 5.5]. Basal myocyte percentage 
shortening of 6.36 ± 0.73 % was increased to 7.18 ± 0.54 % by sub-maximal 
isoprenaline. The addition of 10-6 M milrinone increased percentage shortening to 
9.43 ± 1.02 %. This increase was, however, not significant when assessed by either 
t-test or one-way ANOVA (repeated measures) (n=5). Despite this, when 10-5 M 
rolipram was added in addition to milrinone, percentage shortening rose to a peak of 
14.27 ± 1.17 % (P<0.01 by one-way ANOVA (repeated measures), n=5). (Milrinone 
was used in this instance at the lower concentration of 10-6 M as initial attempts 
combining 10-5 M milrinone with 10-5 M rolipram often led to calcium overload-
induced arrhythmias in the cells. The reduction in milrinone concentration reduced 
this occurrence, and still enabled the additive effect of the two PDE inhibitors to be 
demonstrated.) 
 
5.3.3 The effects of adding milrinone and rolipram to cardiomyocytes 
pre-stimulated with the adenylate cyclase stimulator forskolin 
Similar effects of PDE3 and PDE4 inhibition were seen when forskolin was used in 
place of isoprenaline. 
 
Submaximal forskolin increased percentage shortening from a basal of 4.34 ± 0.58 % 
to 6.83 ± 1.31 % (P<0.05 by one-way ANOVA (repeated measures), n=9), similar to  
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Figure 5.5 Effects of adding rolipram to rat cardiomyocytes already stimulated 
with both isoprenaline and milrinone 
Rat cardiomyocytes were stimulated with a fixed sub-maximal concentration of 
isoprenaline (10-9–10-8 M) before the cumulative addition of the PDE3 inhibitor 
milrinone and the PDE4 inhibitor rolipram. Horizontal bars indicate the presence of 
isoprenaline and milrinone or rolipram. 
**P<0.01, n=5. 
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the effects of submaximal isoprenaline. The addition of 10-5 M milrinone further 
increased percentage shortening to 9.53 ± 1.53 % (P<0.05 by one-way ANOVA 
(repeated measures), n=9; P<0.01 by t-test, n=9) [figure 5.6]. Repetition of the 
experiment using 10-5 M rolipram in place of milrinone showed an increase in 
percentage shortening from a basal of 6.76 ± 0.88 % to 8.70 ± 0.88 % with 
submaximal forskolin, followed by a further increase to 11.20 ± 1.04 % with rolipram 
(P<0.05 by one-way ANOVA (repeated measures), n=8; P<0.01 by t-test, n=8) [figure 
5.6]. 
 
When combined in the presence of forskolin, milrinone and rolipram showed a similar 
additive effect to that seen in the presence of isoprenaline [figure 5.7]. Sub-maximal 
forskolin increased percentage shortening from a basal of 4.53 ± 0.48 % to 6.81 ± 
0.71 % (P<0.05 by one-way ANOVA (repeated measures), n=8). 10-6 M milrinone 
then increased percentage shortening to 9.19 ± 0.80 % (P<0.05 by one-way ANOVA 
(repeated measures)), and the further addition of 10-6 M rolipram raised percentage 
shortening to 12.53 ± 0.83 % (P<0.001 by one-way ANOVA (repeated measures)). 
(For these experiments the concentration of rolipram was reduced to 10-6 M, to avoid 
the high incidence of arrhythmias that were again seen when the experiment was 
initially conducted using rolipram at the higher concentration of 10-5 M.) 
 
5.4 Discussion 
The data presented in this chapter show that PDE3 and PDE4 clearly play an 
important functional role in rat cardiomyocytes, and that PDE inhibition sensitises 
cardiomyocytes to β-adrenergic stimulation. Despite the negative results in chapter 
four (where milrinone and rolipram, both alone and in combination, failed to increase  
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Figure 5.6 Effects of the addition of either milrinone or rolipram to rat 
cardiomyocytes pre-stimulated with forskolin 
Rat cardiomyocytes were stimulated with a fixed sub-maximal concentration of 
forskolin (1–3 × 10-6 M) before the cumulative addition of the PDE3 inhibitor 
milrinone or the PDE4 inhibitor rolipram. Horizontal bars indicate the presence of 
FSK and milrinone or rolipram. 
*P<0.05, **P<0.01 by t-test, n=9 (forskolin plus milrinone), n=8 (forskolin plus 
rolipram). FSK, forskolin. 
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Figure 5.7 Effects of adding rolipram to rat cardiomyocytes already stimulated 
with both forskolin and milrinone 
Rat cardiomyocytes were stimulated with a fixed sub-maximal concentration of 
forskolin (1–3 × 10-6 M) before the cumulative addition of the PDE3 inhibitor 
milrinone and the PDE4 inhibitor rolipram. Horizontal bars indicate the presence of 
isoprenaline and milrinone or rolipram. 
*P<0.05, ***P<0.001, n=8. 
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rat cardiomyocyte basal percentage shortening), when intracellular cAMP levels were 
raised by application of either the β-adrenergic agonist isoprenaline or the adenylate 
cyclase stimulator forskolin, the addition of milrinone or rolipram caused a further 
significant increase in cardiomyocyte percentage shortening. When PDE3 and PDE4 
inhibition occurred simultaneously, isoprenaline- or forskolin-stimulated percentage 
shortening increased to levels equal to the maximum percentage shortening effected 
by a saturating concentration of isoprenaline. That it was possible to maximally 
increase percentage shortening using PDE inhibition in this fashion suggests that the 
positive effect of IBMX on rat cardiomyocyte percentage shortening (chapter four) 
was indeed due to PDE inhibition, and not due to non-PDE effects of IBMX (this is of 
relevance because IBMX has been shown to cause release of Ca2+ from intracellular 
stores in a cyclic nucleotide-independent manner in neuronal cells (Usachev & 
Verkhratsky 1995)). 
 
The presence of non-specific PDE inhibition in the form of IBMX was able to shift 
the isoprenaline-response curve leftwards with a decrease in EC50 from 5.1 × 10-9 M 
to 1.1 × 10-9 M, demonstrating an increase in cardiomyocyte sensitivity. The 
difference between the two curves at an isoprenaline concentration of 3 × 10-9 M 
compares well with the increase in percentage shortening effected by the addition of 
milrinone and rolipram to submaximal isoprenaline. There was no statistically 
significant difference in maximum percentage shortening reached with isoprenaline 
alone and with isoprenaline in the presence of IBMX (15.81 ± 0.55 % vs. 15.63 ± 1.73 
%). The combined effect of milrinone and rolipram on percentage shortening in the 
presence of submaximal isoprenaline was enough to effect a maximal increase also 
(14.27 ± 1.17 %), suggesting that the effects of IBMX on the isoprenaline 
 183
concentration-response curve can be explained solely in terms of PDE3 and PDE4 
inhibition.  
 
The apparent inability of 10-5 M rolipram to shift the isoprenaline concentration-
response curve is more puzzling, especially given that 10-5 M rolipram was able to 
significantly potentiate the effect of a submaximal concentration of isoprenaline on 
cardiomyocyte percentage shortening. It is possible that the two-curve method used 
successfully with IBMX did not have the resolution to detect the presumably smaller 
shift in the curve that one might expect rolipram to effect, and indeed the isoprenaline 
concentration-response curve with rolipram does appear to be shifted leftwards of the 
control curve to a small extent. However, the difference between the curves was not 
statistically significant when calculated by the F-test, and so must be ascribed to 
chance. 
 
The decision to continue to pursue a functional effect of rolipram was vindicated by 
the results of the second method, clearly showing that 10-5 M rolipram significantly 
raised isoprenaline-stimulated percentage shortening from 7.82 ± 1.40 % to 9.77 ± 
1.71 %. This result was nearly identical to that seen with 10-5 M milrinone, which 
effected a similar rise in isoprenaline-stimulated percentage shortening from 7.87 ± 
0.58 % to 9.92 ± 1.04 %. Milrinone is, however, a relatively more potent inhibitor 
than rolipram (IC50s 56 nM and 1 µM, respectively), so these two results cannot be 
equally compared. Milrinone at 10-5 M was used initially when an effect of PDE3 
inhibition had yet to be seen in rat cardiomyocytes, warranting a high concentration of 
the PDE3 inhibitor. When milrinone was used at the lower concentration of 10-6 M, 
the effect of isoprenaline-stimulated percentage shortening was not statistically 
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significant. Despite this, the further addition of 10-5 M rolipram increased percentage 
shortening to maximal levels of greater than 14 %, compared to the <10 % percentage 
shortening level seen when rolipram alone was combined with submaximal 
isoprenaline. This suggests that even though 10-6 M milrinone did not have a 
significant effect on percentage shortening, it was still increasing intracellular levels 
of cAMP. (As discussed in the previous chapter, although milrinone at high 
concentrations can also inhibit PDE4, this loss of PDE3 specificity does not occur at 
concentrations lower than approximately 15 µM milrinone (Shakur et al. 2002)). 
 
The effects of PDE3 and PDE4 inhibition on cardiomyocytes pre-stimulated with 
submaximal concentrations of forskolin were almost identical to those seen with 
isoprenaline, with both milrinone and rolipram having significant potentiating effects. 
When combined, milrinone and rolipram also boosted forskolin-stimulated percentage 
shortening close to maximal (with the increase due to rolipram of similar magnitude 
to that seen in the isoprenaline experiment, even though the concentration of rolipram 
was lower). However, unlike the isoprenaline experiments, 10-6 M milrinone was able 
to effect a statistically significant increase in percentage shortening in the presence of 
forskolin, suggesting that PDE3 can control cAMP that is not linked to β-adrenergic 
receptors but still affects contractility. 
 
These contractility results can be compared with published research by several groups 
also investigating the effects of PDE inhibition on isolated cardiomyocytes. Verde et 
al. showed that PDE3 inhibition with 3 × 10-8 M cilostamide, and PDE4 inhibition 
with 3 × 10-8 M Ro 20-1724, potentiated the effect of submaximal isoprenaline  
(10-9 M) on ICa,L in adult rat ventricular myocytes (Verde et al. 1999). Later work 
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from the same group showed that similar effects of PDE3 and PDE4 inhibition could 
be seen on isoprenaline-stimulated ICNG (Rochais et al. 2004). 10-6 M cilostamide and 
2.5 × 10-8 M rolipram also both increase cAMP production in neonatal rat ventricular 
myocytes stimulated with 5 × 10-9 M noradrenaline, as measured by a PKA-based 
FRET probe for cAMP (Mongillo et al. 2004). Nikolaev et al. demonstrated, using 
ventricular myocytes from mice genetically engineered to express a different cAMP 
FRET probe, that 10-4 M rolipram and 10-6 M milrinone again increased intracellular 
cAMP levels in cardiomyocytes stimulated with 10-7 M isoprenaline. 
 
The research groups whose work is discussed above have all adopted different 
methods in order to study the dynamics of cAMP production and breakdown in the 
cardiomyocyte, and to investigate the still poorly understood phenomenon of cAMP 
signal compartmentation. As cardiomyocyte percentage shortening responds to 
changes in intracellular cAMP levels, this too can be viewed as a further method of 
studying cAMP. All these methods use different techniques to achieve the same end 
of getting a “readout” of the cAMP signal, often using different types of 
cardiomyocyte as their model (adult/neonatal, fresh/cultured, rat/mouse etc.). Taken 
together, these differences in technique likely explain many of the differences in 
results that have been seen so far. Relevant to the work presented in this thesis is the 
difference between measuring cardiomyocyte contractility and more direct 
measurements of intracellular cAMP production. The increases in cardiomyocyte 
percentage shortening seen when PDE inhibition and β-adrenergic stimulation are 
combined are the end result of multiple molecular events that depend on cAMP. As 
discussed in chapter one, once activated by cAMP, PKA has multiple targets 
(including the L-type Ca2+ channel, the activity of which is essentially used as a proxy 
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for cAMP levels by Verde et al.) whose phosphorylation contributes to altering the 
flow of calcium into and out of the cytosol and increasing contractility. 
Dephosphorylation depends on the activity of protein phosphatases – whose activity is 
not dependent on cAMP – and therefore cAMP levels can return to basal while the 
effects of PKA phosphorylation remain. Cyclic nucleotide gated channels and FRET 
probes are an attempt to measure cAMP levels directly, but both methods have 
limitations. CNG channels (not native to cardiomyocytes) are adenovirally delivered, 
requiring 24 hr cell culture, and while highly sensitive are effectively only reporting 
changes in cAMP levels at the sarcolemmal membrane. Furthermore, certain 
assumptions must be made about how the CNG channels are distributed in the 
sarcolemmal membrane, and whether they might preferentially associate with areas 
such as lipid rafts or caveolae. This in turn might mean a stronger CNG current could 
be generated simply due to the channels’ close association with a given receptor, 
rather than an actual stronger cAMP signal from that receptor. FRET probes are able 
to visualise cytosolic cAMP production, but their utility is governed by the nature of 
the probe itself and its location. Early cAMP FRET probes such as that used by 
Mongillo et al. consist of two fluorescent proteins (CFP and YFP) bound to the 
regulatory and catalytic subunits of PKA. Adenoviral delivery of the probe implies 
over- and possible ectopic-expression of PKA. Secondly, PKA can be tethered to 
specific subcellular sites within the cardiomyocyte by AKAPs, raising the possibility 
that pools of cAMP could exist away from the anchored FRET probes and thus go 
undetected. (Alternative cAMP FRET probes have since been developed which do not 
use PKA, an example of which is the HCN2 probe used by Nikolaev et al., itself 
based on the cAMP-binding domain of the hyperpolarisation-activated CNG 
potassium 2 channel. While the PKA-based probe revealed a highly-localised pattern 
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of cAMP production in neonatal cardiomyocytes following β-adrenergic stimulation – 
one which seemed to match the sarcomeric z-lines – no such pattern was seen in a 
similar experiment in mouse cardiomyocytes that constitutively expressed the HCN2 
probe. Such results serve as a demonstration that even techniques that purport to 
directly show where cAMP is being produced may not produce as clear and 
unequivocal answers as might be hoped.) 
 
While the above mentioned studies are all in agreement with the contractility data in 
this chapter that PDE3 and PDE4 inhibition potentiate the β-adrenergic response, they 
also make several observations that are not matched by corresponding effects on 
cardiomyocyte percentage shortening. In each of the quoted studies, PDE4 inhibition 
had a greater effect than PDE3 inhibition. While cilostamide increased isoprenaline-
stimulated ICa,L in adult rat cardiomyocytes by a further 30 % compared to basal,  
Ro 20-1724 raised the current a further 50 % compared to basal (Verde et al. 1999). 
Measurements of ICNG showed that 10-6 M cilostamide boosted the isoprenaline-
stimulated current by approximately 3-fold, equivalent to 40 % of the value obtained 
using a saturating concentration of the forskolin analogue L-858051, yet substituting 
10-5 M rolipram for cilostamide gave a maximal increase in ICNG equal to the effect of 
saturating L-858051 (Rochais et al. 2004). Direct measurements of cytosolic cAMP 
production using FRET probes showed a similar pattern of results. In neonatal rat 
ventricular myocytes, the addition of 10-6 M cilostamide to 5 × 10-9 M noradrenaline 
increased the FRET signal to a level approximately twice that seen with cilostamide 
alone; the effect was transient in nature, returning to baseline levels in approximately 
three minutes. In contrast, a combination of rolipram and noradrenaline produced a 
maximal and sustained increase in the FRET signal (Mongillo et al. 2004). 
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Interestingly, when Mongillo et al. repeated their experiments using forskolin in place 
of noradrenaline they found that cilostamide had a greater effect, although still 
transient in nature, while the effect of rolipram was much decreased. Such transient 
effects of PDE3 inhibition on cAMP levels were not seen when measuring ICNG, 
which responds to subsarcolemmal, rather than cytosolic, increases in cAMP. 
 
No transient effect of PDE3 inhibition was observed in the contractility experiments 
presented in this chapter, and the effects of 10-5 milrinone on isoprenaline- and 
forskolin-stimulated contractility were nearly identical, with absolute rises in 
percentage shortening of 2.05 % and 2.70 %, respectively. However, as mentioned 
above, milrinone at the lower concentration of 10-6 M caused a statistically significant 
effect only on forskolin-stimulated percentage shortening, not on isoprenaline-
stimulated contractility, suggesting a similarity with the results of Mongillo et al. 
 
Differences between the effects of PDE3 and PDE4 inhibition on both isoprenaline-
stimulated and forskolin-stimulated contractility were also less apparent in the 
contractility data. Percentage shortening when 10-5 M milrinone was added to 
submaximal isoprenaline or forskolin was 9.92 ± 1.04 % and 9.53 ± 1.53 %, 
respectively; when 10-5 M rolipram was added to isoprenaline or forskolin, percentage 
shortening was 9.77 ± 1.71 % and 11.20 ± 1.04 %, respectively. In both the 
isoprenaline and forskolin sets of experiments, the combination of PDE3 and PDE4 
inhibition induced a maximal percentage shortening increase. Taken together, the 
contractility data only weakly support the proposal that PDE4 plays a much greater 
role in controlling the cAMP signal from β-adrenergic receptors, at least as it relates 
to contractility. 
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CHAPTER 6 FUNCTIONAL EFFECTS OF PDE1, PDE5 
AND PDE7 INHIBITION 
 190
6.1 Introduction 
Relatively little research has been carried out into the roles of PDE1 and PDE5 in the 
cardiomyocyte until comparatively recently, partly due to a lack of suitable inhibitors 
and partly due to erroneous beliefs that PDE1 and PDE5 were absent from these cells. 
However, measurements of PDE activity using the SPA (chapter three) showed that 
both guinea pig and human cardiomyocytes contained a large amount of PDE1 
activity, capable of metabolising both cAMP and cGMP, and that cardiomyocytes 
from these same species also contained significant amounts of PDE5 activity (rat 
cardiomyocytes contained a lesser amount of PDE1 activity, active against cGMP 
only, and did not show any evidence of PDE5 activity). Further investigation into 
PDE1 and PDE5 function in the cardiomyocyte was clearly warranted; given the 
results from chapter three, guinea pig cardiomyocytes were considered most suitable 
and were the main subject of experimentation, with human cardiomyocytes being 
used when available.  
 
PDE1 is a dual cAMP/cGMP phosphodiesterase, raising the possibility that its 
inhibition might lead to a simultaneous increase in levels of both cyclic nucleotides 
and a possible masking by cGMP of any cAMP-mediated effect on contractility. The 
effects of cGMP are primarily mediated by activation of protein kinase G (PKG), and 
so in an attempt to control for this possibility, the PKG inhibitor Rp-8-BR-cGMPS 
was employed (Biolog Life Science Institute, Germany). This cyclic nucleotide 
derivative is metabolically stable and resistant to degradation by endogenous PDEs; it 
is also more lipophilic than the alternative Rp-cGMPS (Biolog data), ensuring entry 
into the target cells. By inhibiting PKG, any negative contractile effects of PDE1-
controlled cGMP whould be abolished, allowing a cAMP effect to be revealed. 
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A non-vascular role for cardiac PDE5 has been suggested in recent years, with  PDE5 
inhibition shown to have a negative effect on cardiac contractility under conditions of 
β-adrenergic stimulation, both in vivo in humans (Borlaug et al. 2005) and in vitro in 
isolated mouse cardiomyocytes (Takimoto et al. 2005; Takimoto et al. 2007). 
Experiments measuring a cGMP CNG-channel current have also (surprisingly) 
suggested the presence of functional PDE5 in isolated rat cardiomyocytes (Castro et 
al. 2006); for this reason it was decided not to exclude rat cells from the PDE5 
experiments. This was despite the apparently negative results of chapter three, where 
the PDE5 inhibitor UK 114542 failed to decrease cGMP-PDE activity in rat 
cardiomyocyte lysates. 
 
No functional cardiomyocyte studies have previously been carried out using PDE7 
inhibitors. The effects of PDE7 inhibition using the specific inhibitor BRL 50481 
were investigated using rat cardiomyocytes at an early stage in this work, and the 
results are also presented in this chapter. The lack of significant effects, coupled with 
the absence of PDE7 activity measured using the same inhibitor in the SPA (chapter 
three) and the need to prioritise other lines of investigation, meant that further work 
on PDE7 activity using guinea pig and human cells was not carried out. For these 
reasons the main focus of this chapter is on PDE1 and PDE5. 
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6.2 Methods 
The PDE1 inhibitor UK 90234 (Pfizer) and the PDE5 inhibitor UK 114542 (Pfizer) 
were employed in these experiments. As in earlier experiments, cardiomyocytes were 
exposed to PDE inhibitors either alone or in combination with isoprenaline. The 
procedure for establishing a submaximal concentration of isoprenaline was the same 
as previously described. Where PDE inhibition led to an apparent decrease in 
isoprenaline-stimulated percentage shortening, PDE inhibitors were washed out while 
maintaining the concentration of isoprenaline. An increase in percentage shortening at 
this point would demonstrate a true reversible negative effect of PDE inhibition, and 
control for a possible spontaneous decrease or desensitisation over time. 
 
Rp-8-BR-cGMPS was used at a concentration of 10-5 M, in line with published 
research on cardiomyocytes using this same compound (Layland et al. 2002; 
Yamamoto et al. 1997). Cells were exposed to Rp-8-BR-cGMPS for a minimum of 20 
min to allow for penetration of the cell membrane, in line with manufacturers 
instructions. Due to a lack of suitable guinea pig cardiomyocytes, only a limited 
number of experiments were carried out using Rp-8-BR-cGMPS. 
 
Control experiments carried out using the PDE5 inhibitor UK 114542 as part of the 
SPA work featured in chapter three had found that 10-6 M UK 114542 also inhibited 
some PDE1 activity, but the lower concentration of 10-7 M was still capable of 
significant PDE5 inhibition without affecting PDE1 activity. For this reason UK 
114542 was used at 10-7 M and 3 × 10-7 M in the contractility experiments described 
below. 
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6.3 Results 
6.3.1 Inhibition of PDE1 using UK 90234 does not affect cardiomyocyte 
percentage shortening 
Multiple experiments carried out with the PDE1 inhibitor UK 90234 failed to show 
that PDE1 inhibition could affect percentage shortening in guinea pig, rat or human 
cardiomyocytes. 
 
In guinea pig cardiomyocytes, the PDE1 inhibitor UK 90234 was applied in a 
cumulative fashion from 10-9 M to 10-5 M [figure 6.1]. No significant effect of PDE1 
inhibition on contractility was seen. Basal percentage shortening was 5.30 ± 0.82 %; 
this decreased to 4.60 ± 0.87 % at the highest concentration of UK 90234, but the 
difference was not statistically significant by t-test (n=10). UK 90234 was also 
applied to guinea pig cardiomyocytes pre-stimulated with submaximal isoprenaline; 
3 × 10-9 M isoprenaline increased percentage shortening from 3.97 ± 0.68 % to 6.05 ± 
0.64 %, and further addition of 10-6 M UK 90234 saw a small decrease in percentage 
shortening to 5.52 ± 0.74 % [figure 6.2]. While statistically significant (P<0.05 by 
t-test, n=7), it is difficult to ascribe any great biological significance to this minor 
difference. UK 90234 at 10-6 M had been shown by SPA (chapter three) to inhibit 
significant amounts of cAMP-PDE activity in guinea pig and human cardiomyocytes; 
there were also concerns that it might inhibit PDE5 at higher concentrations. 
 
UK 90234 was applied to human cardiomyocytes (two cells from one sample of 
failing left ventricle, one cell from a different sample of failing left ventricle, and two 
cells from a sample of failing right ventricle), again in a cumulative fashion from  
10-9 M to 10-5 M [figure 6.3]. While there was a significant decrease in percentage  
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Figure 6.1 UK 90234 concentration-response curve in guinea pig cardiomyocytes 
Percentage shortening of guinea pig cardiomyocytes when exposed to increasing 
concentrations of UK 90234. Data are mean ± S.E.M. 
No effect of this PDE1 inhibitor is seen at concentrations from 10-9 M to 10-5 M, 
n=10. 
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Figure 6.2 UK 90234 does not increase isoprenaline-stimulated percentage 
shortening in guinea pig cardiomyocytes 
Guinea pig cardiomyocytes were stimulated with a sub-maximal concentration of 
isoprenaline before the addition of the PDE1 inhibitor UK 90234. Horizontal bars 
indicate the presence of isoprenaline and UK 90234. Data are mean ± S.E.M. 
*P<0.05 by t-test, n=7. 
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Figure 6.3 UK 90234 concentration-response curve on human cardiomyocytes 
No effect of this PDE1 inhibitor is seen at concentrations from 10-9 M to 10-5 M, n=5. 
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shortening from a basal of 1.29 ± 0.37 % to 0.49 ± 0.17 % with the maximum 
concentration of UK 90234 obtained in each experiment, this was small in absolute 
terms (P<0.05 by t-test, n=5). 
 
Experiments carried out at an earlier date had tested the higher concentration of  
10-5 M UK 90234 on rat cardiomyocytes pre-stimulated with isoprenaline. 
Isoprenaline at 3 × 10-9 M raised percentage shortening from 6.01 ± 0.46 % to 9.39 ± 
1.16 %, but no significant effect of subsequent addition of 10-5 M UK 90234 was 
seen, with percentage shortening measured at 8.80 ± 1.47 % (no significant difference 
by t-test, n=6) [figure 6.4]. Given that little PDE1 expression had been measured in 
rat cardiomyocytes, and that UK 90234 had no effect on cAMP-PDE activity in rat 
cardiomyocyte lysate (chapter three), it was decided that it would not be a prudent use 
of resources to pursue PDE1 function in rat cardiomyocytes before any results had 
been seen in guinea pig or human cardiomyocytes. 
 
A limited number of further investigations for PDE1 function were carried out in 
guinea pig cardiomyocytes, using Rp-8-BR-cGMPS at 10-5 M to block the activity of 
PKG. However, even in the presence of PKG inhibition, inhibition of PDE1 using 10-6 
M UK 90234 failed to have a significant effect on cardiomyocyte percentage 
shortening, either alone or combined with a sub-maximal concentration of 
isoprenaline. Percentage shortening of 2.38 ± 1.35 % with 10-5 M Rp-8-BR-cGMPS 
remained unchanged with the addition of 10-5 M UK 90234, at 2.48 ± 1.60 % (no 
significant difference by t-test, n=3) [figure 6.5]. In the presence of 10-5 M  Rp-8-BR-
cGMPS, a sub-maximal concentration of isoprenaline increased percentage shortening 
from 2.11 ± 0.39 % to 3.79 ± 1.16 %; further addition of 10-6 M UK 90234 had no  
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Figure 6.4 UK 90234 does not increase isoprenaline-stimulated percentage 
shortening in rat cardiomyocytes 
No significant difference between isoprenaline and isoprenaline + UK 90234 by t-test, 
n=6. 
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Figure 6.5 UK 90234 does not increase guinea pig cardiomyocyte percentage 
shortening when PKG activity is blocked using Rp-8-Br-cGMPS 
Guinea pig cardiomyocytes were exposed to PKG blockade before the addition of the 
PDE1 inhibitor UK 90234. Horizontal bars indicate the presence of Rp-8-Br-cGMPS 
and UK 90234. 
No significant difference by t-test, n=3. 
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significant effect, with percentage shortening measured at 4.10 ± 0.79 % (no 
significant effect by t-test, n=3) [figure 6.6]. 
 
6.3.2 PDE5 inhibition with UK 114542 
PDE5 inhibition with UK 114542 at a concentration of 1–3 × 10-7 M did not have any 
significant effect on basal contractility in guinea pig cardiomyocytes. Basal 
contractility of 2.78 ± 0.23 % was unchanged by 10-7 M UK 114542 (2.88 ± 0.31 %) 
and 3 × 10-7 M UK 114542 (2.90 ± 0.45 %) (no significant differences between 
groups by one-way ANOVA (repeated measures), n=4) [figure 6.7]. 
 
When UK 114542 was tested on guinea pig cardiomyocytes pre-stimulated with 
isoprenaline, a slight negative inotropic effect of PDE5 inhibition was seen. 
Submaximal isoprenaline increased percentage shortening from 3.48 ± 0.66 % to 5.09 
± 0.70 %. UK 114542 was added at 10-7 M, and the concentration then increased to  
3 × 10-7 M. Percentage shortening decreased at both concentrations of the PDE5 
inhibitor, to 4.21 ± 0.67 % and 3.91 ± 0.66 %, respectively; the second decrease with 
the greater of the two concentrations of UK 114542 was statistically significant 
(P<0.05 by one-way ANOVA (repeated measures), n=5). Percentage shortening did 
not, however, return to its original isoprenaline-stimulated levels on washout of UK 
114542, the level remaining at 4.02 ± 0.92 % (no significant difference between 
isoprenaline + 3 × 10-7 M UK 114542 and isoprenaline-only wash by one-way 
ANOVA (repeated measures) n=5) [figure 6.8]. Vehicle control experiments showed 
no effect of DMSO at the relevant concentrations. 
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Figure 6.6 UK 90234 does not increase isoprenaline-stimulated percentage 
shortening in cells treated with the PKG blocker Rp-8-Br-cGMPS 
Guinea pig cardiomyocytes were exposed to PKG blockade before being stimulated 
with sub-maximal isoprenaline; PDE1 activity was then blocked using UK 90234. No 
significant difference between isoprenaline and isoprenaline + UK 90234 by t-test, 
n=3. 
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Figure 6.7 PDE5 inhibition with UK 114542 does not affect guinea pig 
cardiomyocyte percentage shortening  
No significant differences between columns by one-way ANOVA (repeated 
measures) with Bonferroni’s multiple comparison test, n=4. 
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Figure 6.8 The effect of UK 114542 on isoprenaline-stimulated contractility in 
guinea pig cardiomyocytes 
Guinea pig cardiomyocytes were stimulated with sub-maximal isoprenaline, before 
being exposed to two consecutive concentrations of the PDE5 inhibitor UK 114542; 
UK 114542 was then washed out, leaving the isoprenaline concentration unchanged. 
Horizontal bars show the presence of isoprenaline and UK 114542. 
*P<0.05 by one-way ANOVA (repeated measures) with Bonferroni’s multiple 
comparison test comparing all columns except basal, n=5. 
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The effect of UK 114542 on isoprenaline-stimulated contractility was also tested in 
rat cardiomyocytes. Submaximal isoprenaline of 3 × 10-9 M increased rat 
cardiomyocyte percentage shortening from 6.11 ± 0.48 % to 8.85 ± 1.42 %. As with 
guinea pig cardiomyocytes, UK 114542 was added at 10-7 M and the concentration 
subsequently increased to 3 × 10-7 M. Percentage shortening following the first 
addition of UK 114542 was lower at 7.83 ± 1.65 %, but the decrease was not 
statistically significant (by one-way ANOVA (repeated measures), n=4). Percentage 
shortening at the second and higher concentration of UK 114542 was lower again at 
6.00 ± 1.09 %; this second decrease was statistically significant compared to the 
original isoprenaline-stimulated level of contractility (P<0.05 by one-way ANOVA 
(repeated measures), n=4). Importantly, washout of UK 114542 – leaving the 
isoprenaline concentration unchanged – saw percentage shortening return to 8.99 ± 
1.03 %, almost identical to the level seen with isoprenaline alone before PDE5 
inhibition (P<0.05 by one-way ANOVA (repeated measures), n=4) [figure 6.9]. 
 
Limited samples allowed UK 114542 to be tested against isoprenaline-stimulated 
contractility in n=3 failing human cardiomyocytes (two from one sample of failing 
right ventricle, one from a sample of failing left ventricle). Submaximal isoprenaline 
increased cardiomyocyte percentage shortening from 3.11 ± 0.88 % to 5.20 ± 0.92 %. 
Addition of UK 114542 at 10-7 M saw a significant decrease to 4.54 ± 0.93 %, and 
increasing the UK 114542 concentration to 3 × 10-7 M  led to a further significant 
decrease to 4.28 ± 1.19 % (P<0.05 in both instances, by one-way ANOVA (repeated 
measures) comparing all columns except basal, n=3). Washout of UK 114542, again 
leaving the isoprenaline concentration unchanged, saw percentage shortening return to  
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Figure 6.9 The effect of UK 114542 on isoprenaline-stimulated contractility in rat 
cardiomyocytes 
Rat cardiomyocytes were stimulated with sub-maximal isoprenaline, before being 
exposed to two consecutive concentrations of the PDE5 inhibitor UK 114542; UK 
114542 was then washed out, leaving the isoprenaline concentration unchanged. 
Horizontal bars show the presence of isoprenaline and UK 114542. 
*P<0.05 by one-way ANOVA (repeated measures) with Bonferroni’s multiple 
comparison test comparing all columns, n=4. 
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5.05 ± 0.97 % (P<0.05 by one-way ANOVA (repeated measures) comparing all 
columns except basal, n=3) [figure 6.10]. 
 
6.3.3 PDE7 inhibition using BRL 50481 and rat cardiomyocytes 
Inhibition of PDE7 activity using BRL 50481 had no effect on rat cardiomyocyte 
percentage shortening, either under basal conditions or combined with submaximal 
isoprenaline stimulation. 
 
BRL 50481 was added to rat cardiomyocytes in a cumulative fashion from 10-7 M to  
3 × 10-5 M; no effect on percentage shortening was seen [figure 6.11]. Basal 
percentage shortening of 6.32 ± 1.03 % was not significantly altered at the highest 
concentrations of BRL 50481, being 6.72 ± 1.29 % (no significant difference by t-test, 
n=4). When submaximal isoprenaline at 3 × 10-9 M was used to increase percentage 
shortening from 6.03 ± 0.59 % to 7.21 ± 0.91 %, the further addition of 10-5 M BRL 
50481 failed to have a significant effect, with percentage shortening remaining at 7.35 
± 1.11 % (no significant difference by t-test, n=6) [figure 6.12]. 
 
6.4 Discussion 
The experiments presented here represent the first time that PDE1 function has been 
investigated in isolated cardiomyocytes, and the first time that negative inotropic 
effects of PDE5 inhibition have been seen in rat and human cardiomyocytes.  
 
PDE7 inhibition was not found to have any significant effects on rat cardiomyocyte 
contractility. Coupled with the complete absence of any effect of PDE7 inhibition on  
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Figure 6.10 The effect of UK 114542 on isoprenaline-stimulated contractility in 
human cardiomyocytes 
Human cardiomyocytes were stimulated with sub-maximal isoprenaline, before being 
exposed to two consecutive concentrations of the PDE5 inhibitor UK 114542; UK 
114542 was then washed out, leaving the isoprenaline concentration unchanged. 
Horizontal bars show the presence of isoprenaline and UK 114542. 
*P<0.05 by one-way ANOVA (repeated measures) with Bonferroni’s multiple 
comparison test comparing all columns except basal, n=3. 
 208
(0)
0
2
4
6
8
10
-7.0 -6.5 -6.0 -5.5 -5.0 -4.5
log [BRL 50481] M
%
 s
ho
rt
en
in
g
 
Figure 6.11 BRL 50481 concentration-response curve on rat cardiomyocytes 
Rat cardiomyocytes were exposed to the PDE7 inhibitor BRL 50481 as a 
concentration-response curve. 
No effect of this PDE7 inhibitor is seen at concentrations from 10-7 M to 3 × 10-5 M, 
n=4. 
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Figure 6.12 PDE7 inhibition with BRL 50481 does not increase rat 
cardiomyocyte percentage shortening in the presence of submaximal 
isoprenaline 
Rat cardiomyocytes were stimulated with a sub-maximal concentration of 
isoprenaline, before the cumulative addition of the PDE7 inhibitor BRL 50481. 
Horizontal bars indicate the presence of isoprenaline and BRL 50481. 
No significant difference between isoprenaline and isoprenaline + BRL 50481 by 
t-test, n=6. 
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cAMP-PDE activity in the SPA (chapter three), it was felt that it would not be a 
suitable use of resources to attempt to further investigate PDE7 function in guinea pig 
and human cardiomyocytes. The development of more potent and specific PDE7 
inhibitors may allow this issue to be revisited in this future. 
 
Data presented in chapter three demonstrate the presence of large amounts of PDE1 
activity in guinea pig cardiomyocyte lysate, with the PDE1 inhibitor UK 90234 at  
1 µM shown to decrease cAMP-PDE activity by approximately 70 % and cGMP-PDE 
activity by approximately 80 %. Despite this, however, PDE1 inhibition using UK 
90234 had no effect on basal or isoprenaline-stimulated contractility in guinea pig 
cardiomyocytes. PDE1 inhibition also failed to affect human basal and rat 
isoprenaline-stimulated contractility. It was hypothesised that the dual cAMP/cGMP-
phosphodiesterase nature of PDE1 might mean that PDE1 inhibition would lead to an 
increase in both cAMP and cGMP, with a negative inotropic effect of cGMP 
(mediated by PKG) balancing any positive inotropic effect of cAMP. However, 
inhibition of PKG followed by PDE1 inhibition failed to affect guinea pig 
cardiomyocyte contractility. These results, combined with the data from chapter three, 
indicate that there is a substantial pool of cAMP existing in the guinea pig and human 
cardiomyocyte that is under the control of PDE1, but which plays no role in the 
control of contractility. Cyclic nucleotides are, of course, ubiquitous second 
messengers, playing many intracellular roles. It was originally research showing that 
certain hormones such as prostaglandin E1 (PGE1) were capable of increasing 
intracellular levels of cAMP without altering cardiac contractility (Hayes et al. 1979) 
that helped lead to current notions of cyclic nucleotide compartmentation. Rochais et 
al. have demonstrated (using adult rat ventricular myocytes) that stimulation of the 
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PGE1 receptor generates significant increases in intracellular levels of cAMP when 
PDE3 and PDE4 activities are simultaneously inhibited (Rochais et al. 2006); it would 
be interesting to see if a similar effect might be achieved using a PDE1 inhibitor. 
Cyclic AMP can also be involved in longer-term regulation of the cell via the 
transcription factor “cAMP response element binding protein” (CREB). As discussed 
in chapter three, PDE1 has been shown in human embryonic kidney cells to mediate a 
relationship between cAMP levels and Ca2+ oscillations (Willoughby & Cooper 
2006); if such a relationship were to exist in cardiomyocytes it might provide a 
mechanism by which long-term patterns of cardiac contraction could alter 
cardiomyocyte gene expression. (However, CREB does not appear to be crucial in the 
cardiomyocyte, as it has been shown in mice that cardiac-specific inactivation of 
CREB does not impair heart function in any way (Matus et al. 2007)). If PDE1 is not 
linked to cardiomyocyte contractility then techniques that study cyclic nucleotides in 
live cells using CNG channels or FRET probes seem set to provide more insight into 
its role. 
 
PDE5 inhibition with UK 114542 demonstrated a small, negative inotropic effect on 
cardiomyocytes pre-stimulated with isoprenaline. However, this effect was modest in 
guinea pig and human cardiomyocytes – with decreases in percentage shortening of 
approximately 1.18 % and 0.92 %, respectively – and was not reversible in the guinea 
pig. This lack of reversibility calls into doubt that it was a genuine effect of the PDE5 
inhibitor, and suggests that the guinea pig cardiomyocytes may have simply been 
experiencing a slow decline in contractility due either to deteriorating cellular health 
or a desensitisation to isoprenaline. Surprisingly, the effect of PDE5 inhibition was 
greatest in rat cardiomyocytes, where 3 × 10-7 M UK 114542 reversibly decreased 
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isoprenaline-stimulated percentage shortening from 8.85 ± 1.42 % to 6.00 ± 1.09 %. 
This was an unexpected find, as SPA and RTPCR data (chapter three) had failed to 
show any PDE5 activity in rat cardiomyocyte lysates. If this was a genuine PDE5-
mediated effect, then it suggests that even miniscule amounts of PDE5 activity can 
have a significant functional role within the cardiomyocyte; this in turn could be 
thought to support the notion of highly compartmented cGMP-PDE activity in 
cardiomyocytes. These experiments were limited by the concentration of UK 114542 
that could be used without inhibiting significant amounts of PDE1 activity. It is 
possible that a much greater negative effect of PDE5 inhibition on guinea pig and 
human cardiomyocytes would be seen if higher concentrations of PDE5 inhibitor 
could be used. Sildenafil would be more suitable in this regard, but this compound 
still exhibits some PDE1 inhibition (see below). 
 
As discussed in chapter three (and also discussed below), there is data suggesting that 
UK 114542 at the concentrations used is also able to inhibit significant amounts of 
PDE1 activity (Kruuse et al. 2005). This would suggest that any negative inotropic 
effect of UK 114542 in the experiments described above might be due to a 
simultaneous inhibition of both PDE1 and PDE5, rather than inhibition of PDE5 
alone. The use of the PDE5 inhibitor tadalafil in place of UK 114542 would allow 
these concerns to be addressed, as tadalafil is selective for PDE5 compared to PDE1 
by greater than 1,000-fold (Bischoff 2004). 
 
UK 90234 on its own had little or no effect on isoprenaline-stimulated contractility in 
rat or guinea pig cardiomyocytes. This suggests that PDE5 inhibition was at least 
partially responsible for the negative inotropic effects of UK 114542 described above. 
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Potential synergy between PDE1 and PDE5 is itself a potentially interesting topic that 
would also be worthy of research, 
 
While an effect of PDE5 inhibition on rat cardiomyocyte contractility has not 
previously been demonstrated, research by Castro et al. has shown that PDE5 
inhibition in rat cardiomyocytes can increase cGMP levels – suggesting the presence 
of functional PDE5 enzyme (Castro et al. 2006). Castro et al. used cGMP-specific 
CNG channels to measure changes in sub-sarcolemmal cGMP levels, and found that 
10-7 M sildenafil potentiated the effect of NO release on ICNG. While this result 
supports the notion of active PDE5 in rat cardiomyocytes, it does not by itself indicate 
whether such activity could influence contractility. Studies on mouse cardiomyocytes, 
however, have also shown a clear negative effect of PDE5 inhibition using sildenafil 
on isoprenaline-stimulated contractility (Takimoto et al. 2005; Takimoto et al. 2007). 
In these experiments, isoprenaline was used to increase sarcomere-shortening (an 
alternative measure of contractility) by more than 200 % in relative terms; the 
application of sildenafil at 10-7 to 10-6 M reduced this increase by approximately 50 
%, without affecting the Ca2+ transient (Takimoto et al. 2005). PDE5 inhibition also 
led to increased levels of cGMP and the activation of protein kinase G (PKG). All 
these effects of PDE5 inhibition were dependent on the presence of functional nitric 
oxide synthase 3 (NOS3). The 2007 study expanded on this work by showing that the 
negative effect of PDE5 inhibition on isoprenaline-stimulated contractility could be 
prevented by treating the cardiomyocytes with an inhibitor of PKG. The authors 
concluded from these data that PDE5 inhibition was able to activate PKG by 
increasing the levels of soluble guanylate cyclase (sGC)-generated cGMP; PKG 
enhances the phosphorylation of troponin-I, decreasing myofilament Ca2+ sensitivity 
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and explaining how contractility decreased without a change in the Ca2+ transient 
(Takimoto et al. 2007). 
 
Activation of PKG is not the only mechanism by which inhibition of PDE5 might 
conceivably affect cardiomyocyte contractility. PDEs should not be considered in 
isolation and there is much theoretical potential for crosstalk between cAMP- and 
cGMP-hydrolysing PDEs. Thus, the increase in cGMP levels that will occur on 
inhibition of PDE5 could potentially affect the breakdown of cAMP by PDE1, PDE2 
and PDE3. 
 
The binding of cGMP to GAF domains on PDE2 activates the enzyme causing 
increased hydrolysis of cAMP. In this way, a rise in cGMP could lead to a 
concomitant decrease in cAMP in the same vicinity. This would provide a viable 
mechanism by which a PDE5-mediated increase in cGMP could in turn have a 
negative inotropic effect by activating PDE2 and decreasing cAMP levels. However, 
as discussed in earlier chapters, PKA may stay active after cAMP levels have 
declined, and so such a negative inotropic effect of increased cGMP might not 
necessarily take place on the timescales present in contractility experiments. An 
obvious way to test this hypothesis would be to see if PDE2 inhibition could prevent 
the negative effect on contractility of PDE5 inhibition. 
 
A study by Mongillo et al. using FRET probes for cAMP and cGMP (Mongillo et al. 
2006) can be used to indirectly shed light on this question. The authors use evidence 
from several different experiments on rat neonatal cardiomyocytes to propose that 
stimulation of β3-adrenergic receptors activates “e”- (originally “endothelial”-) nitric 
 215
oxide synthase (eNOS), leading to production of nitric oxide (NO) and consequent 
stimulation by NO of sGC activity. The cGMP generated by sGC activation serves to 
stimulate PDE2 activity, leading to a decrease in cAMP levels and a dampening of 
β-adrenergic stimulation. This pathway is proposed to provide a mechanism by which 
cardiomyocytes could be afforded some protection from the potentially damaging 
effects of excessive β-adrenergic stimulation and the associated increase in cAMP 
levels. The finding by Castro et al. (discussed above) that PDE5 inhibition only 
increases the cGMP ICNG when the current is stimulated by NO donors (which activate 
sGC), and not by atrial natriuretic peptide (which activates particulate guanylate 
cyclase – pGC), suggests that PDE5 is controlling a sGC-produced pool of cGMP 
only. Coupled with the conclusions of Mongillo et al. that sGC-derived cGMP 
activates PDE2, this suggests a means by which PDE5 crosstalk to PDE2 could occur, 
allowing PDE5 inhibition to activate PDE2. 
 
So far only the possible activation of PDE2 due to PDE5 inhibition has been 
discussed. Although not seen in the data presented in this chapter, PDE5 inhibitors 
could also have potentially a completely opposite effect on contractility through 
cGMP-inhibition of PDE3 activity. The increase in cGMP levels caused by PDE5 
inhibition could competitively inhibit the breakdown of cAMP by PDE3, leading to a 
concomitant increase in cAMP levels. As has already been shown (chapter five), 
PDE3 inhibition significantly potentiates the effect of isoprenaline on 
cardiomyocytes; if this alternative mechanism were in operation, PDE5 inhibition 
would be expected to increase cardiomyocyte percentage shortening. Interestingly, 
despite the majority of research suggesting that PDE5 inhibition negatively modulates 
cardiac contractility, research by Nagendran et al. found that PDE5 inhibition using 
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10-6 M sildenafil (albeit in the absence of β-adrenergic stimulation) significantly 
increased contractility in human right ventricular myocytes – but only those from 
hypertrophied right ventricle, not those from healthy tissue (Nagendran et al. 2007). 
Using their own immunocytochemical data, Nagendran et al. contend that PDE5 
expression in healthy right ventricular myocardium is effectively absent and that it is 
only in the hypertrophied state that PDE5 expression is significantly up-regulated. 
The authors also found that PKG activity was decreased in hypertrophied right 
ventricle. This could explain the unexpected effect of sildenafil, as troponin-I 
phosphorylation by PKG and consequent myofilament Ca2+ desensitisation was 
proposed as the mechanism by which PDE5 inhibition decreased isoprenaline-
stimulated sarcomere shortening in mouse cardiomyocytes (Takimoto et al. 2007). 
However, the limited data on human cardiomyocytes presented in this chapter were 
also obtained using hypertrophied cardiomyocytes (including from right ventricle) and 
show a negative effect of PDE5 inhibition, suggesting a more thorough examination 
of this issue is required. 
 
The issue of cGMP and its possible effects on cardiomyocyte contractility via PDE 
activity is extremely complex, and future studies may need to consider simultaneously 
all PDEs that interact with cGMP. In their review, Zaccolo and Movsesian compare 
the cGMP binding affinities of PDE1, PDE2 and PDE3, which vary by two orders of 
magnitude (Zaccolo & Movsesian 2007). Based on this, the authors postulate that at 
low levels (<50 nM) cGMP will inhibit PDE3, at intermediate levels (200–500 nM) 
PDE2 will be activated, and at high levels (>1 µM) PDE1 may be inhibited. If correct, 
this suggests how different and apparently contradictory effects of inhibiting  
cGMP-hydrolysing PDEs might be reconciled. 
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There remains the final possibility that some of the putative PDE5-mediated 
contractile effects of inhibitors such as sildenafil may be in part due to inhibition of 
PDE1. UK 114542 and sildenafil are known to inhibit PDE1, albeit to a lesser extent 
than PDE5, and concentrations of sildenafil such as the 1 µM used in much research 
might perhaps derive some of their effect through PDE1 inhibition. As noted in 
chapter three, the IC50 values for the two PDE5 inhibitors are as follows: UK114542 – 
PDE1 IC50 93 nM, PDE5 IC50 1.7 nM (Timmons & MacInnes 2002); sildenafil – 
PDE1 IC50 281 nM, PDE5 IC50 3.5 nM (Ballard et al. 1998). Although the PDE1 
inhibitor UK 90234 did not affect cardiomyocyte contractility, this does not preclude 
the possibility that a simultaneous inhibition of PDE1 and PDE5 might be responsible 
for some of the effects discussed above. (As noted in chapter three, however, the work 
of Castro et al. used Ca2+-free external solutions, thus reducing the likelihood of any 
PDE1 activity.) 
 
In conclusion, while PDE1 does not play a significant role in controlling 
cardiomyocyte contractility by itself, use of the PDE5 inhibitor UK 114542 is able to 
have a modest inhibitory effect on β-adrenergic stimulated cardiomyocyte 
contractility. Due to the properties of UK 114542, this effect can currently only be 
ascribed to joint PDE1 / PDE5 inhibition, but other published research supports the 
notion that PDE5 inhibition can have negative inotropic effects. The use of more 
selective inhibitors is required to confirm the presence of active PDE5 in isolated 
cardiomyocytes. 
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CHAPTER 7 PDE CONTROL OF ADRENERGIC 
SIGNALLING THROUGH THE β1 AND β2 
ADRENERGIC RECEPTORS 
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7.1 Introduction 
Data presented in chapter five demonstrated the important role played by PDE3 and 
PDE4 in regulating the cAMP signal produced by stimulation of βARs. The PDE3 
inhibitor milrinone and the PDE4 inhibitor rolipram both potentiated the increase in 
rat cardiomyocyte shortening effected by a submaximal concentration of the βAR 
agonist isoprenaline. Furthermore, when milrinone and rolipram were combined, the 
effect on submaximal isoprenaline-stimulated contractility was enough to increase 
cardiomyocyte percentage shortening to levels equal to those achieved using a 
maximal concentration of isoprenaline alone. The βARs present on rat 
cardiomyocytes are divided primarily into β1 and β2 subtypes, as detailed in chapter 
one, with the β1AR predominating. β2ARs make up only a small minority of the total 
number of βARs present in rat cardiomyocytes, previously measured in this laboratory 
as less than 5 % by radioligand binding (Ranu et al. 2000). However, work also 
carried out in this laboratory by the same author has demonstrated that it is 
nevertheless possible to isolate a small functional effect of β2AR stimulation on rat 
cardiomyocyte contraction. This can be seen in the biphasic curve produced by an 
isoprenaline concentration-response curve carried out in the presence of the β1AR 
antagonist CGP 20712A. The initial component of this curve is due to β2AR 
stimulation, and can be abolished by the β2AR antagonist ICI 118551 (Ranu 1998). 
The effect of PDE inhibition on this functional effect of β2AR stimulation can 
therefore be measured. 
 
The experiments detailed in this chapter were designed to establish if PDE3 and PDE4 
regulated the β1AR and β2AR subtypes in an identical manner when it came to their 
effects on rat cardiomyocyte contractility. Differential effects of PDE3 and/or PDE4 
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inhibition on β1AR- and β2AR-mediated changes in contractility would suggest that 
different patterns of PDE3 and PDE4 activity were associated with each receptor 
subtype. 
 
A precedent for this work is seen in experiments carried out by Rochais et al., also 
using adult rat ventricular myocytes, which used electrophysiological methods to 
study the PDEs involved in the regulation of both membrane cAMP levels (as 
measured by a cyclic nucleotide gated channel current) and the L-type Ca2+ current 
(ICa,L) following stimulation of β1 and β2 adrenergic receptors (Rochais et al. 2006). 
These experiments demonstrated that while inhibition of either PDE3 or PDE4 alone 
would potentiate β1AR-stimulated cAMP production, simultaneous inhibition of both 
PDE isoforms was required for a sustained potentiation of the β2AR cAMP signal. 
Furthermore, inhibition of PDE4 had a significantly greater effect on β2AR-stimulated 
L-type Ca2+ current than PDE3 inhibition. 
 
7.2 Methods 
In order to carry out these experiments it was necessary to separately stimulate the 
β1AR and β2AR. Subtype-specific stimulation of βARs can be achieved in two ways. 
The first is to use subtype-specific agonists to stimulate only the receptor of interest. 
The second is to use the non-selective βAR agonist isoprenaline while simultaneously 
blocking one receptor subtype, thus restricting stimulation to the type not sensitive to 
the antagonist; the experiments presented here used this second method. The use of 
antagonists in this way is a widely used pharmacological technique, thought to 
produce better results due to the greater specificity of antagonists compared to 
agonists. The compound zinterol is often used as a specific β2AR agonist, but data 
 221
obtained in this laboratory have shown that positive effects of zinterol on rat 
cardiomyocyte contractility can be abolished almost entirely by the selective β1AR 
antagonist CGP 20712A, suggesting that the effect of zinterol is in fact being 
mediated predominantly through the β1AR (Ranu 1998). A similar result has also 
been obtained using mouse cardiomyocytes, where it was shown that an increase in 
L-type Ca2+ current caused by application of zinterol could be blocked entirely by 
CGP 20712A (Heubach et al. 2001). The use of antagonists also avoids the possibility 
of specific agonists exhibiting partial agonism only. 
 
The experimental protocol followed in these experiments had the same basic structure 
as previous experiments (detailed in chapter five) with rat cardiomyocytes being 
stimulated with a submaximal concentration of isoprenaline before single 
concentrations of the PDE3 inhibitor milrinone and/or the PDE4 inhibitor rolipram 
were applied. A specific pharmacological antagonist of either the β1AR or β2AR was 
also present throughout the experiments, restricting isoprenaline stimulation entirely 
to the non-antagonised receptor. 
 
Two sets of experiments were carried out using isolated rat cardiomyocytes. The first 
looked at the effect of PDE3 and PDE4 inhibition on β-adrenergic signalling mediated 
entirely by the β1AR. The β2AR was blocked using 5 × 10-8 M ICI 118551 (Del 
Monte et al. 1993b); this was added to the superfusate at the beginning of the 
experiment, and remained present for the duration. This concentration of ICI 118551 
would be expected to produce a two log-unit shift in the isoprenaline concentration-
response curve if the effect were entirely mediated by the β2AR (Ranu 1998). A 
minimum of 20 min was allowed to elapse following addition of ICI 118551 before 
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any isoprenaline was added to the superfusate, to ensure that the antagonist had fully 
equilibrated with its target β2ARs. Cardiomyocytes were then stimulated with a 
submaximal concentration of isoprenaline. Isoprenaline at 3 × 10-9 M was sufficient to 
increase cardiomyocyte percentage shortening above basal in each experiment (if this 
had not been the case then the concentration of isoprenaline would have been raised 
until an increase in percentage shortening was seen, as described in chapter five). 
Milrinone and/or rolipram were added once the isoprenaline-induced increase in 
percentage shortening had stabilised. Milrinone was added at 10-6 M, rolipram at 10-5 
M; these concentrations were used to match the conditions used in previous 
experiments looking at the effects of PDE3 and PDE4 inhibition on isoprenaline-
stimulated contractility (chapter five). One experiment used milrinone and rolipram, 
the second rolipram on its own. Milrinone was always added before rolipram, and as 
such it was not felt necessary to conduct a separate experiment using milrinone on its 
own, as its effect could already be seen from the combined experiment. A graphical 
representation of the time-course of these experiments is shown in figures 7.1 and 7.2. 
 
The second set of experiments looked at the effect of PDE3 and PDE4 inhibition on 
β-adrenergic signalling mediated solely by the β2AR. This was accomplished by 
blocking the β1AR using 3 × 10-7 M CGP 20712A (Del Monte et al. 1993a). This 
concentration would be expected to produce a three log-unit shift in the isoprenaline 
concentration-response curve if the effect were entirely mediated by the β1AR (Ranu 
1998). The antagonist was present throughout the experiment, and 20 min was 
allowed for antagonist equilibration before the addition of a submaximal 
concentration of isoprenaline. If an increase in cardiomyocyte percentage shortening 
was then seen, milrinone and/or rolipram were added. However, the nature of β2AR  
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Figures 7.1-7.4 
Graphical representations of experimental protocols. 
The time-course of the experiment procedes from left to right, and the order in which 
experimental compounds were added to the superfusate runs from top to bottom. A 
vertical section through the diagram indicates which compounds were present 
simultaneously at a given point in the experiment. 
 
 
 
Figure 7.1 Experimental protocol for investigating the effect of PDE3 and PDE4 
inhibition on β-adrenergic stimulation acting through the β1AR. 
 
 
 
Figure 7.2 Experimental protocol for investigating the effect of PDE4 inhibition 
on β-adrenergic stimulation acting through the β1AR. 
β2AR blocker 
isoprenaline 
PDE3i
PDE4i 
Time (not to scale) 
Order of  
addition 
Time (not to scale) 
Order of  
addition 
β2AR blocker 
isoprenaline 
PDE4i
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signalling in the rat cardiomyocyte meant that several other considerations had to be 
taken into account. As described above, the majority of adrenergic receptors in the rat 
cardiomyocyte are β1ARs, with the contractile contribution from β2ARs being limited 
in nature. With the β1AR blocked by CGP 20712A, an isoprenaline concentration-
response curve initially increases cardiomyocyte percentage shortening via 
stimulation of the β2AR. However, the effect is small, and increasing the 
concentration of isoprenaline eventually enables it to out-compete the antagonist CGP 
20712A and begin to stimulate the β1AR as well as the β2AR, producing an overall 
biphasic concentration-response curve (Ranu 1998). CGP 20712A shifts the 
isoprenaline concentration-response curve for the β1AR to the right by approximately 
three log units (Ranu 1998). Isoprenaline at 3 × 10-9 M is sufficient to cause an 
increase in cardiomyocyte percentage shortening when acting through the β1AR, and 
so 3 × 10-6 M isoprenaline will also stimulate the β1AR in the presence of 3 × 10-7 M 
CGP 20712A. Therefore, isoprenaline was added to the cells at 3 × 10-7 M; if no 
increase in percentage shortening was seen then the concentration was increased to 
10-6 M. No higher concentrations of isoprenaline were used. Following a minimum 10 
min exposure to each PDE inhibitor, the PDE inhibitors only were removed from the 
superfusate. A minimum of 15 min was allowed for this washout and for any effect of 
PDE inhibition to dissipate. At this point the superfusate contained CGP 20712A and 
isoprenaline, concentrations of which had remained constant since their respective 
additions. To further confirm that contractility was being stimulated through the β2AR 
only, 5 × 10-8 M ICI 118551 was at this point added to the cells. A subsequent 
decrease in cardiomyocyte percentage shortening would strongly suggest that the 
original increase in contractility seen with isoprenaline at the beginning of the 
experiment had been mediated by the β2AR. In cases where the final addition of ICI 
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118551 did not decrease percentage shortening the results of that experiment were 
discarded. A graphical representation of these experiments is shown in figures 7.3 and 
7.4. Both ICI 118551 and CGP 20712A have been used extensively in this laboratory, 
and have been shown to have little effect on basal cardiomyocyte function. 
 
Table 7.1 Equilibrium dissociation constant KC of isoprenaline for human βARs, 
-log, mol/l 
 β1 β2 
Mitral valve lesion 7.2 ± 0.1 5.9 ± 0.2 
HOCM 7.3 ± 0.2 6.6 ± 0.4 
(Kaumann et al. 1989) 
 
Table 7.2 Log KD values for binding of subtype-specific βAR antagonists to 
human β1-, β2- and β3- ARs 
 β1 β2 β3 
CGP 20712A -8.81 ± 0.03 -6.11 ± 0.05 -5.19 ± 0.09 
ICI 118551 -6.52 ± 0.02 -9.26 ± 0.03 -6.44 ± 0.16 
 
CGP 20712A is 501-fold selective for the β1AR over the β2AR. 
ICI 118551 is 550-fold selective for the β2AR over the β1AR. 
(Baker 2005) 
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Figure 7.3 Experimental protocol for investigating the effect of PDE3 and PDE4 
inhibition on β-adrenergic stimulation acting through the β2AR. 
 
 
 
 
Figure 7.4 Experimental protocol for investigating the effect of PDE4 inhibition 
on β-adrenergic stimulation acting through the β2AR. 
 
Note the period of PDEi washout before the addition of the β2AR blocker, and that the 
β1AR blocker and isoprenaline were still present during this washout. 
 
β2AR blocker 
β1AR blocker 
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7.3 Results 
7.3.1 Signalling through the β1AR only 
Both PDE3 inhibition with milrinone and PDE4 inhibition with rolipram significantly 
increased cardiomyocyte percentage shortening in the presence of isoprenaline and 
the β2AR antagonist ICI 118551. A combination of milrinone and rolipram had a 
greater effect on percentage shortening than either compound used alone [figures 7.5 
and 7.6]. 
 
For the experiments assessing the effects of milrinone and rolipram combined, initial 
basal cardiomyocyte percentage shortening of 4.79 ± 0.36 % in the presence of 5 × 10-
8 M ICI 118551 was increased to 6.88 ± 0.64 % by exposure to submaximal 
isoprenaline of 3 × 10-9 M (P<0.05 by one-way ANOVA (repeated measures), n=8). 
Addition of 10-6 M milrinone increased percentage shortening from the isoprenaline-
stimulated level to 8.96 ± 0.98 % (P<0.05 by one-way ANOVA (repeated measures), 
n=8). The addition of 10-5 M rolipram in addition to the isoprenaline and milrinone 
already present in the superfusate further increased percentage shortening to 12.78 ± 
1.09 % [figure 7.5] (P<0.001 by one-way ANOVA (repeated measures), n=8) [figure 
7.5]. 
 
When assessing the effects of rolipram alone, basal percentage shortening of 3.93 ± 
0.37 % in the presence of ICI 118551 was increased to 6.79 ± 1.11 % by submaximal 
isoprenaline (P<0.05 by t-test, P<0.05 by one-way ANOVA (repeated measures), 
n=7). This figure is similar to the level of percentage shortening achieved by  
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Figure 7.5 The effects of PDE3 inhibition with milrinone and PDE4 inhibition 
with rolipram on β1AR-stimulated rat cardiomyocyte contractility 
Rat cardiomyocytes in which the activity of the β2AR adrenergic receptor was 
antagonised by ICI 118551 were stimulated with a sub-maximal concentration of 
isoprenaline, the isoprenaline acting through the β1AR only. The effect of PDE3 
inhibition using milrinone and PDE4 inhibition using rolipram on rat cardiomyocyte 
percentage shortening was then measured. Horizontal bars indicate at which point 
each experimental drug was present in the superfusate. Data are mean ± S.E.M. 
*P<0.05, ***P<0.001 by one-way ANOVA (repeated measures) using Bonferroni’s 
multiple comparison test to compare each column with the next, n=8. 
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Figure 7.6 The effect of PDE4 inhibition with rolipram on β1AR-stimulated rat 
cardiomyocyte contractility 
The activity of the β2AR was antagonised and the rat cardiomyocytes stimulated with 
isoprenaline in the same manner as shown in figure 7.5. The effect of PDE4 inhibition 
on cardiomyocyte percentage shortening using rolipram was measured. 
*P<0.05 by one-way ANOVA (repeated measures) comparing all columns, with 
Bonferroni’s multiple comparison test; #P<0.05 by t-test; n=7. 
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submaximal isoprenaline in the milrinone plus rolipram set of experiments above 
(6.56 ± 0.80 %), indicating a low variability in the effect of isoprenaline on the β1AR  
contractile response. The addition of 10-5 M rolipram increased percentage shortening 
from the isoprenaline-stimulated level to 8.57 ± 1.54 % (P<0.05 by t-test, n=7) [figure 
7.6]. 
 
The effects of milrinone and rolipram on the β1AR contractile response are seen to be 
approximately equivalent (percentage shortening of 8.70 ± 1.30 % and 8.57 ± 1.54 %, 
respectively). 
 
7.3.2 Signalling through the β2AR only 
PDE3 inhibition with milrinone potentiated the limited increase in cardiomyocyte 
percentage shortening seen with β2AR stimulation, but PDE4 inhibition with rolipram 
had no effect. However, a combination of milrinone and rolipram had a large effect on 
the β2AR contractile response, increasing percentage shortening to the same level as 
when PDE3 and PDE4 inhibition was combined with β1AR stimulation [figures 7.7 
and 7.8]. 
 
For the experiments assessing the effects of combining milrinone and rolipram, basal 
cardiomyocyte percentage shortening of 4.83 ± 0.30 % in the presence of 3 × 10-7 M 
CGP 20712A was increased to 5.46 ± 0.16 % by submaximal isoprenaline. This 
increase was not, however, statistically significant when assessed by t-test or one-way 
ANOVA (repeated measures) (n=5). Addition of 10-6 M milrinone nonetheless 
increased percentage shortening to 7.20 ± 0.60 % (P<0.05 by t-test, n=5). (Inclusion 
of data from a 6th repetition of the experiment – one where the rolipram data must be
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Figure 7.7 The effects of PDE3 inhibition with milrinone and PDE4 inhibition 
with rolipram on β2AR-stimulated rat cardiomyocyte contractility 
Rat cardiomyocytes in which the activity of the β1AR adrenergic receptor was 
antagonised by CGP 20712A were stimulated with a sub-maximal concentration of 
isoprenaline, the isoprenaline acting through the β2AR only. The effect of PDE3 
inhibition using milrinone and PDE4 inhibition using rolipram on rat cardiomyocyte 
percentage shortening was then measured. The PDE inhibitors were subsequently 
washed out, leaving CGP 20712A and isoprenaline only; the β2AR antagonist ICI 
118551 was then added to demonstrate that the isoprenaline-induced increase in 
percentage shortening had been mediated through the β2AR. Horizontal bars indicate 
at which point each experimental drug was present in the superfusate. 
*P<0.05 by t-test; ***P<0.001 by one-way ANOVA (repeated measures) comparing 
all columns, with Bonferroni’s multiple comparison test, n=5. 
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Figure 7.8 The effects of PDE4 inhibition with rolipram on β2AR-stimulated rat 
cardiomyocyte contractility 
Activity of the β1AR was antagonised and the rat cardiomyocytes stimulated with sub-
maximal isoprenaline in the same manner as shown in figure 7.7. The PDE4 inhibitor 
rolipram was subsequently added. Following washout of rolipram only, the β2AR 
antagonist ICI 118551 was again added to demonstrate that the isoprenaline-induced 
increase in percentage shortening had been mediated through the β2AR. Horizontal 
bars indicate at which point each experimental drug was present in the superfusate. 
*P<0.05, **P<0.01, both by one-way ANOVA repeated measures comparing all 
columns, with Bonferroni’s multiple comparison test, n=6. 
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excluded from a full one-way ANOVA (repeated measures) analysis due to the 
arrhythmia suffered by the cell upon the final rolipram addition – shows that the effect 
of 10-6 M milrinone on the β2AR contractile response becomes statistically significant 
by analysis with one-way ANOVA (repeated measures) as well. In this case, 
isoprenaline-stimulated percentage shortening of 5.72 ± 0.29 % was significantly 
increased by milrinone to 7.44 ± 0.54 % (P<0.05 by one-way ANOVA (repeated 
measures), n=6)). The addition of 10-5 M rolipram to cells already stimulated with 
isoprenaline and milrinone in the presence of CGP 20712A further increased 
percentage shortening to 12.59 ± 1.05 % (P<0.001 by one-way ANOVA (repeated 
measures), n=5). Upon washout of PDE inhibitors, leaving CGP 20712A and 
isoprenaline, percentage shortening decreased to 3.72 ± 0.53 %, below the original 
baseline level established before the addition of isoprenaline (P<0.001 by one-way 
ANOVA (repeated measures), n=5). (This decrease below basal suggests that the 
limited effect of β2AR stimulation was no longer operating. Alternatively, it is worth 
noting that a drop in percentage shortening to below the original baseline was also 
seen following maximal isoprenaline stimulation of rat cardiomyocytes in early 
experiments investigating the effect of IBMX on the isoprenaline concentration-
response curve (described in chapter 5), necessitating the initial stimulation of the 
cells with a single high concentration of isoprenaline before any curves were carried 
out in order to control for this phenomenon. In both cases the cells have been 
subjected to large increases in intracellular cAMP levels.) The addition of 5 × 10-8 M 
ICI 118551 at this point was still able to effect a further, small, drop in percentage 
shortening to 2.41 ± 0.40 %, however this decrease was not statistically significant by 
t-test or one-way ANOVA repeated measures (n=5) [figure 7.7]. Although this lack of 
a significant effect of β2-blockade at this stage in the experiment may seem to suggest 
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that the original isoprenaline effect was not in fact mediated by the β2AR, the 
decrease below baseline seen on PDE inhibitor washout suggests that there was little 
βAR effect left to block. A highly significant demonstration that the concentrations of 
isoprenaline and CGP 20712A used were able to produce a β2AR-mediated effect on 
contractility is provided by the next set of experiments, assessing the effect of 
rolipram alone. 
 
Basal cardiomyocyte percentage shortening of 5.13 ± 0.42 % in the presence of 
3 × 10-7 M CGP 20712A was increased by submaximal isoprenaline to 7.60 ± 0.70 %, 
the increase being statistically significant this time (P<0.01 by one-way ANOVA 
(repeated measures), n=6). The addition of 10-5 M rolipram to cardiomyocytes 
stimulated in this way had no effect on percentage shortening, which remained at the 
same level (7.59 ± 0.99 %, no significant difference by one-way ANOVA (repeated 
measures), n=5) and did not significantly change when the rolipram was washed out 
after a 10 min exposure (7.49 ± 0.82 %), leaving CGP 20712A and isoprenaline only. 
The effect of isoprenaline was completely reversed by the addition of 5 × 10-8 M ICI 
118551, with percentage shortening decreasing to 4.30 ± 0.99 % (P<0.05 by one-way 
ANOVA (repeated measures), n=5) [figure 7.8]. This confirms that the original 
isoprenaline-stimulated increase in percentage shortening was mediated entirely via 
the β2AR, as blockade of this receptor entirely abolished the effect of βAR stimulation 
on cardiomyocyte contractility. 
 
While the effect of β1AR stimulation on cardiomyocyte percentage shortening was 
identical to that of general βAR stimulation, β2AR stimulation often evoked a more 
complex response. In eight of a total of twelve experiments in which the β2AR was 
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stimulated, an initial transient increase in percentage shortening was seen upon 
isoprenaline addition, before the increase in percentage shortening stabilised at a 
lower level (by contrast, no such effects of β1AR stimulation were seen in a total of 
fifteen experiments); these effects occurred over a period of 10–20 min. In some 
instances of β2AR stimulation the drop after the transient peak returned percentage 
shortening to basal levels, necessitating an increase in isoprenaline concentration 
before the addition of PDE inhibitors. In these eight experiments, basal cardiomyocyte 
percentage shortening in the presence of 3 × 10-7 M CGP 20712A was 4.89 ± 0.27 %. 
Upon addition of 3 × 10-7 M isoprenaline, percentage shortening increased to a peak 
of 7.05 ± 0.29 % (P<0.001 by one-way ANOVA (repeated measures), n=8) before 
returning to a steady-state level of 5.70 ± 0.29 % (P<0.01 by one-way ANOVA 
(repeated measures), n=8) [figure 7.9]. (In the three out of twelve experiments where 
the isoprenaline concentration was increased to 10-6 M, transient peaks were seen in 
two cases.) 
 
Corresponding results from all the above experiments are presented side by side in 
figures 7.10 and 7.11 for comparison. The data are shown as the increase in 
percentage shortening from basal. 
 
7.4 Discussion 
The aim of the experiments detailed in this chapter was to study the effect of PDE3 
and PDE4 inhibition on isoprenaline-stimulated cardiomyocyte contractility at the 
level of separate βAR receptor subtypes. This was successfully accomplished, with 
data showing a differential effect of PDE inhibition on β1AR- and β2AR-mediated 
contractile increases. 
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Figure 7.9 Comparison of peak and steady-state rat cardiomyocyte percentage 
shortening following β2AR stimulation with 3 × 10-7 M isoprenaline in the 
presence of 3 × 10-7 M CGP 20712A  
In eight out of a total of twelve experiments in which the β2AR was stimulated, a 
transient peak in rat cardiomyocyte percentage shortening was observed before a fall 
to a lower steady-state level. Graph shows percentage shortening under basal 
conditions, peak isoprenaline-stimulated percentage shortening, and steady-state 
isoprenaline-stimulated percentage shortening. CGP 20712A was used to antagonise 
the β1AR throughout. 
**P<0.01, ***P<0.001, both by one-way ANOVA repeated measures comparing all 
columns, with Bonferroni’s multiple comparison test, n=8. 
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Figure 7.10 Data from figures 7.3 and 7.5 presented side by side 
An aid to comparison of the effects of PDE3 and PDE4 inhibition on the β1AR and 
β2AR contractile reponses. The data are presented as the increase in percentage 
shortening from the baseline value. *P<0.05, **P<0.01, ***P<0.001, all by one-way 
ANOVA (repeated measures) comparing all columns, with Bonferroni’s multiple 
comparison test. #P<0.05 by t-test. 
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Figure 7.11 Data from figures 7.4 and 7.6 presented side by side 
An aid to comparison of the effects of PDE4 inhibition on the β1AR and β2AR 
contractile reponses. The data are presented as the increase in percentage shortening 
from the baseline value. *P<0.05 by t-test; **P<0.01 by one-way ANOVA (repeated 
measures) comparing all columns, with Bonferroni’s multiple comparison test. 
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Responses obtained to PDE3 and PDE4 inhibition when isoprenaline stimulation was 
restricted to the β1AR were broadly similar to those obtained under conditions of 
general βAR stimulation (detailed in chapter five). When the β2AR was blocked using 
5 × 10-8 M ICI 118551, both 10-6 M milrinone and 10-5 M rolipram applied 
individually potentiated the β1AR contractile response to an equal extent. When the 
two PDE inhibitors were combined together at those same concentrations, a greater 
increase in the β1AR contractile response was seen. This increase raised percentage 
shortening to levels close to that seen under the same conditions but in the absence of 
any specific β-blockade (12.15 ± 1.30 % with β1AR stimulation compared to 14.27 ± 
1.17 % with non-specific βAR stimulation, chapter five). 
 
With signalling restricted to the β2AR through the use of 3 × 10-7 M CGP 20712A, the 
effect of submaximal isoprenaline on cardiomyocyte contractility was of a different 
nature to that seen with β1AR stimulation. While a definite increase in percentage 
shortening was seen, in two thirds of cases a transient peak in percentage shortening 
was observed before the cell reached a steady state at a lesser increase. That the 
increase in percentage shortening observed was attributable to stimulation of the 
β2AR only is confirmed by the negative effect of ICI 118551 on this response. 
Although a non-significant effect on the already below-basal level of percentage 
shortening in the milrinone plus rolipram experiments, the effect is clearly seen in the 
rolipram-only experiments, where the addition of 5 × 10-8 M ICI 118551 at the end of 
the experiment reduced the isoprenaline-stimulated contractility to basal levels, so 
excluding the possibility that the effect had been β1AR mediated. 
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As with the β1AR contractile response, PDE3 inhibition was able to potentiate the 
β2AR contractile response. While this was to a lesser extent than seen with the β1AR, 
the response to 10-6 M milrinone came on top of a much smaller increase in 
percentage shortening due to the limited β2AR effect on contractility. Milrinone was 
still able to increase cardiomyocyte percentage shortening by approximately 1.7 % 
above this level, compared to the 2.1 % rise seen with the β1AR. 
 
Where the two receptors differed was that PDE4 inhibition with 10-5 M rolipram did 
not have any effect on the β2AR contractile response. However, despite this lack of 
response, when rolipram was added to milrinone the combined effect on the β2AR 
contractile response was of equal magnitude to the effect of PDE3 and PDE4 
inhibition on β1AR-stimulated contractility. This indicates that β2AR-derived cAMP is 
theoretically able to effect a maximal increase in rat cardiomyocyte percentage 
shortening upon receptor stimulation, and that it is the action of PDEs 3 and 4 that 
normally restricts this. This is particularly interesting when one considers that the 
β2AR makes up only a small percentage of the total number of βARs in the rat 
cardiomyocyte. 
 
The β1AR contractility results suggest that PDE3 and PDE4 are (in a functional sense 
only) arranged “in parallel” to regulate β1AR cAMP, so that inhibition of either PDE 
allows some extra cAMP to “escape” from its compartment, and inhibition of both 
allows a much greater release of cAMP. In contrast, the β2AR contractility results 
would suggest that PDE3 and PDE4 are in this case arranged primarily “in series”. 
This arrangement would mean that inhibition of either PDE alone would be 
insufficient to raise cAMP levels, as the remaining active PDE would take up the 
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“workload” of its inhibited companion. Inhibition of both PDEs simultaneously would 
thus be required for a significant rise in cAMP levels. However, the fact that PDE3 
inhibition can increase the β2AR contractile response to a limited extent suggests that 
this explanation can at best be only partially true. Another interpretation of the 
contractility data is that some β2ARs are indeed regulated by PDE3 and PDE4 
arranged in series, but that there is also another population of β2ARs where a more 
parallel arrangement of PDE3 and PDE4 is in operation. The complex internal 
architecture of cells such as cardiomyocytes will most likely ensure that it is not 
possible to impose such simple explanations on these and related phenomena. 
 
As detailed in chapter one, while both β1- and β2ARs are both able to couple to Gs, 
and so produce positive inotropic effects, the β2AR is also able to couple to Gi and 
signal through pathways unavailable to the β1AR (Daaka et al. 1997). This coupling to 
Gi occurs via PKA phosphorylation of the β2AR, switching it from a conformation 
that couples to Gs to one that couples to Gi. 
 
Research by Baillie et al. using rat cardiomyocytes has revealed a role for PDE4 in 
the switching of the β2AR from Gs to Gi coupling (Baillie et al. 2003). Baillie et al 
have shown that members of the PDE4D sub-family are recruited to the β2AR via 
β-arrestins within minutes following isoprenaline stimulation. The recruited PDE4D is 
able to regulate the activity of PKA in the vicinity of the β2AR, and so control the 
level of PKA phosphorylation of the β2AR and its consequent coupling to Gi. This in 
turn affects the associated activation of ERK1/2, phosphorylation of which increases 
when PDE4 activity is inhibited using rolipram (Baillie et al. 2003). 
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As described above in the results section, stimulation of β2ARs often resulted in 
cardiomyocyte percentage shortening increasing to a transient peak, before settling 
again at a lower level. It is possible that this phenomenon is due to a shift in β2AR 
coupling from Gs to Gi – the peak increase in percentage shortening occurring when 
all β2ARs are signalling through Gs, and the subsequent drop in percentage shortening 
due to the switch to Gi coupling and a consequent drop in cAMP production. This 
hypothesis could be tested by treating cells with pertussis toxin, which blocks the 
action of Gi via ADP-ribosylation of its α-subunit. Also required is that G-protein 
switching by the β2AR occurs on a timescale of minutes rather than hours, allowing 
an effect to be seen in the typical 5–15 min of isoprenaline exposure used in 
contractility experiments. The fact that PDE4D recruitment to the β2AR following 
isoprenaline challenge in rat cardiomyocytes reaches >30 % of maximum in 5 min 
and approximately 45 % of maximum in 10 min suggests that these molecular events 
do indeed happen on such a timescale (Baillie et al. 2003). Cardiomyocyte ERK1/2 
phosphorylation also increases following 10–20 min isoprenaline challenge, again 
indicating that Gi switching of the β2AR has occurred (Baillie et al. 2003). 
 
Knowing that recruitment of members of the PDE4D sub-family to the β2AR is 
connected to its Gi switching, and that increased PKA phosphorylation is responsible 
for the switch, it is tempting to speculate that the lack of a β2AR contractile response 
in response to rolipram is caused by enhanced Gi switching. In this explanation, the 
PDE4 inhibition due to rolipram would enable PKA activity to be sustained, so 
allowing greater phosphorylation of the β2AR and an increase in its coupling to Gi. 
This in turn would prevent any increase in cardiomyocyte percentage shortening. 
Unfortunately such speculation provides too convenient an answer, and is argued 
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against by the fact that a combination of PDE3 and PDE4 inhibition serves to produce 
a very large increase in β2AR contractility, taking the cardiomyocyte close to 
maximum contractility. Indeed, the issue of Gi switching by the β2AR is difficult to 
reconcile with both the contractility data presented in this chapter, and the positive 
effects on cAMP levels following cardiomyocyte β2AR stimulation in the studies 
discussed below. It is worth remembering that while recruitment of PDE4D isoforms 
to the β2AR has been reported, current in-use pharmacological inhibitors such as 
rolipram target all PDE4 family members. If the number of β2ARs switched to Gi is 
less than total, then some receptors will still be signalling to Gs and able to stimulate 
production of cAMP linked to contractility. The simultaneous inhibition of PDE4s A, 
B and C, in conjunction with PDE3 inhibition, may then be enough to boost those 
levels of cAMP sufficiently to effect the observed large increase in cardiomyocyte 
percentage shortening. 
 
Two other published studies have looked at the effects of PDE inhibition on β1AR and 
β2AR mediated responses in cardiomyocytes. As described in the introduction to this 
chapter, Rochais et al. measured both membrane cAMP production and L-type Ca2+ 
current in rat ventricular myocytes (Rochais et al. 2006). Nikolaev et al. used an 
alternative approach, in which transgenic mice were generated to constitutively 
express a cytosolic FRET reporter sensitive to cAMP (Nikolaev et al. 2006). At the 
most basic level of comparison, these two studies also both show clear differences in 
β1AR and β2AR mediated responses. 
 
Due to its use of adult rat ventricular myocytes, the study by Rochais et al. offers the 
closer comparison to the contractility data presented in this chapter. The one 
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important difference is that the use of adenovirally-delivered CNG channels requires 
the culturing of the myocytes for 24 hours. Membrane cAMP production was 
calculated via patch clamping and measurement of the CNG channel current (ICNG). 
Cardiomyocytes were stimulated with isoprenaline at 5 × 10-6 M, and β1- and β2ARs 
were blocked using 10-6 M CGP 20712A and 10-6 M ICI 118551, respectively. Both 
PDE3 inhibition using 10-6 M cilostamide and PDE4 inhibition using 10-5 M  
Ro 20-1724 potentiated the β1AR-stimulated CNG current to a significant extent, with 
the effect of PDE4 inhibition being slightly greater than that of PDE3 inhibition; in 
both cases the increase in ICNG was sustained over several minutes (as discussed in 
chapter four, cilostamide and Ro 20-1724 have IC50 values towards their respective 
target PDEs that are very similar to those of milrinone and rolipram, respectively). By 
contrast, PDE3 and PDE4 inhibition individually had only a limited and transient 
effect on β2AR-mediated ICNG. However, when cilostamide and Ro 20-1724 were 
combined, a much greater and sustained potentiation of β2AR ICNG was seen, greater 
than the effect of a maximal concentration of IBMX. This powerful effect of 
combined PDE3 and PDE4 inhibition on β2AR-mediated responses matches the 
effects on contractility described in this chapter, but the very minor and transient 
effect of PDE3 inhibition on β2AR ICNG is at odds with the significant effect of 
milrinone on the β2AR contractile response.  
 
It is possible that the same transient increases in cAMP were present in the 
contractility experiments but were sufficient in duration to activate PKA. The reversal 
of PKA phosphorylation and activation of target proteins is dependent on the action of 
phosphatases, and so PKA-mediated effects can endure long after cAMP levels have 
declined. The concentration of ICI 118551 used in these experiments was also 
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considerably higher at 10-6 M than the concentration used in contractility experiments 
in this thesis (5 × 10-8 M). At high concentrations, ICI 118551 has negative inotropic 
effects in transgenic mouse cardiomyocytes overexpressing the β2AR and failing 
human cardiomyocytes (Gong et al. 2002). It is proposed that ICI 118551 is able to 
bind to and stabilise a conformation of the β2AR in which the receptor couples to Gi; 
high levels of β2AR or Gi expression are required in order to produce this negative 
inotropic effect, explaining why it is not seen in healthy human (or rat) 
cardiomyocytes (Gong et al. 2002). ICI 118551 at 10-6 M may still be activating Gi to 
an unknown extent, with effects on rat cardiomyocyte contractility that are unseen in 
the basal state but are of consequence when the cell is stimulated. 
 
Results obtained by Rochais et al. when measuring β1AR- and β2AR-stimulated 
L-type Ca2+ current again point to differences in the responses mediated by the two 
receptor subtypes. Both PDE3 and PDE4 inhibition potentiated β1AR and β2AR 
increases in ICa,L, but the effect of PDE4 inhibition was much greater than that of 
PDE3 inhibition on the β2-ICa,L. This is the opposite of the contractility data in this 
chapter, which show no effect of PDE4 inhibition alone on β2AR-stimulated 
contractility. 
 
The study by Nikolaev et al. stands in some contrast to the above results obtained 
with rat cardiomyocytes. Using transgenic mice expressing a FRET reporter that 
indicates cytosolic levels of cAMP, the authors found that PDE3 inhibition using  
10-6 M milrinone had only a very small potentiating effect on β1AR generated cAMP, 
in contrast to the near maximal potentiating effect of 10-7 M rolipram. β2AR mediated 
rises in cytosolic cAMP were considerably less, with PDE3 and PDE4 inhibition 
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having similar potentiating effects when used in isolation, and a combination of  
PDE3 and PDE4 inhibition having a similar effect on the β2AR cAMP signal to the 
non-specific inhibitor IBMX (yet still lower in absolute terms than cAMP increases 
effected by the β1AR). Nikolaev et al. also observed that β1AR-derived cAMP was 
able to diffuse throughout the cytosol, but β2AR-derived cAMP was restricted in its 
diffusion to the local area surrounding the stimulated receptors. The application of 
milrinone and rolipram did not enable the β2AR signal to diffuse further, suggesting 
that PDEs other than PDE3 and PDE4 might be involved in restricting β2AR-cAMP 
diffusion. If this is the case, then the cAMP under the control of these putative other 
PDEs does not appear to be connected to contractility, as PDE3 and PDE4 inhibition 
is sufficient to maximally boost the β2AR contractile response. 
 
In conclusion, distinct differences do exist between the β1AR and β2AR in terms of 
their effects on contractility and cAMP levels, and in their regulation by PDE3 and 
PDE4. Results from current studies do not however point to a single, easily definable 
conclusion. This is due in part to the nature of GPCR research and cardiomyocyte 
biology, where issues are invariably more complex than they may at first appear. 
Secondly, the studies discussed above and the work presented here on contractility all 
use different methods to study cAMP and its affects. CNG channels measure cAMP 
production only at the membrane, and require the use of cultured cardiomyocytes. 
Culturing of cardiomyocytes is known to alter their physical appearance and leads to a 
decrease in the number of t-tubules present in the membrane (Gorelik et al. 2006). 
This may alter their calcium handling characteristics and could also be indicative of 
further changes in cardiomyocyte membrane architecture that might alter the 
relationship between receptors and their subcellular effectors. This is a crucial point as 
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it is the three-dimensional relationships between subcellular components of the 
cardiomyocyte that are believed to define the compartmentation of intracellular 
signals. The FRET reporter measures changes in cytosolic cAMP levels but relies on 
the use of transgenic mice. The regulation of contractility itself is governed by many 
factors alongside cAMP levels, including the activity of PKA and associated 
phosphatases. Visualisation methods such as FRET show what is happening directly 
to levels of cAMP, but measurements of cardiomyocyte contractility come closest to 
modelling the actual in vivo response, and it is this that is most important if studies are 
to lead to the development of new pharmaceuticals and other medical advances. It has 
been suggested that combinations of β-blockade and PDE inhibition could be of 
benefit in the treatment of heart failure (Movsesian 2003). Further research may 
enable the use of PDE inhibitors and β-blockers to selectively boost the signal from 
targeted βAR subtypes, activating cell survival pathways or perhaps increasing 
inotropy via PDE4 while avoiding the known deleterious effects of long-term PDE3 
inhibition in the failing heart. 
 
 248
CHAPTER 8 EFFECTS OF PDE INHIBITION ON 
HUMAN EMBRYONIC STEM CELL-DERIVED 
CARDIOMYOCYTES 
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8.1 Introduction 
Embryonic stem cells (ESCs) are currently of great interest to the scientific 
community, due to the potential they offer for biomedical research and regenerative 
medicine (Harding et al. 2007). ESCs are derived from the inner cell mass of the 
blastocyst, and have the ability to form any adult cell type. Like all stem cells, they 
possess the ability to divide indefinitely with at least one daughter cell remaining 
uncommitted to any particular cell lineage and specialisation. Key to the potential of 
ESCs is the fact that they can be maintained in culture in an undifferentiated state for 
a potentially unlimited number of generations. Under the right conditions ESCs can be 
induced to differentiate into any one of the majority of cell lineages, and the 
differentiation into cardiomyocytes of both mouse and human ESCs has been 
accomplished (Mummery et al. 2002). Human embryonic stem cell-derived 
cardiomyocytes (hESCMs) promise much to both the researcher and the physician for 
the understanding and treatment of heart failure and other cardiac disease (Harding et 
al. 2007). In the burgeoning field of cardiac regeneration, hESCMs offer the best hope 
for a cell capable of regenerating damaged myocardium; hESCMs could also be used 
as a tool for the screening of pharmaceuticals, where it is crucial that the human 
response to a candidate drug molecule is known (Harding et al. 2007). 
 
The current standard in pharmacology is to use cardiomyocytes obtained from adult 
human myocardium. However, this tissue, especially of a healthy phenotype, is 
extremely difficult to obtain regularly and in any great mass. The use of hESCMs 
could provide an effectively unlimited supply of genuine human cardiomyocytes (as 
opposed to other animal cells), against which any number of drugs could be tested. 
The establishment of cultured hESCMs in a high-throughput system would enable 
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these cells to be applied to the screening of compounds on an industrial scale, 
something impossible with current sources of human cardiomyocytes. Human ESCMs 
also present themselves as an alternative to the adult cardiomyocyte (whether from 
human or laboratory animal) for basic laboratory pharmacological research. As 
evidenced in this thesis, the adult cardiomyocyte provides an excellent tool for 
research into the complex mechanisms governing myocardial contraction. Much has 
been learnt of the pathology underlying heart failure through the study of human 
cardiomyocytes taken from samples of failing human heart. Adult cardiomyocytes 
preserve, at a cellular level, the function found in the myocardium as a whole, such 
that the decreased contractile ability and lack of sensitivity to isoprenaline found in 
the failing heart at the organ level, is also found at the level of the individual 
cardiomyocyte (Harding et al. 2007). 
 
Yet adult cardiomyocytes have a number of disadvantages. These cells can be reliably 
obtained from explanted failing heart, and healthy cells isolated from unsuitable donor 
hearts. However, as stated above, the supply of such tissue is limited and advances in 
medical technology will only serve to decrease availability further. One alternative is 
simply to use animal cardiomyocytes, yet there are a number of disadvantages 
associated with all adult cardiomyocytes, even if one ignores the species differences.  
Chiefly, these relate to the culturing and transfection of such cells. Adult 
cardiomyocytes have effectively lost the ability to divide and propagate; while they 
are routinely maintained in culture for up to 48 hours, cardiomyocytes already show 
signs of dedifferentiating and losing their cardiac phenotype in this time (Piper et al. 
1988). Transfection of adult cardiomyocytes to express novel proteins or overexpress 
native ones is possible using adenoviral vectors, but the process has a low efficiency 
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and requires culturing. ESCMs, by contrast, are transfected much more easily, 
offering the possibility of a model system capable of the highly efficient expression of 
whichever proteins are of interest (Harding et al. 2007). 
 
Compared to the study of adult cardiomyocytes, the study of hESCMs is still in its 
infancy, and much work is required before these cells are ready for use in 
pharmacological screening programmes or routine medical implantation. To this end, 
work is being undertaken to characterise hESCMs in terms of pharmacological 
responses, in order that these might be compared with what is already known of adult 
cardiomyocytes. Much of this work is being undertaken here in the laboratories of the 
National Heart and Lung Institute, where β-adrenergic and muscarinic responses of 
hESCMs have been investigated (Brito-Martins et al. 2008). The beating rates of 
human embryonic stem cell-derived cardiomyocytes (hESCMs) are initially low, at 
40–50 beats per minute (BPM) (He et al. 2003), compared with a beating rate of 110 
BPM for adult human heart in the absence of autonomic tone (Harding et al. 2007), 
although this increases with time (see results below); the average size of the 
cardiomyocytes produced is small at 60 days (25 × 10 µM) (Snir et al. 2003) 
compared to adult human cardiomyocytes (20 × 120 µM) (Del Monte et al. 1995). 
Construction of cumulative isoprenaline concentration-response curves has shown 
hESCMs to have an EC50 for isoprenaline of 12.9 nM; isoprenaline also significantly 
increases mean beating rate by approximately 144 % (Brito-Martins et al. 2008). This 
compares with a range of 1.2–2.8 nM (subjects under 40 years of age compared with 
those over 50) in non-failing adult human cardiomyocytes (Davies et al. 1996) and 
>10 nM in failing adult human cardiomyocytes (Harding et al. 1992) (care must be 
taken in such comparisons, however, as it is percentage shortening being measured in 
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adult cardiomyocytes, rather than beating rate). Failing heart is believed to revert to a 
foetal phenotype (Molkentin & Dorn II 2001); the immaturity of hESCM might 
therefore explain the closer relationship between the EC50 values of hESCM and 
failing heart. This might even prove to be beneficial in the modelling of failing 
cardiomyocytes. 
 
The experiments presented in this chapter were carried out as part of the overall 
investigation in this thesis into developing a model for human cardiomyocyte 
phosphodiesterases. If hESCMs are to be developed into a pharmacological screening 
system, it is important to understand how they respond to PDE inhibition, and how 
these responses might change as the hESCMs age and develop. It is in this context 
that the PDE inhibitors IBMX, milrinone and rolipram were tested on hESCMs of two 
different developmental ages. 
 
8.2 Methods 
Contractility experiments were carried out according to the methodology described in 
chapter two; this was broadly similar in nature to contractility experiments carried out 
on adult cardiomyocytes, with the exception that no electrical stimulation was used 
due to the spontaneous beating nature of the hESCMs. 
 
All hESCMs were derived from the H7 cell line, as described in chapter two. Two sets 
of hESCMs were used, “early” and “late”. Each set consisted of a number of 
coverslips onto which were adhered spontaneously beating clusters of hESCMs; each 
coverslip could be used for multiple experiments. Early hESCMs were aged an 
average of 5.7 weeks (measured from the day of differentiation), late hESCMs an 
 253
average of 12.8 weeks. As described in chapter two, each coverslip was allowed to 
equilibrate with the superfusate for a minimum of 30 min before any experimental 
drugs were added. It has already been demonstrated in this laboratory that although 
basal beating rate will drop over the first 30 min following transfer of coverslips from 
culture to superfusion, it is stable from 30 min to 4 h of superfusion (Brito-Martins et 
al. 2008). All experiments were completed within this time window. 
 
Beating rate affects amplitude, thus measurements of amplitude were inappropriate. 
Furthermore, as it is beating clusters of cells that are being tracked (rather than a 
single cell), the concept of cardiomyocyte percentage shortening becomes somewhat 
more arbitrary and of decreased utility. Measurements of amplitude and related 
parameters such as relaxation can become innacurate over prolonged periods of time 
if the beating cluster moves or changes shape to any extent; the lack of high-contrast 
edges as seen in individual adult cells also makes it more likely that a tracked spot 
will shift position over time. Measurements of beating rate are immune to these 
problems, and have the advantage that a much lower level of tracking accuracy will 
still produce reliable results. 
 
Each coverslip had the potential to be used in multiple experiments (allowing for 
practical tissue culture considerations); to ensure that no residual effects of PDE 
inhibition or β-adrenergic stimulation remained from one experiment to the next, only 
one experiment was carried out per coverslip per day. In the case of the early 
hESCMs, the same six coverslips were used for all experiments, each coverslip being 
used once for each experimental condition. Where only n=5 experiments are recorded, 
one coverslip was not used due to infection destroying the cells (an unavoidable 
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hazard of repeatedly taking the coverslips in and out of culture). DMSO 
concentrations in the vehicle control experiments were matched to those used with 
IBMX (which featured the highest vehicle concentration of 0.1 % at 10-4 M IBMX).  
 
Following washout of PDE inhibitors / DMSO at the end of each experiment, 1 µM 
isoprenaline was added to the superfusate. This provided a saturating concentration of 
the β-adrenergic agonist and served two purposes: the first was to provide 
confirmation that the beating cells being measured were indeed cardiomyocytes – no 
increase in beating rate would occur with spontaneously beating skeletal myotubes 
(Reinecke et al. 2000) and contraction would be inhibited in the case of smooth 
muscle (Nakahira et al. 2001); the second was to provide a maximum beating rate that 
could then be compared with the effect of a PDE inhibitor (in terms of chronology, 
this technique was not used until the experiments with the early hESCMs, which were 
carried out at a later date than those using the late hESCMs). 
 
8.3 Results 
8.3.1 Early hESCMs 
Early hESCMs were an average of 5.7 weeks old at the time of use. Non-specific PDE 
inhibition with IBMX caused a significant increase in the spontaneous beating rate of 
the cardiomyocyte clusters, but PDE3 inhibition with milrinone and PDE4 inhibition 
with rolipram had no such effect. Vehicle control experiments demonstrated that 
DMSO had no effect on beating rate at the concentrations used. 
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8.3.1.1 Effects of IBMX on early hESCMs 
IBMX was applied to spontaneously beating hESCMs (average age 31 days / 4.5 
weeks) in a cumulative fashion from 10-9 M to 10-4 M. IBMX significantly increased 
beating rate from a basal of 39.0 ± 17.9 BPM to a maximum of 72.3 ± 18.9 BPM at an 
IBMX concentration of 10-4 M (P<0.001 by t-test, n=6). When normalised to BPM 
increase above basal, the EC50 for IBMX was 1.13 × 10-5 M [figure 8.1]. Similar EC50 
values of 9.43 × 10-6 M and 8.44 × 10-6 M were calculated when the data were 
displayed in alternate forms, either with BPM increase expressed as a percentage of 
basal BPM, or with BPM expressed as a percentage of the BPM rate achieved by the 
same cells using 1 µM isoprenaline [figures 8.2 and 8.3, respectively]. The latter 
shows that the effects of 10-4 M IBMX on basal BPM were equal to those of a 
saturating concentration of isoprenaline The basal beating rate before addition of 
IBMX was 50.7 ± 12.1 % of the isoprenaline response; this increased to 106.1 ± 11.2 
% of the isoprenaline response with the maximum concentration of IBMX (P<0.001 
by t-test, n=6). 
 
8.3.1.2 Effects of PDE3 inhibition with milrinone on early hESCMs 
As with IBMX, milrinone was applied to spontaneously beating hESCMs (average 
age 38 days / 5.4 weeks) in a cumulative fashion from 10-9 M to 10-5 M. In contrast to 
the effect of IBMX, only a very small and likely biologically insignificant increase in 
beating rate was observed using milrinone. The basal beating rate of 53.3 ± 12.2 BPM 
was increased to 59.0 ± 13.7 BPM (P<0.05 by t-test, n=6) [figures 8.4 and 8.5]. When 
compared with the effect of 1 µM isoprenaline on the same cells, it can be seen that 
the influence of milrinone was minor compared to that of isoprenaline; beating rate 
was 57.9 ± 4.0 % of the isoprenaline response at basal, compared to 63.8 ± 4.6 % at  
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Figure 8.1 hESCM (early). IBMX concentration-response curve, absolute BPM 
increase 
The effect of increasing concentrations of the non-specific PDE inhibitor IBMX on 
early hESCM is shown as the absolute increase in BPM. Data are mean ± S.E.M. 
EC50 1.13 × 10-5 M, 95 % CI 3.93 × 10-6 to 3.25 × 10-5 M, n=6. 
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Figure 8.2 hESCM (early). IBMX concentration-response curve, BPM increase 
as percentage of basal BPM 
EC50 9.43 × 10-6 M, 95 % CI 1.73 × 10-6 to 5.14 × 10-5 M, n=6. 
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Figure 8.3 hESCM (early). IBMX concentration-response curve. BPM presented 
as the percentage of the response to 1 µM isoprenaline 
EC50 8.44 × 10-6 M, 95 % CI 9.31 × 10-7 to 7.65 × 10-5 M, n=6. 
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Figure 8.4 hESCM (early). Milrinone concentration-response curve, absolute 
BPM increase 
The effect of increasing concentrations of the PDE3 inhibitor milrinone on early 
hESCM is shown as the absolute increase in BPM. Data are mean ± S.E.M. 
n=6. 
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Figure 8.5 hESCM (early). Milrinone concentration-response curve, BPM 
presented as the percentage of the response to 1 µM isoprenaline 
n=6. 
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maximum response. 
 
8.3.1.3 Effects of PDE4 inhibition with rolipram on early hESCMs 
Rolipram was applied to spontaneously beating hESCMs (average age 48 days / 6.8 
weeks) in a cumulative fashion from 10-9 to 10-5 M. Basal beating rate of 66.8 ± 17.9 
BPM was increased to 76.4 ± 17.0 BPM; this increase was, however, not statistically 
significant (no significant difference by t-test, n=5) [figure 8.6]. When looked at in 
terms of the response to 1 µM isoprenaline on the same cells, it can be seen that the 
basal beating rate was greater as a percentage of the isoprenaline response than in the 
above experiments (75.7 ± 6.3 %), but although increased by rolipram (to 87.9 ± 4.5 
%) the effect was not significant (no significant difference by t-test, n=5) [figure 8.7]. 
 
8.3.1.4 Vehicle control using DMSO 
DMSO was applied in a cumulative fashion to early hESCMs (average 44 days / 6.3 
weeks) in the same manner as above; maximum DMSO concentration was 0.1 %, in 
line with the maximum vehicle concentration used in the above experiments. DMSO 
caused a small, non-significant, decrease in beating rate from a basal of 74.0 ± 12.5 
BPM to 69.6 ± 13.2 BPM (no significant difference by t-test, n=5) [figure 8.8]. 
Beating rates as a percentage of the effect of 1 µM isoprenaline were 82.0 ± 3.7 % at 
basal, and 76.3 ± 5.2 % at maximum DMSO [figure 8.9]. 
 
8.3.2 Late hESCMs 
Late hESCMs were an average of 12.8 weeks old at the time of the two experiments 
detailed below. Unlike with the early hESCMs, both IBMX and milrinone had  
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Figure 8.6 hESCM (early). Rolipram concentration-response curve, absolute 
BPM increase 
The effect of increasing concentrations of the PDE4 inhibitor rolipram on early 
hESCM is shown as the absolute increase in BPM. Data are mean ± S.E.M. 
n=5. 
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Figure 8.7 hESCM (early). Rolipram concentration-response curve, BPM 
presented as the percentage of the response to 1 µM isoprenaline 
n=5. 
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Figure 8.8 hESCM (early). DMSO vehicle control, absolute BPM increase 
Concentration of DMSO matched to that used in IBMX experiments; n=5. 
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Figure 8.9 hESCM (early). DMSO vehicle control, BPM presented as the 
percentage of the response to 1 µM isoprenaline 
n=5. 
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significant positive effects on the spontaneous beating rate of the studied 
cardiomyocyte clusters. 
 
8.3.2.1 Effects of IBMX on late hESCMs 
IBMX was tested in a cumulative fashion from 10-9 M to 10-4 M on n=5 coverslips 
(average age 84 days / 12.1 weeks). No effect of IBMX was seen in two cases. 
However, in both instances basal spontaneous beating rates were already high, at 178 
BPM and 154 BPM, respectively. When these two negative results were excluded, it 
was possible to see that IBMX had significantly increased beating rate in the 
remaining three cases, from a basal of 96.0 ± 3.1 BPM to 129.0 ± 2.1 BPM (P<0.01 
by t-test, n=3) [figure 8.10]. The EC50 for IBMX was 7.95 × 10-6 M. When the 
increase in BPM is displayed as a percentage of the basal BPM, it can be seen that the 
increase was less in relative terms than that seen with the early hESCMs [figure 8.11]. 
 
8.3.2.2 Effects of PDE3 inhibition using milrinone on late hESCMs 
Milrinone was tested in a cumulative fashion from 10-9 M to 10-4 M on n=4 coverslips 
(average age 95 days / 13.5 weeks). In terms of chronological order of experiments, 
these were the first hESCMs that milrinone had been tested on, and so the higher 
concentration of 10-4 M was used initially. Unlike with the early hESCMs, PDE3 
inhibition using milrinone increased spontaneous beating rate of the measured clusters 
from a basal of 72.0 ± 14.0 BPM to a maximum of 103.0 ± 14.1 BPM (P<0.05 by t-
test, n=4) [figure 8.12]. While there is the possibility that milrinone will inhibit some 
PDE4 activity at 10-4 M (see earlier chapters for discussion), there was still a 
significant increase in BPM at the lower milrinone concentration of 3 × 10-5 M (94.0  
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Figure 8.10 hESCM (late). IBMX concentration-response curve, absolute BPM 
increase 
The effect of increasing concentrations of the non-specific PDE inhibitor IBMX on 
late hESCM is shown as the absolute increase in BPM. Data are mean ± S.E.M. 
EC50 7.95 × 10-6 M, 95 % CI 1.69 × 10-6 M to 3.74 × 10-5 M, n=3. 
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Figure 8.11 hESCM (late). IBMX concentration-response curve, BPM increase 
as percentage of basal BPM 
EC50 7.40 × 10-6 M, 95 % CI 3.34 × 10-6 M to 1.64 × 10-5 M, n=3. 
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Figure 8.12 hESCM (late). Milrinone concentration-response curve, absolute 
BPM increase 
The effect of increasing concentrations of the PDE3 inhibitor milrinone on late 
hESCM is shown as the absolute increase in BPM. Data are mean ± S.E.M. 
It was not possible to fit a sigmoidal curve to the data; n=4. 
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± 14.5 BPM, P<0.05 vs. basal by t-test, n=4). However, the data produced by the late 
hESCMs was of lower quality than that obtained with the early hESCMs, and accurate 
fitting of a concentration-response curve proved difficult [figure 8.12]. Curve-fitting 
was achieved by normalising the BPM data to percentage of maximum response; this 
gave an EC50 of 1.76 × 10-5 M [figure 8.13]. 
 
8.3.2.3 Vehicle control experiments 
Due to a lack of surviving late hESCM clusters, it was not possible to carry out a full 
set of vehicle control experiments. However, two experiments using DMSO 
concentrations matched to those present in the IBMX experiments indicated that, as 
with the early hESCMs, DMSO had little effect on spontaneous beating rate at the 
concentrations used. 
 
8.4 Discussion 
The experiments presented here provide clear proof-of-principle that human 
embryonic stem cell-derived cardiomyocytes can serve as a model system for the 
testing of PDE inhibitors and other related compounds. The data show that PDE 
inhibition results in a definite change in the spontaneous beating rate of hESCM 
clusters; in the case of IBMX this change is clearly proportional to the concentration 
of the PDE inhibitor, and results in a classic sigmoidal concentration-response curve. 
Furthermore, the use of a saturating concentration of isoprenaline provides a useful 
alternative point of comparison between different clusters and experiments (as well as 
confirming each time that the cells being studied are indeed cardiac muscle cells). 
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Figure 8.13 hESCM (late). Milrinone concentration-response curve, BPM 
normalised to percentage of maximal response (top of curve fixed at 100 %) 
EC50 1.76 × 10-5 M, 95 % CI 9.92 × 10-6 M to 3.13 × 10-5 M, n=4. 
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The EC50 for IBMX was 1.13 × 10-5 M for early hESCMs and 7.95 × 10-6 M for late 
hESCMs (determined from absolute BPM increase). This might suggest that hESCMs 
become more sensitive to PDE inhibition as they develop, although the broad 95 % 
confidence interval for the latter EC50 makes it difficult to draw too firm a conclusion. 
These EC50 values compare to an IBMX EC50 for adult human (diseased) 
cardiomyocytes of between 1.56 × 10-6 M and 4.92 × 10-6 M (depending on how 
calculated, chapter four). This appears to make these adult human cardiomyocytes 
more sensitive to IBMX than their ESC-derived counterparts. However, the 
differences between all three EC50 values are small, and more data would be required 
to determine if there were real age-linked changes in sensitivity to PDE inhibition. 
 
Of particular interest is the fact that a response to PDE3 inhibition was only seen in 
late hESCMs, with no effect of the PDE3 inhibitor milrinone seen in early hESCMs. 
The EC50 for milrinone in late hESCMs was 1.76 × 10-5 M; this compares to  
1.46 × 10-6 M in the adult human cardiomyocytes. Effects of PDE3 inhibition were 
not seen at low concentrations; combined with the approximately 10-fold lower 
sensitivity compared to adult cells – and the complete lack of a milrinone response in 
early hESCMs – this suggests that cardiomyocyte PDE3 expression is still limited at 
this developmental stage, and that PDE3 activity does not reach a position of 
significant importance in terms of control of contractile function until the 
cardiomyocyte reaches a more mature state. However, it must be remembered that the 
data pertaining to adult human cardiomyocytes was obtained using diseased cells 
only. 
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The absence of a response to PDE4 inhibition with rolipram is not in itself particularly 
surprising, given the results already obtained with adult cardiomyocytes (chapter 
four). Experiments on hESCMs using isoprenaline or forskolin in combination with 
rolipram will be necessary to establish if functional PDE4 is present at this stage of 
cardiomyocyte development. 
 
Further experiments with hESCMs and PDE inhibition are required to determine 
whether these cells might be best employed for pharmacological screening or as a 
research tool to replace the adult cardiomyocyte. It would be interesting to see if the 
same patterns of PDE compartmentation evident in adult cardiomyocytes were also 
found in ESC-derived cardiomyocytes. Both functional β1- and β2-adrenergic 
receptors exist in hESCMs; the proportion of the isoprenaline response due to 
β2-adrenergic receptors has been measured at 17–37 % (Brito-Martins et al. 2008), in 
the range for non-failing human ventricle (Brodde 1991). Experiments similar in 
nature to those carried out on rat cardiomyocytes in chapter seven would establish if 
hESCMs had the same functional associations found to exist between PDE3 and 
PDE4 and the β1- and β2-adrenergic receptors. However, the lack of a fully-developed 
cellular architecture in hESCMs might make it difficult to extrapolate results on 
cAMP signalling and related issues to adult cardiomyocytes; for example, T-tubule 
structures have not been detected in hESCMs by electron microscopy even after 60 
days (Snir et al. 2003).  
 
In conclusion, while the potential utility of the human embryonic stem cell-derived 
cardiomyocyte as a subject for modelling cardiomyocyte PDE responses has been 
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demonstrated, much in the way of further research will be needed to develop a 
practical model system. 
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CHAPTER 9 GENERAL DISCUSSION 
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9.1 Summary table comparing PDE activity and functional 
effects between species for PDEs 1–5 
Table 9.1 Summary table 
 Rat Human Guinea pig hESCM 
~90 % reduction 
in cAMP-PDE 
activity 
 
 
~100 % reduction 
in cGMP-PDE 
activity 
~90 % reduction in 
cAMP-PDE activity 
 
 
 
~89 % reduction in 
cGMP-PDE activity 
~90 % 
reduction in 
cAMP-PDE 
activity 
 
~97 % 
reduction in 
cGMP-PDE 
activity 
(Activity not 
assessed) 
IBMX 
Increases basal 
and iso-
stimulated 
contractility 
Increases basal 
contractility 
 
Increases basal 
contractility 
Increases basal 
beating rate 
EC50 3.94 × 10-5 M 1.56–4.92 × 10-6 M 1.29 × 10-5 M 
Early: 1.13 × 10-5 M 
Late: 7.95 × 10-6 M 
No significant 
reduction in 
cAMP-PDE 
activity 
 
~39 % reduction 
in cGMP-PDE 
activity 
~67 % reduction in 
cAMP-PDE activity 
 
 
 
~85 % reduction in 
cGMP-PDE activity 
~56 % 
reduction in 
cAMP-PDE 
activity 
 
~80 % 
reduction in 
cGMP-PDE 
activity 
(Activity not 
assessed) 
PDE1-
inhibition 
No effect on iso-
stimulated 
contractility 
No effect on basal 
contractility 
No effect on 
basal or iso-
stimulated 
contractility 
(Not tested 
functionally) 
No significant 
reduction in 
cAMP-PDE 
activity 
 
~44 % reduction 
in cGMP-PDE 
activity 
 
No significant 
reduction in cAMP-
PDE activity 
 
 
No significant 
reduction in cGMP-
PDE activity 
No significant 
reduction in 
cAMP-PDE 
activity 
 
~22 % 
reduction in 
cGMP-PDE 
activity 
(Activity not 
assessed) PDE2-
inhibition 
(Not tested 
functionally) 
(Not tested 
functionally) 
(Not tested 
functionally) 
(Not tested 
functionally) 
(Table continued on next page) 
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 Rat Human Guinea pig hESCM 
~36 % reduction 
in cAMP-PDE 
activity 
 
~39 % reduction 
in cGMP-PDE 
activity 
~27 % reduction in 
cAMP-PDE activity 
 
 
No significant 
reduction in cGMP-
PDE activity 
~26 % 
reduction in 
cAMP-PDE 
activity 
No significant 
reduction in 
cGMP-PDE 
activity 
(Activity not 
assessed) 
PDE3-
inhibition 
Only affects iso- 
and FSK-
stimulated 
contractility 
Increases basal 
contractility 
Increases basal 
contractility 
Increases basal 
contractility only in 
late hESCM 
EC50 NA 1.46 × 10-6 M 4.73 × 10-7 M 
Early: NA 
Late: 1.76 × 10-5 M 
~25 % reduction 
in cAMP-PDE 
activity 
No significant 
reduction in cAMP-
PDE activity 
No significant 
reduction in 
cAMP-PDE 
activity 
(Activity not 
assessed) 
PDE4-
inhibition Only affects iso- and FSK-
stimulated 
contractility 
No effect on basal 
contractility alone 
or with milrinone 
No effect on 
basal 
contractility 
alone or with 
milrinone 
No effect on basal 
contractility 
No significant 
reduction in 
cGMP-PDE 
activity 
~18 % reduction in 
cGMP-PDE activity 
~19 % 
reduction in 
cGMP-PDE 
activity 
(Activity not 
assessed) 
PDE5-
inhibition 
Counteracts iso 
stimulation 
Counteracts iso 
stimulation 
Counteracts iso 
stimulation 
(Not tested 
functionally) 
 
9.2 A suitable model for human cardiomyocyte PDEs 
9.2.1 PDE activity 
One of the key aims of this project was to determine which of the animal species 
studied would make the most suitable model for human cardiomyocyte PDE activity 
and function. From the results obtained and summarised in the table above, it is clear 
that the results obtained for the isolated guinea pig cardiomyocytes were a much 
closer match to the human cardiomyocyte results than were those of the rat. The 
clearest expression of this is seen in the PDE activity results obtained by SPA and 
presented in chapter three. No significant differences were found between guinea pig 
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and human cardiomyocytes when measuring both cAMP-PDE and cGMP-PDE 
activity, as determined through the use of isoform-specific PDE inhibitors. 
 
Of particular interest was the unexpected finding that PDE1 activity contributed a 
large part of the cAMP-PDE activity (and the majority of cGMP-PDE activity) in the 
guinea pig and human cardiomyocytes tested (PDE1 activity was only detectable in 
rat cardiomyocytes when assaying cGMP-PDE activity; as discussed in chapter three, 
this may reflect the expression of different PDE1 isoforms in rat cardiomyocytes as 
compared to guinea pig and human). This represents the first such discovery of 
significant PDE1 activity in guinea pig and diseased human cardiomyocytes (another 
study has since been published also demonstrating significant PDE1 activity in human 
cardiomyocytes, suggesting that PDE1C is the main isoform present in the 
myocardium (Vandeput et al. 2007)). The confirmation of PDE5 activity in guinea pig 
and human diseased cardiomyocytes is equally important, and a finding that has been 
the subject of some dispute previously. The findings of PDE1 and PDE5 activity in 
guinea pig and human cardiomyocytes were reflected in the RTPCR results, which 
clearly showed appreciable levels of PDE1 and PDE5 expression in those cells. Rat 
cardiomyocytes, by contrast, showed little or no PDE1 and PDE5 expression.  
 
9.2.2 Functional effects of PDE inhibition 
Functional studies measuring the effect of PDE inhibition on cardiomyocyte 
percentage shortening also showed the guinea pig to be a closer model to human than 
the rat (chapter four). IBMX sensitivity was in the order human > guinea pig > rat; 
both guinea pig and human cardiomyocytes also responded to PDE3 inhibition under 
basal conditions, whereas rat cardiomyocytes did not. Human embryonic stem cell-
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derived cardiomyocytes showed promise as a potential model for adult human 
cardiomyocytes, with the more developed hESCMs responding to both IBMX and 
milrinone (chapter eight). 
 
9.2.3 The importance of finding a model 
The finding of a suitable model for human cardiomyocyte PDEs is extremely 
important from scientific, medical and commercial points of view. The key aim of 
biomedical science is to use the results of basic research to further the understanding 
of disease processes; the central role played by PDEs in modulating cardiomyocyte 
cyclic nucleotide signalling makes it clear how important the understanding of PDEs 
is to combating heart failure and other cardiac disease. Furthermore, a better 
understanding of human cardiomyocyte PDEs will lead to a more effective use of 
resources in pharmaceutical research and cut down on unnecessary animal 
experiments. By using the correct animal model, the drugs so developed will have a 
far better chance of achieving the desired results when administered to human 
subjects, as well as minimising unwanted side-effects (it is equally important to make 
sure that drugs do not exhibit unwanted PDE inhibitory activity, especially if this 
might affect the heart). This in turn reduces the risk of a drug being found unsuitable 
for medical use only late in its development, helping cut down the problem of phase II 
attrition whereby promising candidate molecules are rejected at a late stage in testing; 
by this time many years of work and large amounts of money may well have been 
expended, making it of vital commercial importance that as few candidates as possible 
fail late in the process. 
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9.3 New insights into cardiomyocyte PDEs 
9.3.1 PDE activity versus function 
As well as demonstrating the suitability of the guinea pig versus the rat for modelling 
human cardiomyocyte PDEs, the experiments described in this thesis have led to new 
insights into cardiomyocyte PDE function as whole. A key observation from the early 
chapters is that levels of PDE activity in the cardiomyocyte do not necessarily reflect 
the importance of a given PDE to contractility. An example of this can be seen with 
the guinea pig, where PDE3 activity levels were much lower than PDE1 levels, yet 
PDE3 and not PDE1 inhibition was able to significantly increase guinea pig 
cardiomyocyte percentage shortening. The results from rat cardiomyocytes at first 
seemed to indicate that PDE inhibition did not affect contractility at all (chapter four), 
despite the relative level of PDE3 activity being the same as for guinea pig and human 
cardiomyocytes. However, the importance of PDE3 and PDE4 in controlling rat 
cardiomyocyte contractility was revealed when the cells were pre-stimulated with 
submaximal concentrations of isoprenaline or forskolin (thus raising cAMP levels). It 
was then seen that inhibition of PDE3 and PDE4 could, under these new 
circumstances, maximally boost rat cardiomyocyte percentage shortening. 
 
By comparing the effect of a combination of isoform specific PDE inhibitors with that 
of IBMX, the SPA results indicated that all cardiomyocyte PDE activity (at 0.5 µM 
cyclic nucleotide substrate) could be accounted for by PDEs 1, 2, 3, 4, 5 and 7, 
without the need to invoke any of the poorly understood PDEs 8–11. Furthermore, 
experiments performed on rat cardiomyocytes suggested that the potentiating effect of 
IBMX on the isoprenaline response could be explained solely in terms of PDE3 and 
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PDE4 inhibition, as a combination of PDE3 and PDE4 inhibition with submaximal 
isoprenaline maximally increased cardiomyocyte percentage shortening (chapter five). 
 
9.3.2 PDEs and β-adrenergic signalling 
Further studies presented in this thesis using rat cardiomyocytes have profoundly 
increased understanding of the role PDEs play in modulating signals from individual 
subtypes of the β-adrenergic receptor (chapter seven). The experiments described in 
chapter five showed that a combination of submaximal isoprenaline with PDE3 and 
PDE4 inhibition would maximally increase rat cardiomyocyte percentage shortening. 
The work presented in chapter seven expanded on this, revealing significant 
differences in the way in which β1- and β2ARs were controlled by PDE3 and PDE4. 
When β-adrenergic antagonists were used to restrict the isoprenaline effect to only 
one βAR subtype, both β1- and β2ARs were still individually capable of maximally 
increasing rat cardiomyocyte percentage shortening when combined with PDE3 and 
PDE4 inhibition. This indicates a significant reserve capacity in the ability of the 
cardiomyocyte to generate cAMP in response to β-adrenergic stimulation. This ability 
is most interesting in the case of the β2AR, whose contribution to the total number of 
βARs is small, and indeed whose very existence in rat cardiomyocytes was once 
disputed. When one considers that a combination of PDE3 and PDE4 inhibition failed 
to have any significant effect on rat cardiomyocyte percentage shortening under basal 
conditions, it is highly interesting that just a minor increase (even an apparently non-
significant one) in percentage shortening mediated via the β2AR alone can be 
maximally boosted if PDE3 and PDE4 are simultaneously inhibited. This result 
underlines the importance and power of β-adrenergic stimulation in modulating 
cardiomyocyte activity. 
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Given that such unequivocal results were obtained by combining a single, 
submaximal concentration of isoprenaline with PDE4 inhibition, it was perplexing 
that a similar effect could not be seen when attempting to determine the effect of 
PDE4 inhibition on the isoprenaline concentration-response curve (chapter five). The 
experiments in chapters five and seven used submaximal isoprenaline concentrations 
with exposure times of approximately 5–15 minutes; in contrast, a full isoprenaline 
concentration-response curve requires approximately 45 minutes to complete, and the 
experimental protocol required performing two such curves in succession. It is 
possible therefore that PDE4 inhibition with rolipram might have a positive effect on 
the isoprenaline concentration-response curve via an influence on β1AR-mediated 
contractility, but that this response is in practice masked by a negative effect of the 
β2AR. In this scenario, a long exposure to isoprenaline during the course of the 
experiment leads the β2AR to switch from a Gs-coupled form to Gi coupling; the 
consequent depression of contractility counterbalances any β1AR-mediated positive 
effects. In the experiments detailed in chapter seven, the sometimes transient effects 
of isoprenaline on β2AR mediated contractility do indeed indicate that some form of 
β2AR desensitisation was occurring. However, this effect was slight and a positive 
effect of β2AR stimulation on contractility could still be maintained over the duration 
of the experiments. As discussed in detail in chapter seven, the issue of PDE4 and 
control of the β2AR is still not entirely clear, with a number of contradictions left to 
resolve; the answer may be found when pharmacological tools enabling 
discrimination between PDE4 isoforms become available. 
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9.3.3 PDE1 and PDE5 
As mentioned above, taking together the results from the SPA in chapter three and the 
functional experiments on PDE1 and PDE5 inhibition in chapter six reveals the 
difficulties of trying to make predictions about PDE functional importance from 
knowledge of whole-cell enzyme activity alone. The large amounts of PDE1 activity 
in guinea pig and human cardiomyocytes would seem to suggest that these enzymes 
must fulfil an important role within the cell, yet functional experiments failed to find 
any influence of PDE1 on contractility. Secondly, the much lower amounts of PDE1 
activity and expression in the rat beg the question as to why the guinea pig and human 
might need significant cardiomyocyte PDE1 when the rat does not. Clearly more 
research is needed in this area, and, as discussed in chapter six, given the potential 
crosstalk between PDEs it may prove necessary to consider all cGMP-hydrolysing 
PDEs simultaneously in experiments.  
 
The issue of PDE5 also proved complex. The results from chapter three appeared to 
indicate that only guinea pig and human cells displayed significant levels of PDE5 
expression, and possible PDE5 activity. Yet the greatest effect of the PDE5 inhibitor 
UK 114542 on isoprenaline-stimulated contractility – an inhibitory effect – was seen 
in rat cardiomyocytes. This may in part reflect the robust nature of rat cardiomyocytes 
compared to guinea pig and human cells, which makes them such a suitable model for 
experimentation. This robust nature makes it easier to obtain stable cells and thus 
measure the small changes in percentage shortening that occur with PDE5 inhibition. 
Further research in this area, including the use of PDE5 inhibitors with greater 
specificity, is clearly needed and will be discussed below. 
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9.4 Limitations 
The experiments presented in this thesis were carried out on cardiomyocytes isolated 
from healthy rat hearts, healthy guinea pig hearts and diseased human hearts. An 
obvious limitation is that healthy cardiomyocytes were being compared with diseased, 
and that this might not take into account cellular changes that arise due to the disease 
state. From a safety pharmacology point of view however, it is diseased human heart 
that will be exposed to new pharmaceuticals. Data obtained from the study of such 
tissue is therefore of arguably as great a value as that obtained from the study of 
healthy heart. A second, more practical, issue is that obtaining tissue from healthy 
human hearts is extremely difficult, as such tissue is simply not available except in 
rare instances. There is therefore also a purely pragmatic reason for using diseased 
human cardiomyocytes. Furthermore, the starting point for this work was to study the 
PDEs in isolated cardiomyocytes, rather than whole heart or tissue. Knowledge in this 
area was felt to be limited and the intention was to obtain important basic 
pharmacological data, rather than to try and conduct an in-depth study using a variety 
of animal models. For this reason it made sense to begin by studying cardiomyocytes 
isolated from healthy animal hearts. Human cardiac tissue from failing and 
hypertrophied hearts was readily available and – with relatively little research carried 
out on such cells elsewhere – could provide useful and novel data. By contrast, a 
study using cardiomyocytes from animal failing heart models would be complex and 
difficult to set up, and would be best carried out once data had been obtained on more 
basic model systems. 
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9.5 Future work 
There is much in the way of future work that could be carried out following on from 
the results presented in this thesis. 
 
The use of alternative and more specific PDE inhibitors might reveal further insights 
into cardiomyocyte function. The issue of PDE inhibitor potency and specificity is 
one of great importance to the field, and is not always considered as carefully as it 
might be. More research into PDE7, for example, may have to await the development 
of a more potent inhibitor; there are additionally PDEs 8–11 for which no specific 
inhibitors yet exist (although as noted above, there is no current evidence that these 
PDEs play any role in controlling cardiomyocyte contractility).  
 
As noted in chapter three, molecular biology allows the expression of PDEs to be 
measured at the level of isoforms of a single PDE family, for example discriminating 
between PDE4 A, B, C and D forms. Pharmacological technology by contrast lags 
behind, with currently available PDE inhibitors only capable of distinguishing 
between members of different families. The ability to inhibit the activity of, say, 
PDE4D while leaving PDE4s A, B and C unaffected would be of great utility in 
determining the functional role of these different isoforms. However, homology 
between active sites may render the development of such inhibitors difficult if not 
impossible. Technologies such as RNA interference may allow the inhibition of PDE 
family subtypes at the level of expression, although any effects achieved would not be 
reversible in the context of contractility experiments. 
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The discovery of significant amounts of PDE1 activity in guinea pig and human 
cardiomyocytes, and the discovery that PDE5 is also active in cardiomyocytes from 
all three species studied, clearly shows that much more research is warranted into both 
the roles of these enzymes and the interactions between all cGMP-hydrolysing PDEs. 
The experiments using PDE1 inhibition in combination with PKG inhibition should 
be extended into human cardiomyocytes, and possibly combined with inhibitors of 
other cGMP-PDEs. The use of PDE2 inhibition might enable the discovery of the 
mechanism by which PDE5 inhibition decreases isoprenaline-stimulated contractility, 
and a careful comparison between cardiomyocytes from human left and right ventricle 
for the effects of PDE5 inhibition is also required. The discovery that PDE5 may play 
a role in the mechanisms underlying cardioprotection in ischemia-reperfusion (Das et 
al. 2005), and the fact that there is likely to be considerable important crosstalk 
between PDEs including PDE5, shows how important these issues might be for the 
development of new medical treatments for cardiac disease. 
 
As discussed in earlier chapters, FRET technology is proving an extremely powerful 
way of investigating cAMP function in intact, living cardiomyocytes. Currently only 
used in rat and mouse cardiomyocytes, the transfection of FRET reporters into guinea 
pig or human cardiomyocytes might be used to unambiguously reveal where in the 
cell PDE1 activity is located, and thus perhaps allow its function to be inferred. At the 
present time, a variety of FRET experiments have been carried out on cardiomyocytes 
from different sources (neonatal rat, transgenic mouse etc) using a variety of probes 
(Mongillo et al. 2004; Nikolaev et al. 2006). The role of different PDE isoforms has 
been looked at, as has the ability of β1- and β2ARs to produce different patterns of 
cAMP production. What is needed is a comprehensive synthesis of all these 
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experiments, combining in a single model system subtype-specific β-adrenergic 
stimulation with isoform-specific PDE inhibition. A limitation to FRET techniques is 
that it can be difficult to determine precisely which region (or compartment) of the 
cell the diffuse fluorescent signal is coming from. The use of a powerful new imaging 
technique such as scanning ion conductance microscopy (Gorelik et al. 2006) might 
enable the precise localisation of given β-AR receptors on the cell surface, such that 
the subsequent use of FRET might then show if cAMP production was associated 
with the identified receptors. 
 
Another way of investigating the function of phosphodiesterases such as PDE1 would 
be to generate a cardiac-specific knockout for the enzyme of interest. Generating such 
an animal is, however, a complex and lengthy process, and there is no guarantee of 
success. It might be that PDE1 function is of such importance that any attempt at 
generating a knockout (even cardiac specific) would prove embryonic-lethal. Also of 
note is the fact that, for practical reasons, most knockout animals are mice. All the 
experiments detailed in this thesis might also be applied to mouse cardiomyocytes, 
although mouse cardiomyocytes are more difficult to obtain and work with than those 
from rat and guinea pig, and there would not be much to be gained from doing this 
that would prove edifying when it came to modelling the human cardiomyocyte. 
Mouse embryonic stem cells might be used to generate cardiomyocytes with 
mutations that would prove lethal in adult mice, and so could provide a means to 
circumvent the problems of embryonic-lethality described above. 
 
One of the key aims of studying the progression of heart failure at the molecular level 
is to identify the changes that differentiate the failing cardiomyocyte from the healthy. 
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A full picture of how PDE expression and activity might change as healthy human 
cardiomyocytes begin to fail, and whether this changes according to the specific 
category of disease, would be of supreme importance to the understanding of heart 
failure (such an aim does require large amounts of healthy human heart tissue as well 
as diseased, something that can be difficult to obtain). It would not be sufficient, 
however, to just use whole-cell biochemical analysis to accomplish this aim. As 
shown in this thesis, such information, while useful, is incomplete unless 
accompanied by a functional analysis. Research by Lehnart et al. shows how PDE4D 
expression within the ryanodine receptor complex can be reduced in failing 
cardiomyocytes, thus allowing increased PKA-mediated RyR phosphorylation, 
increased Ca2+ leakage and a promotion of heart failure (Lehnart et al. 2005). This 
indicates how it is equally important to know how PDE activity and distribution is 
changing on a sub-cellular level. This again might be accomplished using FRET 
technologies. 
 
9.6 Summary 
It can be seen from the above that the aims of identifying a suitable model for human 
cardiomyocytes, performing an in-depth study of PDE expression and activity in 
cardiomyocytes, and using specific PDE inhibitors to carry out functional 
comparisons between species, were clearly met in this project. Furthermore, the work 
carried out led to many new insights into the roles of PDEs within the cardiomyocyte. 
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